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Abstract 
Women develop pulmonary arterial hypertension (PAH) more frequently than men 
suggesting that female sex and/or female sex hormones i.e. estrogens play a role in disease 
pathogenesis. Building evidence also implicates a role for microRNAs (miRNAs) in PAH. 
Little is known surrounding the interplay between sex/estrogens and miRNAs in PAH. 
Examining the sexual dymorphism in miRNAs with regards to PAH disease may provide 
insight into the sex bias observed in PAH.  
Loss-of-function BMPR-II mutations underlie heritable PAH. Here, we showed that in 
pulmonary artery smooth muscle cells (PASMCs) explanted from a pulmonary 
hypertensive mouse model with a knock-in BMPR-II mutation (BMPR-II
R899X+/-
) there 
were differences in miRNA expression between sexes. Among the 20 miRNAs examined, 
9 miRNAs exhibited significant change in expression within female BMPR-II
R899X+/- 
compared to female wild-type (WT) PASMCs but remained unchanged in male PASMCs. 
Of interest miRNA-96 demonstrated significant down-regulation in female BMPR-
II
R899X+/-
 but remained unchanged in male BMPR-II
R899X+/-
. In silico prediction software 
demonstrates the 5-HT1B receptor as a putative target of miRNA-96. The 5-HT1B receptor 
has previously been implicated in PAH development as it is thought to play a role in 
pulmonary artery vasoconstriction and pulmonary artery remodelling, two major hallmarks 
of PAH. To verify if 5-HT1B was a true target of miRNA-96 we carried out a 3’UTR 
luciferase reporter assay. Indeed we found over-expression of miRNA-96 could down-
regulate the luciferase output of the luciferase reporter construct containing the 3’UTR of 
the 5-HT1B receptor. The down-regulation of miRNA-96 within the female BMPR-
II
R899X+/- 
mouse PASMCs was associated with a concomitant increase in 5-HT1B mRNA 
and protein. This expression pattern was re-iterated in PASMCs explanted from female 
PAH patients. Here, we found female PAH patients had a decrease in miRNA-96 
expression and an increase in 5-HT1B mRNA and protein but again expression remained 
unchanged in male patients compared to non-PAH controls.  Interestingly we also found 
only female PAH patient PASMCs were proliferative to the mitogen serotonin (5-HT). 
This could be explained by the expression pattern of 5-HT1B observed. Next we examined 
the effect of miRNA-96 over-expression in human PASMCs. Here, we demonstrated that 
over-expressing miRNA-96 had the ability to reduce 5-HT1B protein expression; however, 
mRNA expression remained unchanged. In addition, we found that over-expressing 
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miRNA-96 prevented serotonin-induced proliferation in PASMCs from female PAH 
patients.  
We have previously shown a relationship between estrogen and 5-HT1B as 17β-estradiol, 
the main pre-menopausal circulating estrogen, increases the protein expression of 5-HT1B 
in human PASMCs. Here, we examined the effect of 17β-estradiol on miRNA-96 
expression. We found that 17β-estradiol decreased miRNA-96 expression suggesting 17β-
estradiol’s effect on 5-HT1B expression could be mediated through a decrease in miRNA-
96. To determine if endogenous 17β-estradiol also influences miRNA-96 expression we 
assessed the expression of miRNA-96 and 5-HT1B expression within whole lung 
homogenates from female and male mice that had been dosed with an aromatase (estrogen 
synthesising enzyme) inhibitor anastrozole. These mice have depleted circulating and local 
lung synthesis of estrogen, and elevated BMPR-II signalling. MiRNA-96 was elevated in 
the lungs from the estrogen-depleted female mice and this was accompanied by a decrease 
in 5-HT1B mRNA expression. No changes in miRNA-96 and 5-HT1B mRNA expression 
were observed within male lung tissue. These results further implicated a role for estrogen 
in regulating miRNA-96 and subsequently 5-HT1B. 
As over-expression of miRNA-96 in cell culture prevented a proliferative phenotype in 
human PASMCs we sought to assess the effect of over-expressing miRNA-96 in vivo. We 
utilised both the BMPR-II
R899X+/-
 and hypoxic mouse model of pulmonary hypertension 
(PH) to examine whether a miRNA-96 mimic could both reverse and prevent a PH 
phenotype. The miRNA-96 mimic was administered intravenously via the tail vein once a 
week for 2 weeks using the MaxSuppressor™ In Vivo RNA-LANCEr II delivery method. 
We first confirmed that in both of these models miRNA-96 was significantly depleted in 
the lungs of diseased mice. Secondly we showed that intravenous injection delivered 
miRNA-96 mimic to the pulmonary arteries. Our in vivo results demonstrated that dosing 
with miRNA-96 mimic reduced the right ventricular systolic pressure (RVSP), right 
ventricular hypertrophy (RVH) and % of remodelled vessels in hypoxic and BMPR-
II
R899X+/-
 female mice. Mice dosed with a negative control mimic showed no effect on PAH 
indices. Interestingly we also showed that hypoxic and BMPR-II
R899X+/-
 mice dosed with 
miRNA-96 mimic had a reduction in 5-HT1B protein expression compared to those dosed 
with negative control mimic.  
This is the first study to observe sexual dimorphism in miRNA expression with regards to 
PAH. We have provided novel data demonstrating how miRNA-96, under the potential 
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influence of estrogen, plays a role in the development of PH in a sex-dependent manner, by 
regulating 5-HT1B expression and serotonin-induced proliferation. Restoring depleted 
miRNA-96 levels may present a novel therapeutic approach in PAH. 
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1.1 The Pulmonary Circulation 
1.1.1 Development of the Pulmonary Circulation 
Throughout embryological development the pulmonary circulation is being continuously 
prepared for a maturation and transition phase which occurs at birth. Development and 
growth of the pulmonary vasculature involves both the initial formation of blood vessels 
and their subsequent outward branching in vasculogenic and angiogenic processes 
respectively (deMello et al., 1997). Endothelial cells (ECs) initiate the formation of tube 
like vessels. The presence of growth factors e.g. vascular endothelial growth factor 
(VEGF) and transforming growth factor-β (TGF-β) have a fundamental role in mediating 
and shaping pulmonary vascular development. Abnormalities in either of their signalling 
pathways have detrimental consequences in both the development and maintenance of the 
normal pulmonary circulation (Morrell et al., 2001; Grover et al., 2003). ECs play a role in 
attracting mesenchymal cells which can then differentiate into smooth muscle cells 
(SMCs) and contribute to the architecture of the lung vasculature (Hall et al., 2000). 
Further vessel branching encompasses migration and proliferation of both ECs and SMCs 
until a dense vascular network is present and ready to function in one of the body’s most 
vital tasks: gaseous exchange. ECs from different tissue vascular beds are thought to 
originate from distinct embryological sites and have a heterogeneous population with 
specific phenotypes (Stevens et al., 2001). Distinct populations can also exist for SMCs 
(Frid et al., 1994). The embryonic origins of proximal and distal pulmonary arteries are 
different with proximal pulmonary arteries deriving from the truncus arteriosus and distal 
pulmonary arteries deriving from the mesenchymal primary capillary plexus (Hall et al., 
2000). Tissue specific phenotypes of both ECs and SMCs can contribute to the observed 
differences to stimuli, such as hypoxia in the pulmonary vs. systemic circulations (Stevens 
et al., 2001).  
1.1.2 The Structure of the Pulmonary Circulation 
In comparison to the systemic vasculature where thick-walled high pressure arteries 
distribute oxygenated blood to peripheral tissues, the pulmonary vasculature consists of 
thin-walled low pressure arteries which carry deoxygenated blood to terminal alveoli. In 
the pulmonary arteries systolic pressure is ~25 mmHg compared to 120 mmHg in systemic 
arteries. Branching from the right ventricle (RV) of the heart the main pulmonary artery 
bifurcates into the right and left pulmonary arteries before entering the parenchyma of the 
right and left lung respectively. The pulmonary arteries continue branching, tracing the 
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course of the bronchial tree until the terminal alveoli at the periphery of the lung pleural 
are reached. Pulmonary arteriograms demonstrate there are 15 orders of pulmonary artery 
(Huang et al., 1996). The orders are categorised using the Strahler ordering system starting 
from the peripheral pre-capillary arteries, termed order 1, up to the main pulmonary artery, 
termed order 15. Order 1 pulmonary arteries are ~20 µm in diameter compared to order 15 
pulmonary arteries which are ~15.12 mm in diameter (Huang et al., 1996). From the main 
pulmonary artery (order 15), there are a predicted ~72 million order 1 pulmonary arteries 
arising, forming the basis of an extensive capillary network structure in conjunction with 
alveolar ducts to ensure optimal gaseous exchange (Huang et al., 1996).  
Similarly to systemic arteries, pulmonary arteries have three concentric layers within the 
vascular wall however differences within the composition of these layers do exist between 
systemic arteries. The inner most layer of the vessel is termed the tunica intima and 
consists of a single layer of ECs which line the lumen of the vessel. The ECs are in 
constant contact with blood and therefore vulnerable to insult from shear stress and 
circulating mediators. ECs can act as environmental sensors, working in conjunction with 
underlying SMCs to adapt the artery to the environment accordingly i.e. mechanical stretch 
and hypoxia increases serotonin synthesis and release from ECs which can act in a 
paracrine fashion to SMCs to elicit an effector response e.g. vasoconstriction (Morecroft et 
al., 1999; Pan et al., 2006). The tunica intima is separated from the middle layer by an 
internal elastic lamina. The middle layer of the vessel is termed the tunic media and 
consists of SMCs arranged around the circumference of the vessel. In between the tunica 
media and the tunica adventitia, the outer most layer, is the external elastic lamina. The 
tunica adventitia consists of fibroblasts and collagen fibres important for vessel stability 
and is tethered to the corresponding segment of the bronchial tree. As the pulmonary 
circulation is a low resistance, low pressure circuit the need for highly muscularised 
arteries is not required. Throughout the 15 orders of pulmonary artery the structure of the 
artery wall changes with regards to the distribution of the elastic lamina and the degree of 
muscularity. The pulmonary arteries in order 15-13 have an abundant elastic portion within 
their tunica media to aid vessel compliance (Elliott et al., 1965). In orders 13-4 there is a 
higher presence of SMCs within the tunica media, however, the continuous layer of SMCs 
gradually becomes more sparsely distributed as the branch extends and continues down to 
order 4 (Elliott et al., 1965; Jones et al., 2011). These pulmonary arteries are termed 
muscularised and partially muscularised accordingly. Further to this the pulmonary arteries 
transition into non-muscularised pulmonary arteries in orders 3-1 upon reaching the 
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capillary network (Jones et al., 2011). The most peripheral distal non-muscularised 
pulmonary arteries consist of a single thin elastic lamina lined by ECs. Pericytes are also 
known to be present within the most distal non-muscularised pulmonary arteries. Pericytes 
are undifferentiated perivascular cells which can contribute to the remodelling of a 
pulmonary artery by transforming into SMCs and by excreting collagen fibres (Wu et al., 
1995; Ricard et al., 2014). 
1.1.3 The Physiology of the Pulmonary Circulation 
During foetal life gaseous exchange between the alveoli and pulmonary arteries is not 
required and the pulmonary vasculature is considered a hypoxic environment. In utero 
blood is oxygenated through the placenta. As a result there is low oxygen tension upon the 
pulmonary vasculature contributing to vasoconstriction of pulmonary arteries and a high 
pulmonary vascular resistance (PVR). In utero, when blood returns to the right atrium of 
the heart the majority of blood flow bypasses the pulmonary circulation crossing the 
foramen ovale (FO) into the left side of the heart. Additionally, blood within the 
pulmonary artery can directly move into the aorta via the ductus arteriosus (DA). Lung 
tissue is adequately perfused through bronchial arteries which branch from the aorta. Upon 
birth and intake of the first breath, the oxygen tension increases, the medial layer of the 
distal pulmonary arteries thins, the PVR decreases and the FO and DA close forcing blood 
from the RV to flow into the pulmonary artery. No longer a hypoxic environment the 
pulmonary arteries fully dilate and partake in gaseous exchange with terminal alveoli. If 
the FO and DA do not successfully close and the PVR remains high after birth, persistent 
pulmonary hypertension of the newborn (PPHN) can result. Vasoconstriction of the 
pulmonary arteries in response to hypoxia (hypoxic pulmonary vasoconstriction, HPV) in 
utero contributes to the hypoxic response in adult pulmonary arteries. In contrast, systemic 
arteries dilate in response to hypoxia.   
After birth the pulmonary vasculature becomes responsible for carrying deoxygenated 
blood returning to the right side of the heart to the pulmonary capillary system before 
transporting oxygenated blood to the left side of the heart where it is subsequently 
distributed throughout the systemic peripheral vasculature. The fundamental role of re-
oxygenation is sophistically engineered by the integration of the dense pulmonary capillary 
network with terminal alveoli. At this interface gaseous exchange occurs via diffusion. As 
the partial pressure of oxygen (O2) in the terminal alveoli is higher than in the pulmonary 
capillaries, O2 received by inspiration diffuses down the pressure gradient and into the 
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blood. Likewise as the partial pressure of carbon dioxide (CO2) is higher in the pulmonary 
capillaries compared to terminal alveoli, it diffuses to the alveoli and is removed upon 
expiration.    
1.1.4 The Regulation of Pulmonary Vascular Tone 
In pulmonary arteries the basal vascular tone is low to facilitate a low resistance, low 
pressure and high flow circuit. This is as a result of a thinner layer of SMCs in comparison 
to the systemic circulation where a high vascular tone exists. At rest the major contributor 
to pulmonary vascular tone (or the resting membrane potential) is the activity of potassium 
channels within pulmonary artery smooth muscle cells (PASMCs). In human PASMCs, the 
voltage dependent potassium channels (Kv) are largely responsible for deciding the resting 
membrane potential (Yuan, 1995). When the cell membrane depolarises the voltage sensor 
within the Kv triggers the Kv channel to open to allow potassium ions (K
+
) to flow out of 
the cell and restore the membrane potential. With regards to PASMCs this restores a low 
vascular tone. Inhibition of Kv channels initiates a sustained increase in membrane 
potential allowing calcium (Ca
2+
) channels to remain open. This leads to increased 
intracellular concentrations of Ca
2+
 resulting in sustained vasoconstriction of PASMCs. 
Hypoxia has shown to inhibit Kv contributing to the vasoconstrictive phenotype observed 
in PASMCs by hypoxia. Interestingly PASMCs from pulmonary arterial hypertension 
(PAH) patients exhibited dysfunctional Kv channels which resulted in more depolarised 
PASMCs and contributed to enhanced vasoconstriction in PASMCs from PAH patients vs. 
non-patients (Yuan et al., 1998). Further to this a loss of function mutation within the 
potassium channel KCNK3 has recently been identified in hereditary forms of PAH 
(HPAH) (Ma et al., 2013). Although a different class of K
+
 channel than Kv, it further 
emphasises the importance K
+
 movement has on pulmonary vascular tone.   
As briefly mentioned above Ca
2+
 mobilisation also has an influence on pulmonary vascular 
tone. PASMC contraction and relaxation cycle is determined by free intracellular Ca
2+
 
levels. Influx of Ca
2+
 can occur via different routes including voltage-gated Ca
2+
 channels.  
When the cell membrane is depolarised voltage-gated Ca
2+
 channels open allowing the 
entry of Ca
2+
. Intracellular Ca
2+
 can initiate further Ca
2+
 release from the sarcoplasmic 
reticulum resulting in a further increase in free Ca
2+
 levels. Ca
2+
 then exerts function 
through interaction with the Ca
2+
-binding protein calmodulin. Ca
2+
-calmodulin then binds 
and activates the kinase, myosin-light-chain-kinase (MLCK) which subsequently 
phosphorylates myosin light chains (MLC). A conformational change occurs and allows 
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cross-bridge interaction between MLC and contractile actin filaments leading to 
contraction of the PASMC. This action is terminated by myosin phosphatase which 
initiates relaxation of the PASMC.  
Pulmonary artery endothelial cells (PAECs) are additionally an important regulator of 
pulmonary vascular tone. As briefly mentioned ECs function to sense and mediate 
signalling to underlying SMCs. Communication between both cell types occurs via the 
release of vasoactive mediators which can be categorised into those which result in either 
vasoconstriction or vasodilation of PASMCs. Prostanoids including prostaglandin I2 (PGI2, 
prostacyclin) and nitric oxide (NO) are both synthesised within PAECs and cause vascular 
relaxation. Another factor secreted by PAECs is endothelin-1 (ET-1) which is a chief 
vasoconstrictor of PASMCs. Orchestrating a fine balance between the vasoactive 
mediators is critical to ensure normal vascular homeostasis. This control from PAECs can 
be disrupted as a result of insult to the endothelial layer e.g. shear stress or hypoxia. This 
disruption is characteristic of many systemic and pulmonary vascular pathologies.   
1.2 Pulmonary Hypertension 
A dense and complete pulmonary vascular network is vital in ensuring sufficient gaseous 
exchange to meet the energy requirements of the body. A diminished pulmonary vascular 
network can occur via either loss or obstruction of pulmonary arteries. Pulmonary 
hypertension (PH) is the term given to a group of progressive, and presently incurable, 
vasculopathies affecting the pulmonary arteries that can ultimately result in their 
obliteration. In simple terms, PH concerns an increase in the pulmonary arterial pressure 
(PAP). Normally a low pressure circuit, an elevation in PAP can contribute towards and 
trigger a cascade of pathogenic characteristics with fatal consequences. 
1.2.1 Clinical Definition and Diagnosis 
Within the clinic PH is defined by a mean PAP (mPAP) of >25 mmHg at rest and 
>30mmHg during exertion (Badesch et al., 2009).  The registry to evaluate early and long-
term PAH disease management (REVEAL) documented an mPAP of ~50 mmHg within 
PAH patients (Badesch et al., 2010). This is in comparison to a normal mPAP of ~14-20 
mmHg. PH can exist in many different forms (Table 1.1). However, most patients will 
typically present at clinic with symptoms including dyspnoea (breathlessness), dizziness 
and fatigue which are all suggestive of an insufficient oxygen supply to demand. These 
symptoms are ambiguous and not specific to PH and as symptoms usually present at 
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advanced stages of disease there is delayed disease onset time to diagnosis time. Due to the 
multiple classifications of PH, a more specific diagnosis is determined after a series of 
investigations which can include electrocardiogram (ECG), echocardiography, 
ventilation/perfusion pulmonary scan, pulmonary angiography, cardiac magnetic resonance 
imaging (MRI), blood tests, abdominal ultrasound scan and finally, right heart 
catheterisation (RHC) and vasoreactivity test. RHC is used to assess patients with an 
unknown cause of PH and is currently the gold standard diagnostic test to confirm the 
classification of pulmonary arterial hypertension (PAH). If a patient is diagnosed with 
PAH they will routinely undergo a vasoreactivity test to examine the potential 
effectiveness of calcium channel blockers (CCBs) as a therapeutic strategy. This evaluation 
involves challenging the patient with a vasodilator compound e.g. inhalational nitric oxide 
(NO), intravenous adenosine or intravenous prostacyclin. A positive acute vasodilator 
response is defined as a reduction in mPAP ≥10mmHg and is only observed within 5-10% 
of patients (Sitbon et al., 2005).  
1.2.2 WHO and NYHA Classification 
The fifth world symposium on PH was documented in 2013 detailing updated 
recommendations in clinical classifications (Table 1.1). Each clinical classification shares 
common pathological features however the purpose of categorising the disease into groups 
aids identification of disease aetiology, patient prognosis and therapeutic management. 
Irrespective of disease aetiology PH patients are additionally classified functional to give a 
standardised measure of disease severity. Functional classification integrates patient 
symptoms with patient limitations and is derived from the New York Heart Association 
(NYHA) scale on heart failure (Table 1.2). Functional classes I-IV rank PH patients 
physical abilities from no daily limitations (class I) to complete incapacity even at rest 
(class IV). Patients within class III represent a widely heterogeneous PH population with 
an extensive range of abilities and limitations and therefore caution must be given when 
extrapolating data from this group. The NYHA scale is beneficial in recommending 
treatment selection and is a broadly accepted predictor of patient survival.  
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Table 1.1 World Health Organisation Classification of Pulmonary Hypertension 
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Table 1.2 New York Heart Association Classification of Functional Status of Patients 
with Pulmonary Hypertension 
    
1.2.3 Epidemiology of Pulmonary Arterial Hypertension 
The epidemiology of PAH has been revised over the years due to new and advanced data 
from more recent longitudinal studies and centralised registries (Humbert et al., 2006; 
Badesch et al., 2010; Ling et al., 2012). In the United Kingdom (U.K.) and Ireland registry 
and the French registry the incidence is 1.1 and 2.4 cases per million respectively 
(Humbert et al., 2006; Ling et al., 2012). A national institutes of health (NIH) study 
conducted in the 1980’s showed the PAH patient had a mean age of 36 years with 62.5% 
of patients being female (female to male ratio was 1.7:1) (Rich et al., 1987b). Within the 
most recent U.K. and Ireland registry, Ling and colleagues collated data from all 8 PAH 
centres and found the mean age was 50 years with 70% of patients being female (Ling et 
al., 2012).  In agreement with this recent data, both the French and REVEAL registries 
show an older mean age of 50 and 53 years respectively with 65% and 80% of patients 
being female (Humbert et al., 2006; Badesch et al., 2010). The reasons underlying the high 
female to male ratio regarding PAH prevalence remain relatively obscure and the female 
susceptibility in PAH is the focus of much current research. Interestingly the 5 year 
mortality rate has reduced over the years from 66% in the NIH registry to 40% in the U.K. 
and Ireland registry (Rich et al., 1987b; Ling et al., 2012).  
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1.2.4 Pathobiology of Pulmonary Arterial Hypertension 
PAH is categorised within the group 1 classification and includes idiopathic PAH (IPAH), 
heritable PAH (HPAH), drug- and toxin-induced PAH, associated PAH (APAH) and 
persistent pulmonary hypertension of the newborn (PPHN). The peripheral and most distal 
pulmonary arteries of the lungs are responsible for the initial genesis of disease. As 
discussed earlier, under normal physiological conditions these pulmonary arteries have an 
absence of SMCs with only a monolayer of ECs and elastic lamina. Evidence from both 
clinical and experimental data highlights within the origins of PAH there is a pathogenic 
transformation within the EC layer. This detrimental alteration can be triggered by either 
exogenous or endogenous insult. For example exogenous stimuli could arise from either 
circulating mediators or a hypoxic environment. PAECs exposed to hypoxia demonstrate 
reduced structural and functional plasma membranes (Block et al., 1989). Furthermore, 
circulating reactive oxygen species (ROS) have also been documented to reduce EC 
membrane integrity (Thies et al., 1991). Or endogenously through heritable genetic 
mutations which could trigger the switching on/off of genes with fatal consequences. The 
majority of HPAH patients present with a loss of function mutation within the bone 
morphogenic protein receptor type II (BMPR-II) gene (Deng et al., 2000; International et 
al., 2000). Loss of BMPR-II in PAECs increases the level of PAECs apoptosis which can 
then expose underlying PASMCs (Teichert-Kuliszewska et al., 2006). Conversely, but 
equally detrimental, loss of BMPR-II signalling in PASMCs leads to their aberrant 
proliferation (Zhang et al., 2003). A dysfunctional endothelial layer can lead to the release 
of either vasoconstrictors or mitogens which can act in a paracrine fashion to neighbouring 
PAECs or underlying PASMCs in the medial layer of the pulmonary artery. For example, 
ET-1 is synthesised in PAECs and expression is increased in PAH patients (Giaid et al., 
1993). Abluminal release of ET-1 from PAECs to underlying PASMCs can trigger 
sustained vasoconstriction and mediate proliferative processes (MacLean et al., 1994; 
Davie et al., 2002). In addition the dysfunctional ECs may cease to produce vasodilatory 
and anti-proliferative mediators. It is demonstrated that levels of NO production are 
attenuated in PAECs from IPAH patients compared to PAEC from healthy controls (Giaid 
et al., 1995; Xu et al., 2004). NO is a potent vasodilator and has anti-proliferative 
properties therefore its loss can augment vasoconstriction and remodelling processes of 
pulmonary arteries. The loss of the EC barrier and the change in the balance of 
pathological vs. physiological mediators creates a destructive micro-environment within 
the distal pulmonary arteries. In normal physiology the peripheral distal pulmonary arteries 
lack a defined SMC layer. However, during the onset and development of PAH, 
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dysfunctional ECs can influence pericytes present in the basement membrane to 
differentiate into SMCs (Ricard et al., 2014). Further to this PASMCs from further up the 
pulmonary arterial branch can migrate to distal portions of the vasculature (Sheikh et al., 
2014). Eventually these once non-muscularised pulmonary arteries will evolve to exhibit a 
muscular phenotype (Figure 1.1). Proliferation of PASMCs within the medial layer of 
distal pulmonary arteries defines the presence of a double elastic lamina which is used 
experimentally to indicate evidence of pulmonary arterial remodelling. PASMCs can also 
contribute to a double elastic lamina through increased production of elastin and collagen 
fibres (Todorovich-Hunter et al., 1988; Rabinovitch, 1998). In addition, enhanced 
muscularisation of already muscular pulmonary arteries in order 4-9 will occur with 
hypertrophy and proliferation of SMCs within their medial layer and neointima formation 
within the lumen. Altogether these actions within the pulmonary arteries will lead to a 
diminution of the luminal area. This distinct loss of blood flow area within the peripheral 
vasculature is an effect termed “vascular pruning” as evident from arteriograms from PAH 
patients (Figure 1.2). Pathological remodelling of pulmonary arteries is currently an 
irreversible process and regression of this PAH hallmark is an attractive therapeutic target.  
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Figure 1-1 Diagrammatic scheme of pulmonary arterial hypertension pathogenesis 
Pulmonary arterial hypertension (PAH) is a severe vasculopathy affecting the pulmonary 
arteries. PAH results from muscularisation of distal non-muscularised pulmonary arteries 
which can lead to their obliteration. Pulmonary arteries already muscularised will undergo 
hypertrophy of the medial smooth muscle cell layer which can lead to a severe reduction in 
lumen size. The overall increase in pulmonary vascular resistance increases the pulmonary 
arterial pressure.    
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Figure 1-2 Pulmonary Vascular Arteriograms 
Pulmonary vascular arteriogram from a healthy (non-PAH) adult lung (left) and from an 
idiopathic PAH patient lung (right). Note the extensive loss of peripheral vasculature in the 
idiopathic PAH patient lung (Reid, 1986).  
 
The consequent increase in pulmonary vascular resistance substantially raises the PAP. 
The REVEAL registry reports a mean PAP of ~50mmHg which is significantly higher than 
the mean PAP of a healthy individual of ~14-20mmHg (Badesch et al., 2010). 
Experimentally within in vivo animal models measurement of right ventricular systolic 
pressure (RVSP) is used as an indicative measurement of PAP. Anatomically the RV of the 
heart precedes the pulmonary artery therefore can be directly influenced by hemodynamic 
properties within the pulmonary circulation. Normally the RV deals with a low pressure 
pulmonary circuit and structurally has a thin ventricular muscle wall, less so than the left 
ventricle (LV) which has to pump against the high pressure systemic circuit (Voelkel et al., 
2006). In light of high pulmonary vascular resistance and PAP in PAH pathology the RV is 
not adequately structurally equipped. Consequently the RV undergoes an adaptive 
hypertrophic transformation to compensate against the increased after-load. Hypertrophy 
of the RV is indicated by an increase in wall thickness and the total gross weight (Voelkel 
et al., 2006). Initially the hypertrophic process is beneficial as it combats the high PVR and 
maintains cardiac output of the RV. However, the adaptive process will eventually become 
maladaptive and the RV will begin to lose its functional contractile ability and fail. RV 
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failure is the primary cause of death within PAH patients thus their survival is largely 
governed by the adaptability of the RV to the increased after-load.    
1.2.5 Current Pulmonary Arterial Hypertension Therapeutics 
Therapeutic success in PAH is impeded by the complex multifactorial nature of the 
disease. In addition, incomplete understanding of the molecular pathways involved, adds to 
the lack of sufficient treatment strategies. In most scenarios the disease manifestation 
predates the onset of symptoms and diagnosis meaning the disease pathology can be well 
progressed by the time therapies are initiated. Present drugs are modelled on mechanisms 
and pathways identified around 15-20 years ago. That said, life expectancy is greater than 
it was as indicated by a reduction in the 5 year mortality rate from 66% in the NIH registry 
from the 1980’s to 40% in the U.K. and Ireland registry from 2012 (Rich et al., 1987b; 
Ling et al., 2012). Even though current therapeutics have greatly improved and prolonged 
patient life quality and survival they are unable to reverse the progression of PAH disease 
characteristics e.g. pulmonary arterial remodelling, and mortality rates remain 
unacceptably high. Thus there is great rationale to investigate new therapeutic routes.   
1.2.5.1 Calcium Channel Blockers 
Intense vasoconstriction of small pulmonary arteries is a major recognised hallmark of PH 
pathogenesis (Rich et al., 1992). Vasoconstriction of PASMCs is ultimately governed by 
the availability of intracellular Ca
2+
. As previously discussed, Ca
2+
 enters SMCs via 
voltage gated channels on the cell surface and initiates a vasoconstrictive cascade 
increasing PVR. Thus the ability to prevent Ca
2+
 influx by blocking the L-type channels 
presents an approach to suppress SMC vasoconstriction and promote vasodilation. Almost 
three decades ago Rich and colleagues described the first use of Ca
2+
 channel blockers in 
pursuit of decreasing PVR in PAH (Rich et al., 1987a). Since then the use of nifedipine, 
amlodipine, or diltiazem has been recognised in the clinic. It is worthy to note Ca
2+
 
channel blockers are only recommended for use in patients who respond positively to an 
initial vasodilatory test which is roughly 5-10% of patients (Sitbon et al., 2005). Thus the 
target and therefore responsive PH patient population is a small minority. 
1.2.5.2 Endothelin Receptor Antagonists 
In 1988 Yanagisawa and colleagues identified endothelin-1 (ET-1) as a highly potent 
vasoconstrictive molecule with fundamental importance in regulation of vascular tone 
(Yanagisawa et al., 1988). Within the vascular network the predominant source of ET-1 is 
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from ECs with the majority of synthesis occurring within the pulmonary circulation (Firth 
et al., 1992). PAECs are critically involved in the pathogenesis of PAH and their 
dysfunction can be attributed by ET-1 (Galie et al., 2004).  Through endothelin receptor A 
(ETA) and endothelin receptor B (ETB), ET-1 can exert vasoconstrictive and proliferative 
properties on PASMCs and PAECs creating a detrimental environment and initiating 
structural arterial remodelling (MacLean et al., 1994; Davie et al., 2002). In PH patients 
circulating ET-1 concentrations are increased and correlate with disease severity (Stewart 
et al., 1991; Giaid et al., 1993). Up-regulation of ETA and ETB receptors has also been 
documented in PH and could account for heightened effects driven by ET-1 (Davie et al., 
2002). The most effective approach at blocking the action of ET-1 is through dual 
antagonism of ETA and ETB as selective inhibition of one receptor can be compensated 
through the action of the other. Experimental data highlights dual receptor blockade can 
reduce human PASMC proliferation, pulmonary haemodynamics and RVH (Eddahibi et 
al., 1995; Davie et al., 2002). However, ETB plays a major role in the clearance of ET-1 
and therefore blockade of this receptor by ETB antagonists could lead to heightened 
circulating ET-1 levels and limits ETB antagonists therapeutic appeal (Fukuroda et al., 
1994). There are currently three FDA (Food and Drug Administration) approved ET-1 
receptor antagonists (ERAs) for the use of PAH; bosentan, macitentan and ambrisentan. 
Bosentan and macitentan are dual receptor antagonists whereas ambrisentan is an ERA 
selective antagonist. Bosentan was the first oral treatment prescribed for use in PAH and 
longitudinal patient studies have shown 2 year survival at 70% (McLaughlin et al., 2005). 
Interestingly in 2012 Gabler and colleagues reported sex differences in treatment response 
to ERAs with women demonstrating better clinical outcome than men (Gabler et al., 2012). 
This suggests that stratification of PAH therapies may improve treatment effectiveness.    
1.2.5.3 Phosphodiesterase 5 Inhibitors 
Nitric Oxide (NO) has long been recognised as an important regulator of vascular tone 
(Furchgott et al., 1980; Ignarro et al., 1988). Deficiencies in NO have been identified in 
PAH patients (Giaid et al., 1995). Within the pulmonary vasculature NO is a critical local 
mediator synthesised in the endothelial layer via conversion of L-arginine by endothelial 
nitric oxide synthase (eNOS). Acting in a paracrine fashion to underlying PASMCs 
endogenous NO activates soluble guanylate cyclase. This activation triggers the conversion 
of guanosine 5’ triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) 
increasing intracellular cGMP levels. cGMP is a second messenger and through cGMP-
Dependent Protein Kinases (PKG) signalling, is key in initiating vasodilation of small 
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pulmonary arteries. The action of cGMP is terminated by cyclic nucleotide 
phosphodiesterase (PDE) enzymes, primarily PDE-5. Within the pulmonary vasculature 
PDE-5 is abundantly and predominantly expressed in PASMCs. Increased levels of PDE-5 
are reported in animal models of PH (Maclean et al., 1997; Corbin et al., 2005). Selective 
inhibition of PDE-5 prevents the hydrolysis of cGMP and thus potentiates the beneficial 
vasodilatory effects brought on by PKG. Selective PDE-5 inhibitors approved for PAH 
therapy include sildenafil, verdenafil and tadalafil. Experimentally sildenafil has been 
shown to restore deficiencies in BMPR-II signalling in in vitro and in vivo models which 
exhibit disrupted BMPR-II pathway (Yang et al., 2013a). Clinically treatment with 
sildenafil reduced PAH patients mPAP, PVR and increased their cardiac index compared 
to placebo controls however, clinical worsening was indifferent between groups (Galie et 
al., 2005). Recently it was observed that male PAH patients were more likely to respond 
better to tadalafil treatment than female PAH patients reiterating the impact gender and/or 
sex has on treatment response (Mathai et al., 2014).  
1.2.5.4 Prostacyclin Analogues 
Prostacyclin is a member of the prostaglandin family sharing a common molecular 
structure to other members such as thromboxane A2 (TA2). Prostacyclin and TA2 have 
paradoxical effects on vascular tone, vasodilation and vasoconstriction respectively, 
emphasising the importance prostaglandins play in maintaining vascular homeostasis. 
Prostacyclin is also a major inhibitor of platelet aggregation; an additional contributing 
factor in PAH development (Moncada et al., 1976; Moncada et al., 1979). Abnormal 
urinary ratios between prostacyclin and TA2 metabolites in favour of TA2 have been 
observed in PH patients (Christman et al., 1992). Within the pulmonary circulation 
prostacyclin synthesis occurs primarily in PAECs and acts in a paracrine fashion to 
underlying PASMCs where it activates G-protein-coupled-receptors (GPCRs) to increase 
intracellular cAMP levels. More recent evidence has also highlighted a role for 
prostacyclin in proliferation (Clapp et al., 2002). Subsets of PH patients present with 
deficiencies in endogenous prostacyclin synthase (PGIS) and subsequent decreased levels 
of circulating prostacyclin (Christman et al., 1992; Tuder et al., 1999). This decrease in 
expression is mirrored in animal models of pulmonary hypertension (Badesch et al., 1989) 
and replenishing prostacyclin decreases disease indices in the mouse and rat hypoxic 
model of pulmonary hypertension (Rabinovitch et al., 1988; Geraci et al., 1999). 
Experimentally the prostacyclin analogue treprostinil has been shown to activate KCNK3 
in PASMCs restoring the K
+
 current and resting membrane potential (Olschewski et al., 
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2006). Similarly it has been demonstrated that the prostacyclin analogue iloprost has the 
ability to inhibit PASMC proliferation through enhancing the BMPR-II signalling pathway 
(Yang et al., 2010). Clinically the approach of augmenting endogenous prostacyclin in PH 
patients arose ~30 years ago and remains at the forefront in treating advanced cases of 
PAH (NYHA class III and IV) (Rubin et al., 1982). However, the short half-life of 
prostacyclin derived therapies still poses a hurdle in today’s treatments. To overcome the 
short half-life, prostacyclin analogues can be administered via a continuous intravenous 
infusion but this can subsequently result in recipient patients being highly susceptible to 
sepsis (Kitterman et al., 2012). Inhaled and orally active prostacyclin analogues are thus 
more appealing.  
1.2.6 Emerging Pulmonary Arterial Hypertension Therapeutics 
Current analysis has highlighted the effectiveness of prescribing double or even triple 
therapy of existing PAH drugs for optimal results (Sitbon et al., 2014). This reinforces the 
concept that PAH needs a multi-hit treatment plan.  The intricate and diverse mechanisms 
involved in pulmonary arterial remodelling and distal pulmonary artery obliteration in 
PAH pathogenesis remain relatively elusive. Discovering novel treatments targeting these 
aspects of disease will certainly prove beneficial. Ongoing research has identified 
fundamental pathways including those involving reactive oxygen species (ROS) (Liu et al., 
2006; Mittal et al., 2007), K
+
 ion channels (Xie et al., 2004), tyrosine kinases (Schermuly 
et al., 2005), epigenetic modulation (non-coding RNAs and histone deacetylases) (Caruso 
et al., 2012; Zhao et al., 2012) and regeneration utilising endothelial progenitor cells 
(Wang et al., 2007).    
1.3 Genetic Control of Pulmonary Arterial Hypertension 
A heritable component of PAH has been recognised since Dresdale observed repeat 
occurrence of the disease within a single family in the 1950’s (Dresdale et al., 1951) 
(Dresdale et al., 1954). From this it took almost 50 years for clinicians and researchers to 
fully identify the first genetic risk factor in heritable PAH (HPAH) as mutations within the 
BMPR-II gene (Deng et al., 2000) (International et al., 2000). HPAH is known to be 
inherited in an autosomal dominant manner meaning only one parent is required to pass on 
the affected gene for the child to be at risk. Genetic mutations are known to occur with 
reduced disease penetrance as only 20% of mutation carriers actually develop disease 
indicating other additional contributing factors are involved. These additional factors are 
thought to be of both genetic and environmental origin. Together this implies that a 
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contribution from a PAH-associated gene mutation is required but not sufficient for HPAH 
to develop. Other genetic risk factors identified include mutations within activin receptor-
like kinase 1 (ALK-1) and potassium channel subfamily K, member 3 (KCNK3). The 
theory of HPAH exhibiting genetic anticipation i.e. disease onset occurring earlier in age 
with each affected generation, has recently been dismissed as there is currently insufficient 
longitudinal data to support such a claim. However, on average HPAH patients present 
earlier in age with more severe haemodynamic impairment and die around 10 years earlier 
compared to non-HPAH patients (Sztrymf et al., 2008; Girerd et al., 2010). Around 6% of 
the PAH population will be classed as a HPAH patient (disease presentation within one or 
more first order blood relative) (Rich et al., 1987b). A gender disparity is observed in 
HPAH with a 2.7:1 female to male ratio suggesting interplay of sex with disease 
prevalence (Loyd et al., 1995).  
1.3.1 BMPR-II Mutations 
Mutations within the gene encoding BMPR-II are associated with ~75% of HPAH patients 
(Machado et al., 2006a). Interestingly ~20% of idiopathic PAH (IPAH) patients also 
present with BMPR-II mutations (Atkinson et al., 2002; Hamid et al., 2009). The nature of 
BMPR-II mutations documented vary between affected families and to date there have 
been ~300 observed (Machado et al., 2006a; Soubrier et al., 2013). Evidence suggests  
disease penetrance of BMPR-II mutation carriers can depend on the location of mutation in 
the BMPR-II gene however data cannot be fully interpreted due to study cohorts involving 
few non-affected carriers (Austin et al., 2009b). Additionally, among affected BMPR-II 
mutation carriers disease severity appears to depend on mutation type e.g. missense 
mutations carry more detrimental ramifications than truncating mutations (Austin et al., 
2009b). The mutations described result in reduced expression or reduced function of the 
BMPR-II receptor. Therefore a reduction in BMPR-II mediated signalling is associated 
with HPAH development.  
1.3.1.1 BMPR-II Signalling Pathway 
BMPR-II is a receptor subtype member of the TGF-β superfamily type II receptors and has 
four functional domains including a ligand binding domain, a transmembrane domain, a 
kinase domain and a cytoplasmic tail domain. In the pulmonary circulation BMPR-II 
signalling is crucial for vascular cell growth and differentiation playing an important role 
in cellular processes such as angiogenesis and vascular repair (Pardali et al., 2012; 
Sountoulidis et al., 2012). BMPR-II receptors are serine-threonine receptor kinases 
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activated by a group of cytokines called bone morphogenetic proteins (BMPs) (Cai et al., 
2012). BMPs regulate both cell proliferation and apoptosis (Figure 3). These pleiotropic 
effects mediated by BMPs are dependent on the cell type involved i.e. BMP signalling in 
PASMCs is anti-proliferative but proliferative in PAECs (Zhang et al., 2003; Teichert-
Kuliszewska et al., 2006). BMP signalling is crucial for the initial development of the 
pulmonary circulation promoting PAEC survival and their vital role in tube-like vessel 
formation (Teichert-Kuliszewska et al., 2006). Canonical BMPR-II signalling is initiated 
by ligand binding to the cell surface BMPR-II receptors (Figure 1.3). The ligand activated 
BMPR-II receptor then recruits a TGF-β type I receptor (i.e. BMPR-I) to form a 
heterodimer complex before signalling proceeds (Derynck et al., 2003). The kinase activity 
of the BMPR-II receptor then phosphorylates and activates the transmembrane region of 
the BMPR-I receptor. The activated BMPR-I receptor is then able to interact with 
intracellular signalling proteins called Sma and MAD (mothers against decapentaplegic) 
known collectively as SMAD proteins (Massague et al., 2005). There are three types of 
SMAD proteins: receptor regulated SMADs (R-SMADs) which include SMAD1/5/8, 
common mediator SMAD (co-SMAD) which includes SMAD4 and inhibitory SMADs (I-
SMADs) which include SMAD6/7. The BMPR-I receptor phosphorylates the R-SMADs 
which form a hetero-oligomer complex with the co-SMAD4. This new SMAD complex 
translocates to the nucleus where it plays a role in the transcription of target genes. SMAD-
target genes include inhibitor of DNA binding (Id) of which there are 4 subtypes. Id 
proteins are functional inhibitors of the basic helix loop helix (BHLH) transcription factors 
and act by prohibiting their DNA binding ability. BHLH transcription factors usually direct 
expression of proliferative and pro-survival genes but this action is lost when they are 
bound to Id (Lasorella et al., 2014). With regards to BMPR-II signalling within the 
pulmonary vasculature, Id1 and Id3 are demonstrated to be important targets (Yang et al., 
2013b). Id3 has a crucial role in regulating PASMCs cell cycle progression (Yang et al., 
2013b). Regulation of SMAD signalling occurs via SMAD ubiquitination and regulatory 
factors (SMURFs) which serve to repress SMAD activity (Shi et al., 2004).  
The mechanisms of how BMPR-II mutations lead to manifestation of PAH remain poorly 
understood. BMPR-II receptors are broadly expressed with high distribution in PAECs 
(Atkinson et al., 2002). BMPR-II mutations are present within the germline i.e. the 
mutation is present within every cell type in the body yet curiously only the pulmonary 
vasculature appears to be consequently affected. Even still loss of function BMPR-II 
mutations cause detriment in a cell specific manner as PAECs display an increased risk of 
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apoptosis whereas on the contrary PASMCs display a heightened proliferative state 
(Teichert-Kuliszewska et al., 2006; Yang et al., 2011b). It has been shown that in patients 
with BMPR-II mutations, BMPR-II protein expression is reduced in PASMCs and PAECs 
along with reduced expression of downstream SMAD signalling proteins (Atkinson et al., 
2002; Yang et al., 2005). This expression profile is replicated in animal models of PAH 
including; hypoxia, monocrotaline and Sugen-Hypoxia (SU-HX) (Takahashi et al., 2006; 
Morty et al., 2007; Mair et al., 2014). Recently it has emerged that females may be pre-
disposed to reduced BMPR-II signalling as PASMCs from female non-PAH patients 
exhibit reduced expression of BMPR-II, SMAD1, Id1 and Id3 compared to male non-PAH 
patients (Mair et al., 2015). Interestingly mice heterozygous for BMPR-II (BMPR-II
+/-
) do 
not spontaneously develop a PH phenotype at baseline but do after exogenous 
administration of the highly potent vasoconstrictor and mitogen serotonin (Long et al., 
2006). More recently a knock-in BMPR-II mutation (BMPR-II
R899X
) specifically induced 
in SMCs demonstrated increased RVSP and pulmonary vascular pruning (West et al., 
2008). Similarly PASMCs extracted from mice expressing global BMPR-II
R899X+/-
 
exhibited an enhanced proliferative phenotype and dysfunctional SMAD mediated 
signalling (Long et al., 2011). In PASMCs from patients with BMPR-II mutations, a 
reduction in SMAD-dependent signalling i.e. anti-proliferative Id signalling, can lead to 
unopposed SMAD-independent signalling i.e. pro-proliferative ERK1/2 (extracellular-
signal-regulated kinases 1/2) signalling (Yang et al., 2008). It was also observed that 
BMPR-II
R899X+/- 
mice developed a mild PH phenotype at 6 months of age. This converging 
evidence demonstrates the importance of BMPR-II signalling in PAH disease development 
and restoration of the BMPR-II signalling pathway represents a novel therapeutic strategy. 
Rescuing the pathway with FK506 prevents a PH phenotype in mice deficient in BMPR-II 
and the SU-HX rat model (Spiekerkoetter et al., 2013). 
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Figure 1-3 Canonical BMPR-II signalling pathway 
A schematic overview of canonical BMPR-II signalling pathway in a pulmonary artery smooth muscle cell. Upon BMP ligand binding BMPR-II forms a 
heterodimer complex with BMPR-I which activates SMAD proteins (1/5/8). SMAD1/5/8 forms a complex with SMAD4 which translocates to the 
nucleus where it can exert control of target gene transcription. The Id proteins are gene targets which function to inhibit proliferation. BMPR= bone 
morphogenetic protein receptor, BMP= bone morphogenetic protein, SMAD= Sma and MAD (mothers against decapentaplegic), Id= inhibitor of DNA 
binding.     
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1.3.2 ALK-1 Mutations 
Novel mutations within the ALK-1 gene were discovered by Harrison and colleagues and 
found to be associated with hemorrhagic telangiectasia type 2 (HHT) and HPAH patients 
(Harrison et al., 2003). ALK-1 is a TGF-β type I receptor and is a serine-threonine receptor 
kinase similar to BMPR-I and BMPR-II. The mutations identified in ALK-1 were missense 
mutations again leading to a loss of function of the receptor. The ALK-1 receptor functions 
in the same signalling pathway as BMPR-II further emphasising the fundamental 
importance a complete TGF-β signalling pathway has in pulmonary vasculature 
homeostasis. With regards to PAH, mutations in ALK-1 are even more detrimental than 
BMPR-II mutations (Girerd et al., 2010).  
1.3.3 KCNK3 Mutations 
Recently, whole-exome sequencing has identified six novel missense variants in the 
KCNK3 gene in both HPAH (those not already harbouring a known mutation) and IPAH 
patients (Ma et al., 2013). The mutation is thought to have incomplete penetrance and 
affect both female and male patients. KCNK3 also known as TASK-1 (TWK-related acid 
sensitive potassium channel) is a member of the two-pore-domain channel superfamily 
involved in K
+
 efflux and plays a critical role in maintaining the resting membrane 
potential therefore in PASMCs it holds a fundamental role in vascular tone. The missense 
variant identified by Ma and colleagues was found within the region responsible for the 
channel gate function which suggests the loss of function mutation could have disruptive 
impact on normal operating function. This was highlighted by the reduction in K
+
 current 
of mutant KCNK3 (Ma et al., 2013). In the setting of PASMCs the loss of function of 
KCNK3 could potentially lead to an increase in vascular tone. It is of interest that KCNK3 
is sensitive to O2 and hypoxia can reduce its function (Osipenko et al., 1997). The 
identification of KCNK3 mutations has provided a new therapeutic target. Current 
prostacyclin based treatments including treprostinil may even mediate their beneficial 
properties through activation of KCNK3 (Olschewski et al., 2006).            
1.4 Serotonin 
1.4.1 Serotonin Biosynthesis and Metabolism 
Serotonin is a central and peripheral neurotransmitter which can also function as a local 
hormone within the vasculature. Serotonin was first isolated from blood serum and 
identified as a potent vasoconstrictor in 1948 (Rapport et al., 1948). The majority of 
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serotonin’s synthesis (80%) and distribution is within enterochromaffin cells in the 
intestinal wall but it is also present in high concentrations in platelets and regions of the 
brain. As blood passes through the intestinal circulation the active uptake of serotonin into 
platelets occurs via the serotonin transporter (SERT) generating a circulating serotonin 
store (Berger et al., 2009).   
Serotonin is known chemically as 5-hydroxytryptamine (5-HT) and is synthesised from the 
primary precursor amino acid L-tryptophan.  Within the peripheral system tryptophan is 
converted to 5-Hydroxytryptophan by the rate-limiting enzyme tryptophan hydroxylase 
(TPH) before being converted to 5-HT by L-aromatic acid decarboxylase. There are two 
recognised isoforms of TPH, TPH1 and TPH2 which share 71% sequence homology 
(Walther et al., 2003). TPH1 is located mainly within the intestinal tract and responsible 
for peripheral 5-HT synthesis (Darmon et al., 1988) whereas TPH2 is exclusively 
distributed within the CNS (Walther et al., 2003). Although the majority of peripheral 5-
HT synthesis occurs in the gut there is convincing evidence supporting local synthesis of 5-
HT within the pulmonary and systemic vasculature specifically the arterial ECs (Eddahibi 
et al., 2006; Ni et al., 2008). In IPAH patient lungs and PAECs it was demonstrated that 
there is increased expression of TPH1 generating a heightened 5-HT microenvironment 
within the pulmonary vasculature (Eddahibi et al., 2006).  
5-HT is chiefly metabolised in the liver via monoamine oxidase-A (MOA) by the process 
of oxidative deamination to produce 5-hydroxyindol-aldehyde before being further 
oxidised to 5-hydroxyindoleacetic acid (5-HIIA). The 5-HIIA metabolite is excreted by the 
kidneys in urine and can serve as a biomarker of 5-HT production. Consistent with its 
synthesis, 5-HT is also locally degraded within the pulmonary vasculature. The actions 
mediated by 5-HT are vast and varying due to the number of distinct 5-HT receptors and 
diverse signalling pathways.  
1.4.2 Serotonin Signalling 
1.4.2.1 The 5-HT Receptors 
Current pharmacological classification highlights there are 14 distinct 5-HT receptors 
arranged into 7 individual classes (5-HT1-7) depending on criteria such as receptor type, 
location and downstream second messenger systems (Hoyer et al., 1994). All 5-HT 
receptors are membrane-bound and most belong to the heptahelical guanine nucleotide-
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binding (G)-protein coupled receptor (GPCR) superfamily with the exception of 5-HT3. 5-
HT3 is a ligand-gated cation channel evoking excitatory actions within the nervous system.  
Structurally GPCRs comprise of seven transmembrane α-helices, an extracellular N-
terminal domain, and an intracellular C-terminal domain and are coupled to their 
intracellular signalling mechanisms via a G-protein. G-proteins exist as trimers consisting 
of α, β and γ subunits with the α subunit containing bound guanosine 5’-diphosphate 
(GDP) and the β and γ subunits forming a βγ complex. Upon 5-HT binding of the 
extracellular domain, a conformational change occurs with the associated G-protein being 
activated and initiating the cells effector response. On the G-protein’s α subunit, bound 
GDP is exchanged for GTP and dissociation from the βγ complex occurs. This allows both 
the α-GTP and βγ-complex to perform individual downstream signalling. The effector 
pathway activated by the α-GTP complex is solely determined by the specific G protein 
involved. There are four G proteins; Gs, Gi/0, Gq and G12/13, each governing somewhat 
divergent intracellular signalling. The fate of GPCR activation and therefore fate of a cell 
can depend greatly on the coupled G-protein. The majority of the GPCR 5-HT receptors 
mediate their downstream signalling transduction through Gi/0 thus decreasing cyclic 
adenosine monophosphate (cAMP) levels apart from receptors of the 5-HT2 subtype which 
couple to Gq and therefore activate phospholipase C (MacLean, 1999).  
5-HT receptors are found throughout the central and peripheral nervous system plus the 
intestinal tract and cardiovascular tissues. This implicates their involvement within several 
disorders and diseases including depression, schizophrenia, migraine, systemic 
hypertension, pulmonary hypertension and irritable bowel syndrome, amongst others. 
Regarding the pulmonary circulation a heterogeneous population of 5-HT receptors have 
been reported. Messenger RNA (mRNA) expression of the 5-HT1B, 5-HT2A, 5-HT2B and 
5-HT7 has been documented within smooth muscle cells and endothelial cells (Ullmer et 
al., 1995).   
1.4.2.1.1 5-HT1 Receptors 
The 5-HT1 receptor family has five distinct isoforms, 5-HT1A, 5-HT1B, 5-HT1D, 5-ht1E and 
5-ht1F all sharing 40-63% sequence homology indicating a common evolutionary origin. 
Preferentially 5-HT1 receptors couple with the Gi/0 protein thus upon receptor activation 
will inhibit adenylate cyclase and reduce the production of cAMP from adenosine 
triphospahte (ATP). 5-HT1A and 5-HT1B are widely expressed in the central nervous 
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system (CNS) with roles pre-synaptically acting as auto-receptors inhibiting neuronal 
firing and hetero-receptors initiating the release of other neurotransmitters (Riad et al., 
2000). 5-HT1A receptors are also found to harbour inhibitory actions within the intestinal 
tract. 5-HT1B receptors are expressed in a variety of vascular beds including cerebral and 
pulmonary arteries. Within human pulmonary arteries the 5-HT1B receptor is the most 
abundantly expressed 5-HT receptor and mediates the majority of 5-HT induced signalling 
making it a favourable target for pulmonary artery specificity (Morecroft et al., 1999). In 
pulmonary arteries 5-HT1B receptor activation triggers not only SMC contraction but 
smooth muscle cell proliferation and therefore can contribute majorly to pulmonary artery 
vasoconstriction and pulmonary artery remodelling, two distinguishable hallmarks of PAH 
(Keegan et al., 2001; Lawrie et al., 2005). The 5-HT1D receptor is less abundantly 
expressed compared to the 5-HT1B receptor yet still provides important function as the 
non-selective 5-HT1B/1D receptor agonist, sumatriptan has proved successful as an anti-
migraine therapy. Definitive physiological roles have yet to be fully established for the 5-
ht1E and 5-ht1F receptors therefore they are denoted in lower case.  
1.4.2.1.2 5-HT2 Receptors 
The 5-HT2 receptor family comprises of the 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes 
which share 46-50% sequence homology. Distinct from the 5-HT1 receptor family the 5-
HT2 receptors are coupled primarily to the Gq/11 protein activating phospholipase C (PLC) 
leading to increased levels of 1, 2-diacylglycerol (DAG) and inositol-1, 4, 5 triphosphate 
(IP3). The 5-HT2A receptor mediates contractile responses within a variety of smooth 
muscle including vascular, bronchial and uterine. With respect to vascular smooth muscle, 
5-HT2A receptors are thought to elicit vasoconstriction in the systemic circulation. In 
accordance with this an anti-hypertensive therapy was established utilising a 5-HT2A 
selective antagonist ketanserin for use in systemic hypertension (Frishman et al., 1995). 5-
HT2A receptors are thought to mediate pulmonary artery vasoconstriction in some animal 
models (Cogolludo et al., 2006) but their involvement in human pulmonary arteries was 
disputed when ketanserin had minimal effect on pulmonary vascular resistance (McGoon 
et al., 1987).  Furthermore 5-HT2A exerts function in platelet aggregation causing 
thrombosis which can contribute to PH pathobiology (Berger et al., 2009; Bampalis et al., 
2011).  
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1.4.2.2 The Serotonin Transporter 
The human SERT was cloned in 1993 and was found to share 88% and 71% homology 
with mouse and rat SERT respectively (Blakely et al., 1991; Ramamoorthy et al., 1993; 
Chang et al., 1996). SERT is encoded by a single gene located on chromosome 17q11.2 
and can be transcriptionally regulated by two alleles for the promoter region. A 44-bp 
insertion or deletion confers an l or s allele respectively. The short or s-allele confers lower 
transcriptional efficiency and the long or l-allele promotes higher transcriptional efficiency 
of the gene (Lesch et al., 1996). Therefore individuals homozygous for the l/l allele will 
have increased SERT expression and activity compared to those homozygous for s/s. 
Indeed PASMCs from l/l carriers present with a 2-3 fold increase in SERT mRNA 
expression compared to s/s carriers (Eddahibi et al., 2001). In a small cohort of IPAH 
patients the SERT l/l polymorphism was detected in 65% of patients compared to 27% of 
non-PAH controls suggesting SERT over-expression could be linked to the development of 
PAH (Eddahibi et al., 2001).   
Located on the cell membrane of neurons, platelets, ECs and vascular SMCs the principle 
role of SERT is to uptake extracellular serotonin for either metabolism or vesicular storing 
in the intracellular portion therefore terminating its action. SERT is a sodium dependent 
transporter belonging to the wider Sodium/chloride (Na
+
/Cl
-
) transporter family and 
therefore utilises Na
+
 influx for serotonin entry into the cell. Firstly Na
+
 binds to the SERT 
protein followed by serotonin and Cl
-
. A conformational change proceeds allowing 
intracellular release of serotonin. To drive the SERT back to its original state a K
+
 ion is 
released.  
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Figure 1-4 Serotonin signalling 
A schematic overview of serotonin (5-HT) signalling in the pulmonary vasculature. Serotonin is synthesised within pulmonary arterial endothelial cells 
via the TPH-1 enzyme. Acting in a paracrine manner, serotonin can activate 5-HT receptors and serotonin transporter on underlying pulmonary arterial 
smooth muscle cells. Activation of 5-HT1 and 5-HT2 receptors leads to the decrease in cAMP levels and the increase in 1,2-Diaglycerol and inositil-1,4,5 
triphospahte respectively. This along with activation of the serotonin transporter can ultimately lead to contraction and proliferation of pulmonary artery 
smooth muscle cells. TPH-1= tryptophan hydroxylase-1, cAMP= cyclic adenosine monophosphate. 
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1.4.2.3 5-HT Signalling Pathways 
As briefly mentioned two prominent pathological mechanisms mediated by serotonin are 
potent vasoconstriction and aberrant proliferation of PASMCs of the small pulmonary 
arteries. It is well recognised that contractile properties of serotonin exist mainly through 
adenylate cyclase activity and ultimately via intracellular Ca
2+
 handling however, the 
intricacies of serotonin mediated downstream signalling regarding proliferation remains 
relatively elusive. The literature supports a role for the mitogen-activated protein kinase 
(MAPK) pathway, generation of ROS and involvement of small G proteins e.g. RhoA and 
Ras amongst others. 
Several studies implicate a critical role for MAPK in the mitogenic effects evoked by 
serotonin. MAPKs are serine/threonine (Ser/Thr) protein kinases meaning they 
phosphorylate the hydroxide (OH) group of the serine or threonine. In total there are 14 
evolutionary conserved MAPKs identified which transmit extracellular stimuli into diverse 
intracellular signalling pathways. Classic MAPK signalling transpires through 
extracellular-signal-regulated kinases 1/2 (ERK1/2), c-Jun amino (N)-terminal kinases 
1/2/3 (JNK1/2/3) and p38.  
Of the conventional MAPK signalling mediators ERK1/2 is the most explored. ERK1 and 
2 were the first MAPK to be cloned and share ~83% homology. Their ubiquitous 
expression confers important fundamental function in various cellular processes. 
Activation of ERK1/2 can occur in response to a plethora of stimuli e.g. growth factors, 
cytokines, activation of cell surface receptors such as receptor tyrosine kinases and 
GPCRs. The ERK1/2 module consists of a series of sequentially acting kinases beginning 
with the small GTP-ase, Ras activating the primary kinase Raf. Activated Raf subsequently 
phosphorylates and activates MAPK kinase (MEK1/2) which finally binds and 
phosphorylates ERK1/2. Upon activation ERK1/2 translocates from the cytoplasm through 
nuclear pores and into the nucleus where it can phosphorylate various transcription factors 
thus controlling transcription of multiple genes e.g. Elk-1, GATA-4 and cyclin D1 and 
mediating a vast range of physiological responses accordingly. Proliferation is a major 
cellular process under regulation of ERK1/2 with ERK1/2 activation required for G1 to S 
phase cell cycle progression. Therefore sustained activation of this signalling cascade 
could trigger aberrant cellular proliferation akin to many diseases e.g. cancer and PAH. 
Indeed Lee and colleagues show that 1µM of serotonin is sufficient to initiate rapid 
phosphorylation and activation of downstream ERK1/2 pathway in PASMCs (Lee et al., 
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2001). This was accompanied by an increase in proliferative response to serotonin which 
could be consequently blocked by not only a MAPKK inhibitor but also the antioxidant 
Tiron thus suggesting the pathway activated by serotonin stimulation is critically involved 
in the formation of ROS and activation of ERK1/2. ERK1/2 mediated proliferation is a 
signalling component downstream of the BMP signalling pathway. In BMPR-II deficiency, 
the loss of anti-proliferative SMAD-mediated signalling leads to unopposed pro-
proliferative ERK1/2 signalling (Yang et al., 2008).    
Another small GTPase activated by serotonin signalling is Rho A. The effector of Rho A in 
PASMCs is Rho kinase (ROCK) which functions to signal the translocation of ERK1/2 to 
the nucleus. Thus again promoting the transcription of proliferative genes e.g. GATA-4 
and cyclin D1. A role for ROCK in pulmonary artery vasoconstriction has also been 
demonstrated as an acute vasodilatory effect in catheterised PH rats was highlighted after 
the administration of the ROCK inhibitor fasudil (Oka et al., 2007). Analysis of the ROCK 
signalling pathway has highlighted ROCK is critical in serotonin mediated SMC 
proliferation as serotonin induced proliferation and subsequent induction of the cyclin D1 
gene was diminished by the ROCK inhibitor Y27632. Y27632 and other ROCK inhibitors 
have been utilised in a number of experimental PH models in vivo where they have shown 
efficacy in reducing PH indices e.g. RVSP, RVH and muscularisation of small pulmonary 
arteries as well as associated ROCK activity (Abe et al., 2004; Abe et al., 2006; Yasuda et 
al., 2011; Chou et al., 2013). In vitro evidence suggests serotonin mediated signalling of 
ROCK occurs through activation of the 5-HT1B receptor as Y27632 was able to inhibit 
ERK1/2 activation through effects of the selective 5-HT1B agonist but not the selective 5-
HT2A agonist (Mair et al., 2008). Likewise the 5-HT1B receptor antagonist GR55562 
blocked the serotonin mediated ROCK activation and induction of the pro-proliferative 
gene cyclin D1 (Liu et al., 2004).        
1.4.3 Serotonin and Pulmonary Arterial Hypertension 
In the 1960’s and 1980’s a subset of patients treated with anorexigenic drugs e.g. aminorex 
and dexfenfluramine (DFEN) developed PAH. The incidence of PAH within this subset of 
patients was 23-fold higher than aged- and sex-matched controls (Abenhaim et al., 1996). 
Anorexigenic drugs function by indirectly acting as serotinergic agonists at the SERT 
causing the efflux of serotonin from platelet stores and preventing its re-uptake thus 
increasing the plasma concentration of “free” serotonin. This PAH “epidemic” 
subsequently led to a plethora of clinical and experimental research implicating the 
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pathogenic role of serotonin in the development of PAH and formed the basis of the term 
coined the “serotonin hypothesis of PAH”. Serotonin can be implicated in PAH disease 
initiation and progression via its synthesis, bioavailability and intracellular signalling and 
therefore can implicate TPH1, SERT and 5-HT receptors respectively. These 5-HT-
candidate genes and their associated processes provide potential therapeutic targets to 
exploit that could interfere with a network of downstream effects having a wide impact on 
disease pathobiology.   
Concerning the cardiovascular system in normal physiology, serotonin is stored in platelets 
owing to low levels of “free” circulating serotonin in plasma. However, in PAH patients 
increased plasma serotonin levels have been documented (Herve et al., 1995). This is 
thought to be partially due to abnormal platelet function which could increase extracellular 
serotonin. Indeed in patients with platelet storage disorders PAH is a risk (Herve et al., 
1990) and experimentally Fawn-hooded rats (which exhibit platelet storage disorder) 
spontaneously develop PH (Sato et al., 1992). Platelet storage disorder in fawn-hooded rats 
is associated with increased SERT expression in lung tissue (Morecroft et al., 2005). 
Additionally, use of selective serotonin re-uptake inhibitors known as SSRI’s in late 
pregnancy are thought to correlate with up to a 6-fold increase in incidence of PPHN 
(Chambers et al., 2006; Kieler et al., 2012; Grigoriadis et al., 2014). PPHN is a severe 
condition which occurs when the resistance in the pulmonary vasculature fails to decrease 
at birth therefore limiting pulmonary blood flow. SSRI’s increase extracellular serotonin 
levels (Ceglia et al., 2004) and have been shown to cross the placental barrier 
accumulating to up to 70% in foetal cord blood (Rampono et al., 2004). Therefore in 
pregnant mothers taking SSRI’s an increase in “free” serotonin could contribute to disease 
pathology in the newborn. In support of this, evidence from experimental PPHN 
demonstrates in vivo infusion of SSRI’s results in a substantial increase in pulmonary 
vascular resistance and reduction in pulmonary blood flow (Delaney et al., 2011). 
Additionally, post-natal examination of foetuses from SSRI dosed rats presented increased 
RVH and pulmonary artery remodelling (Fornaro et al., 2007). This indicates that 
increasing the bioavailability of serotonin, by prohibiting its uptake, may be sufficient to 
trigger detrimental consequences on the pulmonary vasculature. Crucially the potential 
harmful effect of pregnant mothers taking SSRI’s on foetal development of the pulmonary 
circulation is currently unknown. Increased de-novo serotonin synthesis in the pulmonary 
vasculature could also be accountable for heightened “free” serotonin levels. Via the TPH1 
enzyme serotonin synthesis can occur locally within PAECs and act in a paracrine fashion 
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to underlying PASMCs to exert vasoconstrictive and mitogenic properties. TPH1 
expression is augmented in PAECs from IPAH patients in turn increasing the synthesis rate 
of serotonin (Eddahibi et al., 2006). Additional evidence highlighting the importance of 
peripheral serotonin in PAH development stems from TPH1-/- mice. These mice have 
depleted peripheral serotonin and are protected from a hypoxia and DFEN induced PH 
phenotype (Izikki et al., 2007; Morecroft et al., 2007; Dempsie et al., 2008). Moreover 
targeted PAEC knockdown of TPH1 attenuates hypoxia induced PAH in rats supporting 
the critical role local pulmonary serotonin synthesis plays (Morecroft et al., 2012). Chronic 
administration of the non-specific TPH inhibitor, p-chlorophenylalanine (PCPA) or 
LP533401 also reduces a PH phenotype induced by hypoxia or over-expression of SERT 
in SMC (Izikki et al., 2007; Abid et al., 2012).   
Serotonin is considered a chief vasoconstrictor and mitogen within the pulmonary 
circulation and possesses fundamental involvement in increased vascular tone and 
pulmonary artery remodelling in response to a hypoxic environment. This is thought to be 
due to effects mediated by both the 5-HT receptors and SERT. It was originally thought it 
was compulsory for serotonin to be internalised by SERT to evoke mitogenic effects but 
activation of 5-HT1B and 5-HT2A/B receptors also relay proliferative responses. In a rat 
model of hypoxia-induced PH, serotonin exposure enhances the phenotype (Eddahibi et 
al., 1997). Serotonin exhibits contractile responses in all three orders of pulmonary arteries 
within rats i.e. main pulmonary artery, first pulmonary artery branch and pulmonary 
resistance artery. However, serotonin is most potent in the small pulmonary resistance 
arteries (MacLean et al., 1996b). In isolated human pulmonary arteries from PAH patients, 
serotonin augments contractile response (BRINK C., 1988). Exogenous administration of 
serotonin can also uncover a PH phenotype in BMPR2 heterozygous mice (BMPR2
+
/
-
) 
(Long et al., 2006). Here the authors show at baseline BMPR2
+
/
-
 have a similar phenotype 
to wild-type (WT) littermates, however, upon chronic infusion of serotonin the RVSP, 
RVH and pulmonary arterial remodelling is significantly augmented. Additionally, 
pulmonary arteries excised from BMPR2
+
/
-
 mice show enhanced contractile responses to 
serotonin vs. WT and isolated PASMCs exhibit heightened proliferation to serotonin vs. 
WT. This again reiterates BMPR-II mutations do not fully confer disease susceptibility and 
that secondary factors e.g. serotonin are potentially required for disease onset.  
Of the 14 5-HT receptors mainly the 5-HT1B, 5-HT2A and 5-HT2B have been defined with 
regards to PH.  In 1996 the 5-HT1 receptor was identified as the predominant 5-HT 
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receptor mediating 5-HT induced signalling within pulmonary arteries in humans as 5-HT 
and 5-carboxamidotryptamine (5-CT) an unselective 5-HT1 receptor agonist, were 
equipotent at triggering contractile responses. In addition the 5-HT1B/D selective antagonist 
GR55562 inhibited 5-HT induced contractions whereas the 5-HT2A selective antagonist 
ketanserin only inhibited 5-HT induced contractions at non-physiological concentrations 
(MacLean et al., 1996a; Morecroft et al., 1999). In pulmonary arteries the 5-HT1B receptor 
exhibits important roles in vascular contraction and smooth muscle cell proliferation, two 
fundamental contributing characteristics of PAH disease pathogenesis. Specifically, in 
vitro examination has confirmed the 5-HT1B receptor mediates vasoconstriction in isolated 
human pulmonary arteries as the contractile response to the selective 5-HT1B/D agonist 
sumatriptan was inhibited by the 5-HT1B selective receptor antagonist SB224289 and 
unaffected by the 5-HT1D selective antagonist BRL15572 (Morecroft et al., 1999). 
Furthermore, it has been proven that within isolated human PASMCs it is the 5-HT1B 
receptor which partially regulates the calcium binding protein S100A4/Mts1 (MTS1) 
induced proliferation (Lawrie et al., 2005). Accordingly the 5-HT1B receptor is more highly 
expressed in remodelled pulmonary arteries from human PH patients than non-patients 
(Launay et al., 2002). In agreement with this, increased expression of the 5-HT1B receptor 
is observed in experimental models of PAH e.g. fawn-hooded rat model (Morecroft et al., 
2005), hypoxia rat (Heeley R.P., 1998) and piglet shunt-induced PH (Rondelet et al., 2003) 
(Launay et al., 2002). In vivo analysis highlights inactivation of the 5-HT1B receptor by 
either knockdown or receptor antagonism is sufficient to reduce the development of 
hypoxia-induced vascular remodelling, pulmonary artery contraction and overall PAH 
phenotype (Keegan et al., 2001). Proving a critical role for 5-HT1B in hypoxia induced PH 
phenotype.  
Within the pulmonary vasculature the 5-HT2A and 5-HT2B receptors are also localised to 
the PASMCs (Dumitrascu et al., 2011). The 5-HT2A receptor is thought to play a role in 
vasoconstriction of both pulmonary and systemic arteries. Ketanserin, a 5-HT2A selective 
antagonist, has proven successful as a systemic anti-hypertensive therapy (Frishman et al., 
1995) however has displayed insignificance in treating PAH. The unsuccessfulness of 
ketanserin treatment in PAH and the inability for a 5-HT2A selective antagonist to 
distinguish between systemic and pulmonary vasculature has curtailed the attractiveness of 
targeting this receptor subtype in PAH therapy. Nonetheless some experimental animal 
data has presented evidence in support of a role for the 5-HT2A receptor. Respectively the 
5-HT2A receptor is increased and mediates serotonin induced vasoconstriction in a model 
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of PPHN. Ketanserin was able to increase pulmonary blood flow and reduce pulmonary 
vascular resistance in this foetal model further implicating the importance of 5-HT2A 
receptor. Serotonin triggers platelet aggregation which is a pathological trait in PH (Berger 
et al., 2009). This is mediated through the 5-HT2A receptor (Bampalis et al., 2011). 
Additional contribution of the involvement of more than one 5-HT2 receptor in PAH 
emerges as 5-HT2B 
-
/
-
 mice and mice dosed with a 5-HT2B selective antagonist RS-127445 
exhibit a reduced hypoxia induced PH phenotype (Launay et al., 2002). Activity and 
function of the 5-HT2B receptor is also implicated in remodelling processes of pulmonary 
arteries as terguride, a 5-HT2A/B antagonist, diminished proliferation rat PASMCs and 
chronic administration reduced medial wall thickness in the rat monocrotaline model of PH 
(Dumitrascu et al., 2011). Regarding human PAH, increased expression of the 5-HT2B 
receptor was demonstrated in pulmonary arteries from IPAH patients (Dumitrascu et al., 
2011). However, contradictory evidence showing 5-HT2B receptors mediate relaxation in 
pig pulmonary arteries limits the promise of utilising 5-HT2B antagonists in PAH therapy 
(Glusa et al., 2000).   
Higher expression of SERT is recorded in the lungs compared to the brain (Ramamoorthy 
et al., 1993), more specifically SERT is found within PASMCs within the pulmonary 
vasculature (Fanburg et al., 1997; Eddahibi et al., 2001). Upon stimulation with serotonin 
aberrant hyperplasia of PASMCs is demonstrated in cells derived from PAH patients but 
not control patients. This difference is thought to be partly underwritten by an increase in 
SERT expression and activity as proliferation was diminished in the presence of fluoxetine 
and citalopram, two specific SERT inhibitors. Indeed this was the case as lung tissue from 
PAH patients exhibit increased SERT expression where it was predominantly confined to 
PASMCs from muscularised pulmonary arteries (Eddahibi et al., 2001). More specifically 
65% of a small PAH cohort (89 patients) presented homozygous for the l SERT 
polymorphism which corresponded to not only an increase in SERT expression in 
PASMCs but an increase in the PASMCs proliferative response to serotonin and serum 
compared to those with the l/s or s/s polymorphism (Eddahibi et al., 2001). This result 
suggests that the l/l variant of the SERT gene may predispose to PAH or be partially 
involved in pathological processes. However, upon further examination SERT 
polymorphisms were not confirmed in a larger and wider population of PAH patients 
suggesting that the l/l allele may contribute to disease characteristics but may not be 
enough to confer disease susceptibility (Machado et al., 2006b; Willers et al., 2006; 
Baloira et al., 2012).  
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Global over-expression of SERT in mice (SERT+) confers spontaneous development of 
PH in mice aged 5-6 months (MacLean et al., 2004). Pulmonary arterial remodelling and 
RVSP were both increased significantly compared to WT littermates. In agreement with 
this observation, mice over-expressing SERT specifically within smooth muscle cells 
(SM22-5-HTT+) also develop PH although disease is present at 2 months of age in this 
model (Guignabert et al., 2006). Interestingly in both these models the systemic 
haemodynamics are unchanged indicating a pulmonary specific consequence for SERT 
over-expression. Serotonin uptake, via SERT, into platelets was unaffected in the SM22-5-
HTT+ mice indicating physiological effects were specific to SERT over-expression in 
SMCs. Whole blood serotonin levels were not reported in the SERT+ mice therefore it is 
uncertain if increased SERT expression in platelets lead to an increased storage of 
serotonin. Guignabert and colleagues also found the SM22-5-HTT+ mice had markedly 
diminished expression of potassium channels Kv1.5 and Kv2.1 in lung homogenate as a 
direct consequence of the SMC specific SERT over-expression. This reduction in 
potassium channels was restored by treatment with the SSRI’s citalopram and fluoxetine in 
PASMCs (Guignabert et al., 2006). Intriguingly it was subsequently found that only 
female SERT+ mice developed a PH phenotype suggesting interplay with the estrogen 
system (White et al., 2011a). This estrogen-orientated effect was confirmed when a PH 
phenotype was abolished in ovariectomised female SERT+ mice (White et al., 2011a). The 
phenotype was restored upon re-administration of the main circulating oestrogen 17β-
estradiol (E2). In the chronic hypoxic rat model an increase in SERT expression and 
activity is observed within PASMCs (Eddahibi et al., 1999).  
Clinically the therapeutic use of SSRIs in PH patients has shown tentative attenuation of 
PH development and reduction in mortality (Kawut et al., 2006; Shah et al., 2009). This is 
mirrored by experimental data that demonstrates depletion of SERT expression and 
function in either SERT knockout mice or SSRI treated mice reduces a hypoxia induced 
phenotype (Eddahibi et al., 2000; Marcos et al., 2003; Guignabert et al., 2005). SSRI 
treatment is also effective in diminishing monocrotaline induced PH in rats (Guignabert et 
al., 2005). The therapeutic effect of SERT inhibition is in complete contrast to the maternal 
use of SSRI’s resulting in PPHN as discussed earlier. Ultimately the main difference is 
adult vs. foetal exposure of SSRI’s on the pulmonary vasculature. This highlights divergent 
effects of SSRI’s could be due to differences in the pharmacology of the developing 
pulmonary vasculature compared to the mature pulmonary vasculature. Indeed this was 
demonstrated by in vitro analysis of pulmonary arteries from adult and foetal rats (Fornaro 
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et al., 2007). The SSRI fluoxetine generated increased pulmonary artery contraction and 
remodelling in foetal pulmonary arteries and not adult. Other clinical studies have however 
re-iterated harmful effects of SSRIs as reports show an association with SSRI use and 
increased mortality and disease worsening in PAH patients (Sadoughi et al., 2013). On the 
whole this provides convincing evidence implicating a fundamental role for SERT’s 
involvement in pathological hallmarks of PAH development.    
1.5 The Influence of Sex on Pulmonary Arterial Hypertension 
Mostly all classifications of PH including PAH exhibit an enhanced female susceptibility 
with their being up to 4 female patients for every one male patient (Rich et al., 1987b; 
Humbert et al., 2006; Badesch et al., 2010; Ling et al., 2012). This increased female to 
male ratio in PAH prevalence strongly suggests there is an influence of sex in the 
development of PAH. Dresdale noted an increase in frequency of female patients as early 
as the 1950s (Dresdale et al., 1951) yet to date there are still no PAH treatments that 
incorporate this factor. To add to the complexity female PAH patients appear to survive 
longer than males and tend to develop PAH to a lesser degree than males (Humbert et al., 
2010a; Humbert et al., 2010b). Elucidating explanation for these differences is the focus of 
much current PAH research. One fundamental difference between females and males is the 
presence or absence of specific sex hormones. Experimentally some animal models mirror 
the sex bias in PAH. In some models of PH the female sex hormone estrogen is thought to 
be protective (Lahm et al., 2012) whereas other models show it to be causative i.e. the 
hypoxic model produces a more severe phenotype in males but the SERT+ model exhibits 
female susceptibility (Rabinovitch et al., 1981; White et al., 2011a). Altogether this 
conflicting role of estrogen in PAH prevalence and development led to the concept of the 
“estrogen paradox”.  
1.5.1 Estrogen Biosynthesis and Metabolism 
Estrogens are the primary female sex hormone functioning considerably in development 
and maintenance of the female reproductive system. In recent years evidence has 
demonstrated a significant role for estrogens in other systems including the cardiovascular 
system (Knowlton et al., 2012). Estrogens are mainly synthesised in the ovaries in females 
and to a lesser extent the testis in males. Under neural control estrogens are secreted from 
the sex organs as a result of activation of the hypothalamic-pituitary-gonadal (HPG) axis. 
Estrogens are a collective of steroid molecules consisting of estrone (E1), 17β-estradiol 
(E2) and estriol (E3). Within pre-menopausal females E2 is perceived as the most potent 
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estrogen and therefore considered the principle circulating estrogen. E1 is considered 
important after the menopause and E3 is fundamental in maintaining a healthy uterine 
lining during pregnancy (Khosla et al., 1997; Stricker et al., 2006). 
As estrogens are steroid molecules their ultimate precursor molecule is cholesterol. 
Cholesterol is a lipid molecule present in every cell however it will only participate in the 
steroidogenesis pathway depending on the bioavailability of specific enzymes and/or 
control from the HPG axis. Therefore estrogen synthesis is limited to specific areas within 
the body. As previously mentioned estrogen biosynthesis primarily occurs within the 
ovarian follicles however, secondary extra-gonadal sites are also recognised e.g. breast 
tissue, adipose cells and liver (Labrie et al., 1998; Simpson et al., 2001). Additionally local 
estrogen synthesis has been highlighted in both ECs and SMCs of the systemic and 
pulmonary vasculature implicating a fundamental role in vascular homeostasis (Harada et 
al., 1999; Sasano et al., 1999; Mukherjee et al., 2002). The majority of gonadal derived 
estrogens are released into the bloodstream acting in an endocrine manner however extra-
gonadal derived estrogens are thought to act at the site of synthesis in a paracrine manner 
(Labrie et al., 1998). Pregnenolone is converted from cholesterol by the cytochrome P450 
(CYP) 11A1 enzyme, which is subsequently converted to progesterone by 3β- 
hydroxysteroid dehydrogenase (HSD) before being hydroxylased and lyased by CYP17A1 
to form androstenedione. Androstenedione has the ability to produce E2 through using 
either testosterone or E1 as intermediates (Figure 1.5). The CYP19A1 enzyme (aromatase) 
is crucial in both intermediate pathways in production of E2.  
The aromatase gene is present in gonadal and extra-gonadal tissues with its site-specific 
transcription being driven by different signalling pathways at alternative sites in the 
promoter region. For example in gonadal tissue aromatase gene expression is controlled by 
follicle stimulating hormone (FSH) and cAMP associated signalling at the proximal 
promoter (Jenkins et al., 1993) whereas in adipose tissue aromatase gene expression is 
controlled by glucocorticoids and the Janus kinase/signal transducers and activators of 
transcription (Jak/STAT) pathway at the distal promoter (Zhao et al., 1995). Over-
expression of the aromatase gene has been associated with a number of estrogen-positive 
diseases including breast cancer and endometriosis (Noble et al., 1996; Harada, 1997). 
Inhibition of the aromatase enzyme by anastrozole has shown great promise in breast 
cancer patients and is now widely recognised for use in the clinic (Arimidex et al., 2008). 
Most aromatase inhibitors act in a global manner thus can affect normal aromatase 
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function such as maintenance of bone growth (Sasano et al., 1997). It is of interest then to 
modulate aromatase expression in a targeted therapy approach. Specifically the distinct 
tissue specific promoters of the aromatase gene could potentially be exploited to target a 
tissue of interest to alter the expression of aromatase and minimise side effects.  
Expression of aromatase has also been defined within lung tissue giving rise to the 
presence of a local pulmonary vasculature estrogen microenvironment. In non-small cell 
lung cancer (NSCLC) patients, aromatase expression is increased within NSCLC cells 
(Marquez-Garban et al., 2009) and has the ability to predict survival in females with 
NSCLC (Mah et al., 2007). These findings implicate a pathological role for aromatase 
expression and also increased E2 levels in the lung. In addition, a single nucleotide 
polymorphism (SNP) in the aromatase gene has been identified in patients with 
portopulmonary hypertension (PPHTN) (Roberts et al., 2009). The SNP identified in 
PPHTN also correlated with increased plasma levels of E2 further associating a role for 
aromatase and E2 levels in disease. Currently an ongoing phase II clinical trial is 
examining the safety and efficacy of the aromatase inhibitor, anastrozole, in PAH where 
data will be documented on the ability to reduce E2 levels and the effect on right ventricle 
function (ClinicalTrials.gov Identifier: NCT01545336).   
Elimination of estrogens from the body occurs initially via oxidative metabolism. The 
majority of this metabolism exists within the liver and involves a cohort of CYP enzymes. 
The conversion of estrogens to less active water soluble metabolites allows for their 
excretion by the kidneys within the urine. Just as the synthesis of estrogens, extra-hepatic 
regions of metabolism have been identified including breast tissue, brain, lung and 
vasculature. These regions are most likely to correlate with the areas of synthesis (co-
localisation) suggesting that it may not just be estrogens eliciting effect but also their 
metabolites could act as local signalling mediators.  
CYP1A1, CYP1A2 and CYP3A4 are predominantly involved in the metabolism of E2 to 
2-Hydroxyestradiol (2-OHE2) whereas CYP1B1 favours metabolism of E2 to 4-
Hydroxyestradiol (4-OHE2) (Lee et al., 2003a). Additional CYP enzymes involved in the 
metabolism of E2 lead to the formation of further hydroxylated metabolites including 6α, 
6β, 7α, 12β, 15α, 15β, 16α and 16β. CYP enzymes involved in E2 metabolism have region 
selective expression therefore expression of metabolites can vary between areas in the 
body. For example, breast tissue expresses high quantities of CYP1B1 promoting the 
predominant formation of 4-OHE2 (Wen et al., 2007). Increased expression of CYP1B1 is 
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positively correlated with breast cancer suggesting 4-OHE2 mediates malignant processes 
(Wen et al., 2007). Indeed 4-OHE2 has been shown to produce free radicals that can lead 
to DNA damage and is thought to be a more potent mitogen than E2 itself (Nutter et al., 
1991; Mosli et al., 2013). Tobacco smoke has shown to increase CYP1B1 and its E2 
derived metabolites within the lung and expression is more prominent in females than 
males (Peng et al., 2013).  In addition, CYP1B1 expression is localised in smooth muscle 
cells and endothelial cells of the vasculature indicating a role in vascular homeostasis 
(Kerzee et al., 2001; Conway et al., 2009). In a regulatory feedback mechanism, E2 can 
promote its own breakdown by driving the transcription of the human CYP1B1 gene via an 
estrogen response element in the promoter region (Tsuchiya et al., 2005). Gain-of-function 
polymorphisms within the human CYP1B1 gene have been identified in and contribute to 
the development of estrogens-positive cancers (Bailey et al., 1998; Hanna et al., 2000). 
Therefore, inhibition of CYP1B1 has potential therapeutic value in estrogen associated 
cancers. Further metabolism of 2-OHE2 and 4-OHE2 can occur via catechol-O-
methyltransferase (COMT) enzyme activity to produce 2- and 4-methoxyestradiol 
respectively. This detoxification action is thought to act beneficially by preventing the 
formation and action of pathological free radicals from the hydroxyestradiols (Salama et 
al., 2008).  
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Figure 1-5 Estrogen synthesis and metabolism pathway 
Cholesterol is converted to androstenedione via the CYP11A1, 3β-HSD and CYP17A1 
enzymes. From androstenedione, 17β-estradiol can be converted via either estrone or 
testosterone by the 17β-HSD and CYP19A1 enzymes. 17β-estradiol can be metabolised to 
either 2-, 4- or 16-hydroxyestradiol via a variety of CYP enzymes including CYP1B1. The 
2- and the 4-hydroxyestradiols can be further metabolised to 2- and 4-methoxyestradiol 
respectively by the COMT enzyme. CYP= cytochrome P450, HSD= hydroxysteroid 
dehydrogenase, COMT= catechol-O-methyltransferase.  
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1.5.2 Estrogen Signalling 
Estrogens were once solely thought of as hormone regulators of reproductive function 
signalling only within the endocrine system. However, a greater understanding has 
highlighted their wider physiological role. The recognition of extra-gonadal synthesis re-
defined the importance of paracrine estrogen signalling within further biological systems, 
including the cardiovascular. As steroid molecules, estrogens are lipophilic and can easily 
enter into the cell’s cytosol via diffusion to mediate their effector response. Intracellular 
estrogens mediate their response through both direct and indirect genomic signalling. 
Genomic estrogen signalling involves the activation of nuclear receptors estrogen receptor-
α (ERα) and estrogen receptor-β (ERβ). In addition, estrogens also exhibit rapid signalling 
which suggests their involvement in non-genomic signalling i.e. receptor mediated 
signalling cascade. This is strengthened by effects observed from estrogens in non-
nucleated cells (Moro et al., 2005). Thus membrane bound estrogen receptors were 
identified. Evidence suggests ERα and ERβ can additionally act as membrane bound 
receptors but there is also recognition for a third estrogen receptor named G protein-
coupled estrogen receptor 1 (GPER).   
1.5.2.1 Nuclear estrogen receptor signalling 
ERα and ERβ are encoded by the ESR1 and ESR2 genes respectively and are regarded as 
ligand-activated transcription factors. Located within the cytoplasm ligand binding 
promotes receptor dimerisation and mobilisation. Classical direct signalling involves 
translocation of the receptors to the nucleus where they are able to modulate gene 
transcription through binding to estrogen-response-elements (EREs) within the promoter 
region of multiple target genes. Therefore their activation can exert a multitude of effects. 
Most nuclear receptors share structural commonality with an N-terminal domain, a core 
DNA binding domain, a hinge region, a ligand binding domain and a C-terminal domain. 
The N-terminal domain exhibits the main heterogeneity within the receptor family and 
harbours the activation function 1 (AF1) site. The AF1 site binds other transcription factors 
that can act as either co-activators or co-repressors thus regulate the activity of the receptor 
and consequently affect the transcription function. The core DNA binding domain is the 
most highly conserved region and is responsible for recognising and binding to the ERE on 
the target gene.  The hinge region is important in receptor dimerisation and the ligand 
binding domain contains a highly conserved activation function 2 (AF2) site fundamental 
for activation by the specific estrogen ligand. The ligand binding domain also harbours 
sites for heat shock protein (HSP) binding which aids with the process of nuclear 
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translocation in a chaperone manner. The EREs can either be positive or negative and 
enhance or repress gene transcription respectively. For example, recruitment of the co-
regulator p300 to the transcription complex of ERα (not ERβ) results in activation of gene 
transcription (Hanstein et al., 1996), whereas recruitment of short heterodimer partner 
(SHP) leads to inhibition of ERα and ERβ mediated transcription (Johansson et al., 1999). 
The milieu of co-regulators can vary between cell types and ERα and ERβ can tether 
different co-regulators (Misiti et al., 1998; Suen et al., 1998). Thus cell type and receptor 
expression will coordinate different co-regulators and impact on the ability to either 
activate or repress distinct gene transcription. Consequently, this alters translation of 
proteins and ultimately the fate of the cell therefore allows both receptors to exhibit 
divergent effects within the same cell type i.e. in ovarian cancer cells ERα mediates 
proliferative effects of E2 whereas ERβ mediates anti-proliferative effects of E2 (Chan et 
al., 2014). ERs can additionally function in genomic signalling indirectly through 
alternatively interacting with other transcription factors. For example, the cyclin-D1 gene 
and GATA-1 gene contain no ERE however E2 is thought to modulate their expression 
through interaction with cAMP response element (CRE) and direct protein-protein contact 
respectively (Blobel et al., 1995; Sabbah et al., 1999). 
1.5.2.2 Membrane estrogen receptor signalling 
The discovery of an acute E2 mediated effector response indicated there was participation 
of ERs not involved in transcriptional processes. Transcriptional effects are normally 
initiated after a period of time thus the rapid non-genomic effects of E2 have been 
delineated. In addition to their cytoplasmic localisation ERα and ERβ are also known to be 
expressed on the cell membrane. Here they are recognised to engage in downstream 
signalling cascades including ERK/MAPK (Filardo et al., 2000), PI3K and cAMP 
pathways. Furthermore a new membrane bound ER was identified in 2005 termed G 
protein-coupled estrogen receptor 1 (GPER) (Filardo et al., 2000; Filardo et al., 2005). 
GPER is a heptahelical GPCR and is coupled to the G proteins Gs (Filardo et al., 2002) 
and Gi/0 (Broselid et al., 2014). GPER activation stimulates and inhibits adenylyl cyclase 
via the Gs and Gi protein respectively therefore regulates intracellular cAMP levels and in 
turn cAMP can mediate ERK activity (Filardo et al., 2000; Filardo et al., 2002). As well as 
mediating rapid and transient effects of E2, GPER is additionally involved in the 
transcription of genes independently of binding EREs. For example, evidence shows 
stimulation by the selective GPER agonist G-1 up-regulates the expression of c-fos in 
ovarian cancer cells (Albanito et al., 2007). The distribution of GPER is vast with 
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expression identified in the stomach, adrenal gland, spinal cord, heart, lung and kidney 
tissue (Otto et al., 2009). At a cellular level GPER has been identified in smooth muscle 
and endothelial cells within the vasculature (Lindsey et al., 2011). Along with ERα and 
ERβ, evidence demonstrates a pathological role for GPER in malignancies such as lung 
cancer (Jala et al., 2012). A carcinogenic role for GPER is attributed to the highly 
proliferative effects mediated by E2 (Albanito et al., 2007).  
1.5.2.3 Estrogen Signalling within the Cardiovascular System 
Within the cardiovascular system ERs are expressed in both cardiac tissue and vascular 
beds and thought to mediate protective control from multiple cardiovascular pathologies.  
This is in complete contrast to specific cancers where E2 mediated affects through ERs are 
highly pathologic. It is well recognised that pre-menopausal women are at less risk from 
cardiovascular disease (CVD) compared to men suggesting a fundamental protective role 
for E2 and ERs signalling (Maas et al., 2010). This is strengthened by evidence 
highlighting women are more at risk of CVD following the menopause when E2 levels 
substantially decline (Hu et al., 1999). ERα, ERβ and GPER are present within 
cardiomyocytes and cardiac fibroblasts (Grohe et al., 1997; Deschamps et al., 2009) and 
function to control the expression of cardiac-related genes i.e. L-type Ca
2+
 channel, K
+
 
channels (Drici et al., 1996; Johnson et al., 1997). Transgenic mice over-expressing ERα 
specifically within cardiomyocytes are protected against pathological cardiac remodelling 
post myocardial infarction (MI). This protective effect is partly mediated by ERα inducing 
the expression of VEGF gene and promoting angiogenesis (Mahmoodzadeh et al., 2014). 
In agreement with this ERα is increased in human hearts from patients with dilated 
cardiomyopathy in a bid to compensate the loss of normal cardiac function 
(Mahmoodzadeh et al., 2006). Further cardio-protective effects of E2 are mediated through 
ERβ. Pedram and colleagues demonstrated ERβ activation inhibited synthesis of key 
proteins e.g. collagen and fibronectin involved in fibrosis and prevented hypertrophic 
phenotype in angiotensin-II (ANG-II) treated cardiac fibroblasts (Pedram et al., 2008; 
Pedram et al., 2010). In addition, ERβ-/- mice have heightened cardiac fibrosis and 
hypertrophy compared to WT mice conferring a protective cardiac role for ERβ (Fliegner 
et al., 2010). GPER also participates in protective cardiac mechanisms as the GPER 
selective agonist G-1 reduces cardiac contractile dysfunction post-ischemia in ex vivo 
mouse heart preparations (Deschamps et al., 2009).   
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E2 signalling through ERs is also considered beneficial within the vasculature. ERs are 
located within both ECs and SMCs of the systemic and pulmonary vasculature (Karas et 
al., 1994; Venkov et al., 1996; Register et al., 1998; Hodges et al., 2000; Wright et al., 
2015). E2 has shown to promote the release of the potent vasodilators NO and prostacyclin 
through up-regulation of eNOS and PGIS genes in systemic arterial endothelial cells 
(Hishikawa et al., 1995; Mikkola et al., 1995; Ospina et al., 2002). In addition, E2 exerts a 
protective role in atherosclerosis by elevating apolipoprotein-E (APO-E) via ERα 
(Srivastava et al., 1997). A further athero-protective function for ERα has been described 
in a mouse model of vascular injury. Here the authors highlighted E2 reduced proliferation 
of vascular SMCs and medial thickening in a model of vascular injury but this effect from 
E2 was abolished in ERα knockout (KO) mice implicating protective mechanisms are 
mediated via ERα (Pare et al., 2002). ERβ signalling has been shown to be more potent at 
mediating the inhibitory action of E2 on vascular smooth muscle cell (VSMC) proliferation 
than ERα. Watanabe and colleagues demonstrated that VSMCs over-expressing ERβ were 
more capable than those over-expressing ERα to inhibit VSMC proliferation as a result of 
E2 stimulation (Watanabe et al., 2003). ERβ-/- mice develop age-dependent systemic 
hypertension indicating ERβ may play an additional role in vasodilation of systemic 
arteries (Zhu et al., 2002). Indeed a vasodilatory function of ERβ has been documented as 
rapid E2 induction of vasodilation in carotid and femoral arteries is abolished in ERβ-/- 
mice (Guo et al., 2005). This relaxation effect of E2 was also absent in ERα-/- mice 
showing a fundamental role for both receptors. The rapid response observed from E2 
suggests that membrane bound ERα and ERβ were responsible for mediating vasodilation. 
Inhibition of ERK/MAP kinase and PI3K also attenuated the E2 induced vasodilation 
implicating the membrane bound ERs were modulating the rapid effects through kinase 
pathways (Guo et al., 2005). Activation of the membrane bound GPER is thought to 
trigger rapid vasodilation through nitric oxide dependent mechanisms (Meyer et al., 2010). 
The involvement of GPER in the regulation of vascular tone is also emphasised by data 
highlighting vasodilation evoked from G-1 is absent in GPER knockout mice (Haas et al., 
2009). Consistent with this female GPER knockout mice develop age-dependent systemic 
hypertension due to increased peripheral vascular resistance (Martensson et al., 2009).  
It is evident that within the cardiovascular system E2 promotes favourable physiological 
conditions with regards to anti-hypertrophic, anti-fibrotic, anti-proliferation and 
vasodilation. However, E2 does exhibit potential pathological qualities. Patients receiving 
hormone replacement therapy (HRT) with E2 show elevations in plasma prothrombotic 
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fragment 1 and 2 (F1 and F2) indicative of coagulation activity suggesting estrogen has 
prothrombotic properties (Teede et al., 2000). Thrombosis is a major risk factor for many 
CVD (Kannel et al., 1987) and also is the cause of the PH classification chronic 
thromboembolic pulmonary hypertension (CTEPH) (Jenkins et al., 2012). This in 
conjunction with the detrimental effects of excessive E2 in estrogen-related cancers 
conveys that effects mediated by E2 signalling must be regarded with caution.         
1.5.3 Estrogen Pathway and Pulmonary Arterial Hypertension 
As previously, mentioned females have a higher prevalence of PAH compared to males 
and therefore sex represents a major risk factor in PAH development. Regarding this, 
extensive PAH research has examined the pathways and interactions of the main female 
pre-menopausal estrogen, E2.  Within the pulmonary circulation and more specifically 
regarding PAH, E2 presents a complex and ambiguous role. As a predominantly female 
hormone, E2 is assumed detrimental in generating the high prevalence of female PAH 
patients. In agreement with this, heightened exposure to exogenous E2 through both use of 
oral contraceptives and HRT is associated with PAH (Masi, 1976; Morse et al., 1999). On 
the contrary, there is evidence to suggest HRT can prevent the development of PH in 
patients with systemic sclerosis (Beretta et al., 2006). Elevated endogenous levels of E2 
can occur through increasing the estrogen biosynthesis pathway. The bioavailability of the 
enzyme aromatase is a major factor in E2 synthesis. Increased expression of aromatase is 
observed in both the clinical and experimental setting of PH. For example, patients with 
PPHTN present with an SNP in the aromatase gene which is associated with increased 
plasma levels of E2 (Roberts et al., 2009). However the expression of aromatase is 
unchanged in female patient vs. female non-patient isolated PASMCs (Mair et al., 2014). 
Although this is not to suggest that the activity of aromatase is also unchanged and 
warrants further investigation. Aromatase expression is increased in the hypoxic mouse 
and SU-HX rat models of PH which also exhibit correlating increases in E2 levels. Indeed, 
in the SU-HX rat model E2 levels positively correlated with disease severity including 
RVH and muscularisation of pulmonary arteries indicating a pathogenic role for E2 (Mair 
et al., 2014). Within the pulmonary circulation E2 is highly mitogenic causing 
concentration dependent increases in proliferation of PASMCs (White et al., 2011a). This 
estrogenic effect is unique to E2 as other estrogens E1 and E3 do not evoke a proliferative 
response in PASMCs (White et al., 2011a). Endogenous E2 plays a role in several female 
susceptible PH models including SERT+ and DFEN as ovariectomy of these animals 
demonstrates a reversal and prevention of a PH phenotype (White et al., 2011a; Dempsie et 
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al., 2013). As these models demonstrate female susceptibility their findings are perhaps 
more clinically relevant. In addition, E2 is involved in up-regulation of several genes 
including TPH1, SERT and 5-HT1B in PASMCs which are known mediators of PAH 
pathogenesis (White et al., 2011a). Inhibition of E2 synthesis appears an attractive 
therapeutic target to combat the detrimental effects of E2 within the pulmonary circulation. 
Indeed an inhibitor of the aromatase enzyme, anastrozole, is able to reverse the PH 
phenotype established in hypoxic mouse and SU-HX rat models. Intriguingly the beneficial 
effect from anastrozole treatment was only observed in female mice and rats (Mair et al., 
2014). In agreement with this, ovariectomy of female SU-HX rats alleviates high RVSP 
present within this model (Tofovic et al., 2013).    
Conflicting views surrounding the effects modulated by E2 are strengthened by data which 
demonstrates E2 treatment can attenuate increases in RVSP, RVH and pulmonary arterial 
remodelling in male rats from chronic hypoxic models of PH (Lahm et al., 2008). In 
addition, ovariectomy increases the disease severity in monocrotaline (MCT) rat model and 
administration of E2 can rescue an established PH phenotype in MCT treated rats 
promoting the protective effects of E2 (Ahn et al., 2003; Umar et al., 2011). The 
controversial role surrounding E2 has complicated the understanding of its function in 
PAH.  
Regarding ERs in PAH, Rajkumar and colleagues demonstrated increased expression of 
ERα in lungs of female PAH patients compared to female non-patients (Rajkumar et al., 
2010). Consistent with this, ERα expression is increased in pulmonary arteries from 
hypoxic female mice compared to normoxic however there are no observed changes in 
male tissue (Mair et al., 2014). Interestingly, evidence shows an ERα binding site in the 
promoter region of the BMPR-II gene and ERα activation can decrease the expression of 
BMPR2 and its downstream signalling pathway (Austin et al., 2012). As BMPR-II is a 
fundamental aspect of PAH pathogenesis, down-regulation by E2 stimulation may 
contribute to disease development in females. In addition, inhibition of ERα prevents the 
development of a hypoxic phenotype in female mice (Mair et al., 2014) further implicating 
the unfavourable nature of ERα signalling in PAH. ERβ is found to be decreased within 
pulmonary arteries from hypoxic female mice compared to normoxic controls suggesting 
the loss of this receptor may be involved in disease processes (Mair et al., 2014). Indeed, a 
reduction of ERβ is also observed within lung and right ventricle tissue from MCT rat 
model of PH (Matori et al., 2012). This is in line with the inability of E2 to rescue MCT 
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induced PH in the presence of an ERβ antagonist (Umar et al., 2011). Altogether this 
evidence suggests that E2 may exert detrimental effects through ERα and mediate 
beneficial/protective effects through ERβ. Therefore the divergent effects mediated by E2 
and its complex function in PAH may be dependent on receptor distribution and 
expression.  
Data suggests that it might not be E2 per se initiating detrimental effects in the onset and 
development of PAH. As E2 is rapidly metabolised, it may be the pool of metabolites 
which independently influence PAH pathogenesis. As discussed earlier, E2 can be 
metabolised to toxic and non-toxic metabolites by a variety of CYP enzymes. Evidence 
suggests the major E2 metabolising enzyme CYP1B1 is pathologically associated with 
PAH as increased expression is observed in PASMCs from IPAH patients and also 
pulmonary arteries from SERT+ mice, hypoxic mice and SU-HX rats (White et al., 2011b; 
White et al., 2012). Recent data shows inhibition of CYP1B1 reduces and reverses the PH 
phenotype in hypoxic and SU-HX models respectively (White et al., 2012). Furthermore, 
CYP1B1
-
/
-
 mice produce a less severe PH phenotype after exposure to hypoxia compared 
to WT mice (White et al., 2012). CYP1B1 mediated metabolism of E2 favours the 
production of 4-OHE2 but can also be involved in the metabolism to 2-OHE2 and 16α-
OHE1 to a lesser extent (Lee et al., 2003a). 16α-OHE1 is a potent mitogen in human 
PASMCs and levels are increased by hypoxia whereas 2-OHE2 and 4-OHE2 do not initiate 
proliferation (White et al., 2012). In fact 2-OHE2 promotes cell cycle arrest and causes a 
decrease in proliferation within endometrial cancer cells (Gong et al., 2011). Regarding the 
pulmonary vasculature, administration of 2-OHE2 reduced the PH phenotype induced by 
MCT rats (Tofovic et al., 2005). When administered in vivo the proliferative metabolite 
16αOHE1 can produce increases in RVSP, RVH and remodelling of pulmonary arteries 
consistent with PH (White et al., 2012). In addition, HPAH patients exhibit a lower ratio of 
2-OHE1/16α-OHE1 suggesting preferential metabolism to the proliferative metabolite 
16α-OHE1 is associated with disease pathogenesis (Austin et al., 2009a). Altogether, the 
diversity of metabolites produced could create either a pro- or anti-proliferative 
environment within the pulmonary vasculature and ultimately influence the disease 
manifestation. 
1.6 microRNAs 
Around 75% of the human genome is transcribed however only 2% actually encodes 
protein sequences (International Human Genome Sequencing, 2004; Djebali et al., 2012). 
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Thus there is a proportion of non-coding ribonucleic acid (ncRNA) within our cells. 
ncRNA was once thought to serve no functional purpose as it did not contribute to the 
proteome. However research over the past decades has led to an understanding that the 
large quantity of ncRNA is responsible for complex and critical shaping of gene networks 
and can ultimately govern the cellular fate (Santosh et al., 2015). Therefore the repertoire 
of ncRNAs is implicated in biological processes concerned not only in health but also 
disease. The nomenclature of ncRNAs is deciphered either from their known function i.e. 
transfer RNA (tRNA) or nucleotide length i.e. microRNA (miRNA) and long non-coding 
RNA (lncRNA).   
The first miRNA was first discovered in 1993 by the Ambrose and Ruvkun laboratory (Lee 
et al., 1993; Wightman et al., 1993). Then termed “lin-4” the ncRNA was identified in 
caenorhabditis elegans with its temporal expression found to negatively correlate the 
expression of the LIN-14 protein. By definition miRNAs can direct the expression of genes 
in a post-transcriptional manner through either degradation of target mRNA or silencing of 
mRNA translation. Following this, almost 2000 miRNAs have since been identified in 
humans (www.mirbase.org 2014) and their regulatory ability empowers them in cellular 
responses and thus wider physiological consequences.  
1.6.1 The Biogenesis of MicroRNAs 
Genes encoding miRNAs can be located either in intronic, exonic or intergenic regions. 
Intergenic miRNAs have their own promoter site whereas intronic miRNAs are encoded 
within the intron regions of a host gene transcript therefore can be coupled to the same 
transcription start site and transcribed simultaneously with the host gene before being 
spliced. Most miRNAs exist exclusively in a single gene, however, multiple miRNAs can 
arise from a single gene also i.e. exist in a cluster. 36% of miRNAs are found in clusters 
within the human genome (Griffiths-Jones et al., 2008). For a miRNA to be categorised 
into a cluster it must be located within 10 kilobases (kb) from another miRNA or arise 
from a polycistronic primary miRNA transcript. Typically miRNAs within a cluster are not 
only expressed in close proximity of each other but also can be simultaneously expressed 
i.e. during a developmental stage, can regulate the same mRNA or multiple mRNA 
involved within a close biological network/pathway.  
In the canonical pathway miRNAs are synthesised and processed through a series of 
cleavage steps (Figure 1.6). Firstly, within the nucleus large primary miRNA (pri-miRNA) 
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transcripts ~2kb in length are generated via activity of the RNA polymerase II enzyme 
initiating transcription at an upstream promoter site. Pri-miRNAs consist of a double 
stranded hairpin loop with long single stranded sequences at both 5’ and 3’ end. The 5’ end 
harbours a 7-methylguanosine cap and the 3’ end a polyadenylated tail (Cai et al., 2004). 
For authentic pri-miRNAs to be distinguished from other hairpin loop RNAs in humans 
they contain specific basal stem motif elements i.e. UG and CNNC motifs (Auyeung et al., 
2013). This enables them to be recognised and cleaved by a nuclear RNase III superfamily 
enzyme called Drosha and ensure efficient processing (Lee et al., 2003b). This cleavage 
step directs the formation of a ~80 nucleotide (nt) hairpin loop structure with a 2 nt 
overhang at the 3’ end and is named the precursor miRNA (pre-miRNA). In addition, in 
humans the co-factor DiGeorge syndrome critical region gene 8 (DGCR8) is required to 
work in conjunction with Drosha. The Drosha-DGCR8 complex termed the 
microprocessor is crucial for this cleavage step as genetic silencing of Drosha or DGCR8 
can curtail this initial processing stage with downstream consequences evident by the 
reduction in pre-miRNA and mature miRNA (Lee et al., 2003b; Landthaler et al., 2004). 
Pre-miRNAs are then transported out of the nucleus and into the cytoplasm by Exportin 5 
(Exp5) (Yi et al., 2003). Exp5 is a nucleocytoplasmic transport factor which is dependent 
on Ran-GTP. Once in the cytoplasm the long double-stranded RNA (dsRNA) pre-miRNA 
binds to the RNA-binding domain on a cytoplasmic RNase III superfamily enzyme named 
Dicer and undergoes further cleavage to form the 22 nt mature miRNA sequence 
(Bernstein et al., 2001). Analysis of the structure of Dicer by MacRae and colleagues 
revealed the length between the RNA-binding domain and the catalytic domain was 
respectfully ~22 nts in length thus Dicer acts as a molecular ruler ensuring the correct size 
of mature miRNAs are generated (Macrae et al., 2006). As with Drosha, the importance of 
Dicer’s involvement in miRNA processing is highlighted by the effects evident upon 
silencing it. Preventing the function of Dicer through either small interfering RNA 
(siRNA) (Grishok et al., 2001) or mutation (Ketting et al., 2001), leads to accumulation of 
the 80 nt pre-miRNA and reduction in formation of the 22 nt mature miRNA. This 
demonstrates cleavage by Dicer is a fundamental step in miRNA processing. Similarly to 
Drosha, functioning Dicer activity in humans requires the co-factors transactivating 
response dsRNA-binding protein (TRBP) and protein activator of PKR (PACT) 
(Chendrimada et al., 2005; Lee et al., 2006). Cleavage activity by Dicer removes the loop 
region of the pre-miRNA and forms an intermediate miRNA duplex containing the mature 
and the passenger or antisense miRNA. The two strands are also termed 5p or 3p to denote 
the 5’ or 3’ origin respectively. The miRNA duplex is subsequently bound with argonaute 
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2 (Ago2) and becomes part of the RNA-induced silencing complex (RISC) (Hammond et 
al., 2001). Ago 2 is a member of the argonaute protein family which specialise in small 
RNA guided gene regulation. In vitro knockdown of Ago2 prevents miRNA guided 
mRNA cleavage (Meister et al., 2004). Upon binding with the miRNA duplex, Ago2 
initiates the duplex to unwind leaving two separate miRNA strands (Kwak et al., 2012). 
The selection between the two strands for mature or passenger strand is dictated by which 
strand has the lowest thermodynamic stability at the 5’ end (Khvorova et al., 2003; 
Schwarz et al., 2003). It is generally thought that only the mature miRNA is preferentially 
retained within RISC and acquires function while the passenger strand is degraded. 
However evidence suggests prominent roles can exist for the passenger strand also 
(Okamura et al., 2008; Yang et al., 2011a). The mature miRNA still bound to Ago2 and 
encompassed within RISC is now able to facilitate in post-transcriptional regulation of 
mRNA.   
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Figure 1-6 Biosynthesis of microRNAs 
Primary miRNA (pri-miRNA) transcripts are processed by the RNase III superfamily 
enzyme DROSHA in the nucleus to form a ~80 nucleotide precursor miRNA (pre-
miRNA). Pre-miRNAs are then exported out of the nucleus and into the cytoplasm by the 
nucleocytoplasmic transport factor Exportin 5. The pre-miRNA undergoes further cleavage 
by the cytoplasmic RNase III superfamily enzyme Dicer to generate a miRNA duplex 
containing the ~22 nucleotide mature miRNA and passenger strand. The mature miRNA is 
incorporated into RISC where it can now facilitate in post-transcriptional regulation of 
mRNA i.e. repression of mRNA translation or degradation of mRNA.  
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1.6.2 The Function of MicroRNAs 
The RISC complex utilises the mature miRNA to direct the Ago2 protein to the target 
mRNA strand. Ago2 is responsible for the endonuclease activity and is a requirement for 
mediating mRNA cleavage (Meister et al., 2004). The 5’ end of miRNAs contain a seed 
sequence at nt 2-8 which follow base pair complementation with the 3’ untranslated region 
(UTR) of mRNA (Lewis et al., 2003). Most miRNA seed sequences are generally well 
conserved depicting fundamental biological importance. The basis of miRNA-mRNA 
complementation has allowed in silico predictive programmes to generate an abundance of 
putative miRNA targets. Evidence shows miRNAs are not limited/confined to “seed 
match” at the 3’UTR but can also bind to the 5’UTR and coding sequence regions (Tay et 
al., 2008; Zhou et al., 2014). This has added to the complexity of predicting potential 
miRNA targets. Generally complete complementation between miRNA and mRNA results 
in Ago2 mediated cleavage of the mRNA strand whereas incomplete complementation 
between miRNA and mRNA is thought to lead to repression of mRNA translation rather 
than mRNA cleavage and degradation (Zeng et al., 2003). Incomplete “seed matching” can 
prevent the initiation step of mRNA translation from occurring (Humphreys et al., 2005). 
The miRNA can also cause inhibition after mRNA translation activity has already been 
initiated (Nottrott et al., 2006). Incomplete complementation has also shown to initiate 
degradation pathways. For example several studies have highlighted miRNA induced 
mRNA decay is mediated by deadenylation and decapping mechanisms (Wu et al., 2006) 
(Behm-Ansmant et al., 2006). RISC is thought to deliver the mRNA, miRNA and Ago2 to 
cytoplasmic processing bodies (p-bodies) where they are targeted for degradation (Liu et 
al., 2005).  
Ultimately through either repression of target mRNA translation or degradation of target 
mRNA, miRNA regulate the expression of genes in a post-transcriptional manner. In total 
the population of miRNAs are thought to act on ~60% of coding mRNA (Esteller, 2011). 
This enables miRNAs to negatively regulate protein expression and interact with a 
diversity of cellular systems. Mutation within the 3’UTR of the mRNA strand and/or in the 
seed sequence of the miRNA transcript can lead to miRNA-mRNA seed mismatch and a 
disruption of target gene regulation (Chen et al., 2006). Specifically, SNPs within the 
3’UTR of the amyloid precursor protein, which are associated with Alzheimer disease, 
prevent the binding of miRNA-147 and lead to an accumulation of amyloid precursor 
protein which correlates to neuronal death (Delay et al., 2011). Likewise SNPs in miRNA 
seed sequences can affect their biosynthesis and also their functionality i.e. a point 
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mutation identified in the miRNA-96 seed region impairs processing to its mature form 
and its ability to recognise targets  and ultimately is responsible for hearing loss (Mencia et 
al., 2009). Although small in size, miRNAs are thought to be able to exert large impact as 
one miRNA can repress an abundance of different genes. In similar context multiple 
different miRNAs can target the same gene.  
1.6.3 MicroRNAs in Disease 
Since their discovery there has been a plethora of research implicating the role of miRNAs 
in disease. From cancer, cardiovascular disease, neurodegenerative disease and 
autoimmune disorders, miRNAs exert key control of cellular events including 
proliferation, apoptosis, differentiation and metabolism (Lu et al., 2005; Lukiw, 2007; De 
Santis et al., 2010; Small et al., 2011). Understandably a mis-expression of miRNAs or an 
imbalance in miRNA-regulated events could have consequences that may lead to a disease 
phenotype i.e. a change in miRNA expression could have the potential to switch cells from 
a normal to a malignant state. Therefore the expression pattern of miRNAs could be 
disease dependent. Regarding this, it has been documented that specific miRNA profiles 
can identify and distinguish between certain cancers i.e. down-regulation of miRNA-15 
and miRNA-16 are observed in chronic lymphocytic leukaemia whereas over-expression 
of miRNA-21 is documented in glioblastoma (Chan et al., 2005; Cimmino et al., 2005). It 
is also apparent that changes within clusters of individual stem loops can contribute to 
disease pathology. For example, the members of the miRNA-29 cluster, (miRNA-29a, b1/2 
and c) are down-regulated after myocardial infarction (MI) and are implicated in 
maladaptive cardiac remodelling and fibrosis (van Rooij et al., 2008). Studies have also 
revealed that the extent of change within a miRNA’s expression does not necessarily 
correlate with its ability to trigger a disease-related process as anything from a twofold-
tenfold expression alteration has shown to be pathological (Calin et al., 2004; He et al., 
2005). This indicates that even a small change in miRNA expression has the ability to 
generate detrimental consequences. The understanding of unique miRNA expression 
signatures correlating with disease led to the speculation that miRNAs could potentially act 
as disease biomarkers. This would allow miRNAs to be used in screening methods of an at 
risk population for early detection of potential disease and/or allow treatment initiation 
before a disease has had the ability to fully manifest (i.e. early intervention). miRNAs are 
stable and easily detectable within bio-fluids e.g. plasma, serum and urine (Weber et al., 
2010). For example, miRNA-1, miRNA-133a and miRNA-208a were all significantly 
increased in patients complaining of chest pain before the onset of acute MI (AMI) (Wang 
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et al., 2010). In addition, a further study documented increased expression of miRNA-208b 
and miRNA-499-5p after AMI was associated with a greater risk of heart failure and 
mortality (Gidlof et al., 2013). Thus utilising miRNA signatures as biomarkers could be 
useful for diagnosis and prognosis of certain diseases. As aforementioned, SNP’s can exist 
within both the miRNA seed sequence and target mRNA 3’UTR which could prerequisite 
disease therefore screening for such mutations in at risk patients could also be employed as 
biomarkers (Chen et al., 2006; Mencia et al., 2009). 
1.6.4 MicroRNAs as Therapeutics 
As miRNAs are involved in the fine tuning of gene networks and can be implicated in 
disease processes it is crucial that we recognise their importance and potential in advancing 
medical therapies. Endogenous expression of miRNA can either be attenuated by anti-
miRNA-oligonucleotides (AMO) treatment or augmented by miRNA-mimics. 
Experimentally the use of exogenous miRNA manipulation has proven successful in a 
variety of in vivo animal models of disease. For example, administration of anti-miRNA-
214 prevents against the development of a mouse model of renal tubulointerstitial fibrosis 
(Denby et al., 2014) and administration of a miRNA-29b mimic reverses pulmonary 
fibrosis in the mouse (Montgomery et al., 2014). As with all exogenous drug 
administration targeting tissue specificity where the miRNA imbalance is observed can 
prove difficult. Reinstating the balance globally within all cells and tissues is not ideal.  
Introducing a miRNA into a tissue or cell where it wasn’t dysregulated or even present 
before could promote adverse unwanted side effects. Thus delivery to target tissue or cell 
specificity poses a major difficulty in the use of miRNA based therapies. Utilising different 
routes of administration could help overcome this obstacle i.e. inhalational administration 
for bronchial based therapies (Mattes et al., 2009). In addition, the use of tissue-specific 
viral vectors to aid and direct miRNA delivery in a targeted manner could limit the desired 
effect to disease associated cells (Robson et al., 2003).  
Applying the potential use of miRNA based therapies in a clinical setting is now being 
investigated. Currently there are two miRNA-targeted therapies under examination in 
human clinical trials, miravirsen and MRX-34. Miravirsen is a locked-nucleic-acid (LNA)-
modified antisense oligonucleotide against miRNA-122 which functions to reduce 
endogenous activity/levels of miRNA-122 (Janssen et al., 2013). miRNA-122 is 
exclusively expressed within the liver and has a fundamental role in protecting the hepatitis 
C viral (HCV) from nucleolytic degradation thus allowing it to initiate liver disease 
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(Jopling et al., 2005). Miravirsen hybridises to the endogenous miRNA-122 thus 
preventing miRNA-122 interaction with HCV which is then free to be targeted for 
degradation. In phase II clinical trials patients receiving Miravirsen exhibited successful 
reduction in HCV levels in a dose dependent manner (Janssen et al., 2013). MRX-34 is a 
liposomal formulated mimic of miRNA-34 which acts to increase endogenous expression 
of miRNA-34. Pre-clinical studies demonstrated inhibition of cancer cell growth and 
induction of apoptosis in cancer cells in a variety of mouse models (He et al., 2007; Liu et 
al., 2011; Hu et al., 2013). Now in phase I clinical trials, the safety and tolerability of 
MRX-34 is being investigated in patients with primary and secondary liver cancer 
(ClinicalTrials.gov Identifier: NCT01829971).  
1.7 MicroRNAs in Pulmonary Arterial Hypertension 
MicroRNAs were first implicated in PAH pathogenesis in 2010 by Caruso and colleagues 
(Caruso et al., 2010). Here it was documented that miRNA expression was dynamic with 
expression changing throughout disease progression. Since then further evidence has 
highlighted their crucial role in disease onset and development. Dysregulated miRNAs 
have been identified regarding diseases processes such as remodelling of the pulmonary 
vasculature, more specifically PAEC apoptosis and PASMC proliferation, and hypertrophy 
of the right ventricle.  
1.7.1 MicroRNA-17/92 
The polycistronic miRNA cluster 17/92 encompasses 6 individual mature miRNAs 
including miRNA-17, miRNA-18a, miRNA-19a, miRNA-19b, miRNA-20a and miRNA-
92a (www.mirbase.org 2014). In silico analysis revealed the gene encoding BMPR-II was 
a putative target of the miRNA-17/92 cluster. A reduction in BMPR-II expression and 
function is a major hallmark of HPAH and isolated cases of IPAH. It was of interest that 
over-expression of miRNA-17/92 cluster in vitro reduced the protein expression of BMPR-
II in PAECs (Brock et al., 2009). Furthermore the miRNA-17/92 cluster is induced by 
interleukin-6 (IL-6) a cytokine which has previously been implicated in PAH pathogenesis 
(Brock et al., 2009). Increased levels of IL-6 are present in PAH patients and a mouse 
model over-expressing IL-6 spontaneously develops a PH phenotype (Humbert et al., 
1995; Steiner et al., 2009). This evidence suggests the increased IL-6 expression in PAH 
could promote an increase in miRNA-17/92 which consequently decreases expression of 
BMPR-II. This modulation was found to be signal transducer and activator of transcription 
3 (STAT-3) dependent and further evaluation revealed a STAT3 binding site in the 
 Chapter One Introduction 
55 
 
promoter region of the miRNA-17/92 cluster (Brock et al., 2009). Individual miRNAs 
from this cluster have also been associated with PAH in particular miRNA-17 which 
targets the cyclin-dependent kinase inhibitor 1A (p21). Over-expression of miRNA-17 
reduced the expression of p21 and was also associated with an increase in proliferation in 
PASMCs (Doebele et al., 2010; Pullamsetti et al., 2012). Inhibition of miRNA-17 in vivo 
by administration of an antagomir to miRNA-17 reversed the PH phenotype in both the 
hypoxic mouse model and rat MCT model (Pullamsetti et al., 2012).  
1.7.2 MicroRNA-21 
Extensive research into miRNA-21 has highlighted a prominent yet ambiguous role in 
PAH.  Generally miRNA-21 expression is induced in PAH proposing a detrimental role. 
Hypoxia is a major mediator in PAH and has been shown to up-regulate miRNA-21 
expression in human PASMCs and PAECS (Sarkar et al., 2010; Parikh et al., 2012) and 
distal pulmonary arteries in lungs from mice exposed to hypoxia (Pullamsetti et al., 2012; 
Yang et al., 2012). Increasing the expression of miRNA-21 using a miRNA-21 mimic 
increases the proliferative and migratory phenotype of PASMCs. This pathological effect 
is mediated through reduction of the target genes programmed cell death 4 (PDCD4) and 
BMPR-II (Sarkar et al., 2010; Yang et al., 2012). PDCD4 is a tumour suppressor factor 
with pro-apoptotic function. A decrease in expression of PDCD4 reduces the pro-apoptotic 
function and promotes proliferation (Sarkar et al., 2010). Treatment with an anti-miRNA-
21 diminishes PASMC proliferation and reduces the PH phenotype in the hypoxic mouse 
model (Sarkar et al., 2010; Yang et al., 2012). Conversely, evidence from miRNA-21
-
/
-
 
mice revealed an exaggerated PH phenotype compared to WT controls in response to SU-
HX insult (Parikh et al., 2012). This could be due to increased expression of the miRNA-
21 target RhoB. In the pulmonary vasculature RhoB enhances vasoconstriction and 
remodelling of pulmonary arteries and genetic deletion of RhoB reduces the PH phenotype 
in hypoxic mouse model (Wojciak-Stothard et al., 2012). This data confers a protective 
role for miRNA-21. Accordingly, further data from miRNA-21
-
/
-
 mice show a PH 
phenotype mediated by an increase in PAEC apoptosis induced by activation of a 
PDCD4/caspase-3 axis (White 2014). In agreement, mice over-expressing miRNA-21 
show a reduction in PDCD4 activation and a concomitant decrease in SU-HX induced PH 
phenotype (White et al., 2014). Additionally, lung samples from IPAH patients showed a 
down-regulation in miRNA-21 expression (Caruso et al., 2010). MiRNA-21 expression is 
also decreased in lung homogenates in MCT rat model of PH (Caruso et al., 2010).  
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1.7.3 MicroRNA-145 
MiRNA-145 is part of the bicistronic miRNA-143/145 cluster with both mature miRNAs 
playing fundamental roles in SMC physiology. The abundant and exclusive expression of 
miRNA-145 in adult SMCs allows it to be utilised as a phenotypic marker and further 
emphasises its significance in vascular homeostasis (Ji et al., 2007). Multiple studies have 
implicated a protective role for miRNA-145 within the systemic circulation as evidence 
shows a reduction in expression of miRNA-145 in carotid arteries with neointimal 
formation and over-expression of miRNA-145 can reduce neointima formation in balloon 
injured carotid arteries (Cheng et al., 2009b). In addition, SMCs isolated from miRNA-
145
-
/
-
 mice are more susceptible to proliferation and migration than those from WT mice 
(Elia et al., 2009). However, an opposing role for miRNA-145 is indicated within the 
pulmonary circulation. Caruso et al. highlighted miRNA-145 expression was increased in 
tissue samples from PAH patients including PASMCs, pulmonary arteries and whole lung 
(Caruso et al., 2012). Similarly enhanced expression of miRNA-145 was demonstrated in 
lung and RV tissue from mice exposed to hypoxia (Caruso et al., 2012). Furthermore, 
reduction in endogenous miRNA-145 expression by both genetic knockout and inhibition 
using anti-miRNA-145 reduced the PH phenotype in the hypoxic mouse model (Caruso et 
al., 2012). Interestingly, ligands of the TGF-β signalling pathway e.g. BMP-4 are known to 
mediate the transcription of miRNA-145 (Davis-Dusenbery et al., 2011). Silencing of 
BMPR-II has also shown to increase miRNA-145 in PASMCs suggesting miRNA-145 is 
downstream of BMPR-II signalling (Caruso et al., 2012). MiRNA-145 targets inhibitory 
mediators of WNT signalling (Caruso et al., 2012). A reduction in miRNA-145 leads to a 
reduction in WNT signalling and WNT related genes e.g. cyclin D1 (CCND1) which can 
consequently decrease proliferation (Baldin et al., 1993; Caruso et al., 2012).  
1.7.4 MicroRNA-206 
MiRNA-206 has recently been implicated in the proliferative phenotype of PASMCs 
associated with PAH pathogenesis. In the hypoxic rat model of PH, miRNA-206 is down-
regulated in lung samples (Yue et al., 2013). Likewise PASMCs isolated from mice 
exposed to hypoxia show a reduction in expression of miRNA-206 expression and a 
concomitant increase in Notch-3 (Jalali et al., 2012). Notch-3 is a member of the Notch 
family receptors and is specifically expressed in vascular SMCs. Notch-3 is fundamental to 
SMC survival and proliferation and has been demonstrated to be up-regulated in PASMCs 
from PAH patients (Li et al., 2009). Silencing of Notch-3 via genetic knockout prevents 
the obliteration of distal pulmonary arteries and protects mice from a hypoxic induced PH 
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phenotype (Li et al., 2009). A reduction in miRNA-206 is coupled with an increase in 
proliferation and decrease in apoptosis of human PASMCs with a reverse observed upon 
miRNA-206 over-expression (Jalali et al., 2012; Yue et al., 2013).    
1.7.5 MicroRNA-424/503 
MiRNA-424 and miRNA-503 are part of a polycistronic cluster separated by only 250 
nucleotides on the genome (www.mirbase.org 2014). Both miRNA-424 and miRNA-503 
can be transcribed together and their transcription induced by apelin in PAECs (Kim et al., 
2013). Apelin is a peptide and activation of its receptors can promote the release of nitric 
oxide (Tatemoto et al., 2001). Apelin is highly abundant in PAECs and acts as a paracrine 
signalling molecule with neighbouring PASMCs cementing its crucial role in vascular 
homeostasis (Sheikh et al., 2008; Kim et al., 2013). In PAECs isolated from IPAH and 
HPAH patients apelin levels are down-regulated (Chandra et al., 2011). Down-regulation 
of apelin reduces the induction of miRNA-424/503 and therefore increases their targets 
fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor 1 (FGFR1) (Kim et 
al., 2013). Subsequently, an increase in proliferation of PAECs is observed (Kim et al., 
2013). FGF2 levels are increased in PAH patients and associated with disease (Benisty et 
al., 2004). In conjunction with this evidence, mice devoid of apelin (apelin-/-) exhibit an 
exacerbated PH phenotype induced by hypoxia (Chandra et al., 2011). Altogether this 
evidence suggests a protective effect of miRNA-424/503 within the pulmonary circulation. 
In agreement with this over-expression of miRNA-424/503 reduces proliferation of PAECs 
via a decrease in pERK1/2 (Kim et al., 2013). Indeed in an in vivo mouse model of PH 
targeted over-expression of miRNA-424/503 in the lung decreases the disease phenotype 
including the remodelling of pulmonary arteries (Kim et al., 2013).  
1.8 Sex and MicroRNAs 
1.8.1 Sex Differences in MicroRNAs 
The female and male genome shares ~99% content similarity with variation arising from 
the presence of specific genes on the Y sex chromosome. However, it has long been 
recognised that the expression of genes between females and males is substantially 
different implicating that transcriptional and post-transcriptional regulatory modifications 
may play a fundamental role in shaping the architecture of female and male gene 
expression (Ranz et al., 2003; Yang et al., 2006; Reinius et al., 2008). As previously 
discussed, miRNAs are a fundamental part of a cells post-transcriptional regulatory 
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machinery playing a significant role in shaping genetic networks in both physiological and 
pathological processes. The expression of miRNAs has been demonstrated to be different 
in females compared to males highlighting that miRNAs are expressed or regulated in a 
sex-dependent manner (Marco et al., 2013; Wu et al., 2013). Thus sex could be an 
important factor in miRNA-mediated regulation of genetic networks. Online databases 
document the X chromosome encompasses 118 miRNAs whereas the Y chromosome only 
encodes 2 (www.miRBase.org 2014). Sexual dimorphism of miRNA expression is 
apparent in multiple processes including embryological development. For example, within 
the developing foetal lung, sex differences in miRNA expression coincide with important 
developmental stages. These miRNA target genes involved in lung maturation and 
vascularisation suggesting that sex differences in their expression could potentially led to 
structural and functional differences between sexes post-natal (Mujahid et al., 2013). In 
addition, an enrichment of the miRNA-302 cluster was discovered in differentiating male 
embryonic stem cells but not female (Ciaudo et al., 2009). Furthermore, an increase in 
expression of miRNA-21 is observed within male mouse hearts compared to females 
where it is thought to regulate fibrotic-related genes (Queiros et al., 2013).      
Certain diseases have a sex bias in incidence, pathogenesis and treatment response i.e. 
PAH, liver fibrosis, systemic lupus erythematosus (SLE) and specific cancers (Rigamonti 
et al., 2005; Brenner et al., 2007; Shapiro et al., 2012; Ohta et al., 2013). Therefore there is 
rational to speculate/anticipate sex-dependent miRNAs may play a role in development 
and progression of sex bias pathologies. Indeed in a mouse model of SLE which 
replicates/mirrors the sex bias observed in human patients, there was recognition of sex-
specific miRNAs after disease onset (Dai et al., 2013). Likewise male mice are more 
susceptible to experimentally induced liver disease which correlated with reduced liver 
levels of miRNA-29a and miRNA-29b compared to female mice (Zhang et al., 2012).   
1.8.2 Estrogen Regulated MicroRNAs 
Sex hormones signal their effector response through binding and activating nuclear 
receptors. A ligand bound nuclear receptor can directly bind to and interact with DNA at 
promoter regions and thus exert control over transcriptional regulation of genes through 
recruitment of either co-activators or co-repressors. Like most protein coding genes, those 
encoding miRNAs, pri-miRNA, are also transcribed through interaction at their promoter 
sites. It has been demonstrated that the sex hormones E2, progesterone and testosterone all 
influence miRNA levels (Bhat-Nakshatri et al., 2009; Waltering et al., 2011; Bae et al., 
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2012). Therefore sex specific expression of miRNAs could be attributed to by the presence 
or absence of sex hormones. This is demonstrated by evidence showing inhibition of E2 
synthesis, via the aromatase enzyme inhibitor formestane, altered the miRNA expression 
profile in the neonatal mouse brain (Morgan et al., 2011). The main female circulating 
hormone E2 can govern miRNA expression directly through estrogen-response-elements in 
the promoter element of the pri-miRNA gene (Di Leva et al., 2010) or indirectly through 
transcription of estrogen related genes e.g. c-MYC which can in turn interact with 
transcription of pri-miRNA gene (Castellano et al., 2009). E2-related miRNAs could play 
a fundamental role in estrogen positive/orientated diseases e.g. breast cancer, SLE and 
PAH. As previously mentioned sex-specific miRNAs were associated with the sex bias of 
SLE development. In particular, the SLE associated miRNA-182-96-183 cluster and 
miRNA-379 were up-regulated in female diseased mice and not males. It was also 
highlighted that exogenous treatment of estrogen exacerbated the increase in females (Dai 
et al., 2013). Estrogen administration correlates with an exacerbation of SLE pathogenesis 
(Roubinian et al., 1979). Thus estrogen could affect disease development through directing 
expression of specific miRNAs. Furthermore, induction of miRNA-29a and miRNA-29b 
by estrogen is thought to play a role in protecting female mice from experimental liver 
injury (Zhang et al., 2012).  
Estrogen is also thought to exert control of miRNA expression through interaction with 
miRNA processing machinery. For example there is an ERα binding site in the promoter 
region of the Dicer gene and accordingly the expression of Dicer can be increased with 
estrogen stimulation (Bhat-Nakshatri et al., 2009). In the same study estrogen stimulation 
increased the expression of several miRNAs suggesting that miRNA biogenesis could be 
increased by estrogen through an increase in the processing gene Dicer. However, in 
contrast, a similar study showed expression of the Dicer gene was down-regulated by 
stimulation of estrogen (Lin et al., 2007). Differential expression of Dicer has been 
highlighted in ER+ vs. ER- breast cancers (Cheng et al., 2009a). Therefore the discrepancy 
in the two previous studies could be due to the estrogen status of the cells investigated. 
1.9 Hypothesis and Aims 
In summary, PAH is a progressive and presently incurable vasculopathy which affects the 
pulmonary arteries. PAH is characterised by intense irreversible remodelling of the 
pulmonary arteries, high pulmonary arterial pressure and right heart failure. Regression of 
these attributes are the main focus of current and future PAH therapies.  
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One unexplained factor of PAH is an observed high female susceptibility with their being 
up to 4 female patients for every one male patient (Rich et al., 1987b; Humbert et al., 
2006; Badesch et al., 2010; Ling et al., 2012). This increased female to male ratio in PAH 
prevalence strongly suggests there is an influence of sex or sexual dimorphism in the 
development of PAH. In particular there is strong evidence suggesting a causative role for 
female sex hormones in PAH pathogenesis (White et al., 2012; Mair et al., 2014; Wright et 
al., 2015). Anomalous estrogen synthesis, signalling and metabolism have all been linked 
to the remodelling of pulmonary arteries. Many experimental animal models which mirror 
the enhanced female susceptibility are associated with the peripheral serotonin system 
indicating that there is interplay between the estrogen and serotonin pathways (Dempsie et 
al., 2011; White et al., 2011a; Dempsie et al., 2013). Serotonin plays a pathological role in 
pulmonary artery remodelling via the 5-HT1B receptor making it a favourable gene to 
therapeutically target (Keegan et al., 2001; Morecroft et al., 2005).  
Building evidence also implicates a role for microRNAs (miRNAs) in PAH (Caruso et al., 
2010). It is recognised that sex differences exist in miRNA expression and therefore 
miRNAs which are influenced by sex may shape the architecture of female and male gene 
expression differently (Marco et al., 2013; Wu et al., 2013). Sexual dimorphism of 
miRNAs is thought to play a role in the development of sex bias diseases such as SLE with 
expression potentially regulated by the presence or absence of sex hormones (Dai et al., 
2013; Ohta et al., 2013). With regards to PAH, it is currently unknown whether female and 
male differences in miRNA expression exist and could underlie female susceptibility in 
disease onset and development. Little is also known surrounding the interplay between 
estrogens and miRNAs in PAH. Examining the sexual dymorphism in miRNAs with 
regards to PAH disease may provide insight into the sex bias observed in PAH.  
The hypothesis of this thesis was that sex differences in miRNA expression could underpin 
differences in gene expression that may confer female susceptibility in PAH.  
The central research focus of this thesis was to investigate the influence of sex on miRNA 
expression, primarily in PASMCs, from both experimental and clinical PAH samples and 
understand how this could potentially underpin the sex bias in PAH. This was achieved by 
the following research aims: 
1. In vitro identification of female and male sex differences in miRNA expression 
from PASMCs. 
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2. In vitro characterisation and validation of a target for a sex specific miRNA.  
3. In vitro examination of the role of estrogen in regulation of a sex specific miRNA.  
4. In vivo evaluation of miRNA-target regulation. 
5. In vivo investigation of the effect of miRNA modulation on prevention and reversal 
of a PH phenotype in female mice.      
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2.1 Chemicals and Reagents 
All chemicals and reagents were supplied by Sigma-Aldrich (Dorset, United Kingdom) or 
Fisher Scientific (Loughborough, United Kingdom) unless otherwise stated. Materials for 
RNA and protein analysis were obtained from Qiagen (United Kingdom) and Life 
Technologies (Paisley, United Kingdom). All experimental procedures involving RNA 
were carried out using certified nuclease-free reagents and plastics and supplied by 
Ambion, Life Technologies (Paisley, United Kingdom). All cell culture plastics were 
obtained from Corning, Fisher Scientific (Loughborough, United Kingdom).    
2.2 Ethical Approval 
All experimental procedures utilising animals conformed with the United Kingdom Animal 
Procedures Act (1986) and with the “Guide for the Care and Use of Laboratory Animals” 
published by the United States National Institutes of Health (publication No.85-23, revised 
8
th
 edition 2001). All in vivo procedures were performed under project license 60/4404 
held by Professor Margaret R. MacLean, University of Glasgow, and personal license 
60/12915 held by Emma Wallace, University of Glasgow. Ethical approval was granted by 
the University of Glasgow Ethics Committee. All experimental procedures utilising 
primary human pulmonary artery smooth muscle cells conformed with the principles 
outlined in the Declaration of Helsinki and were approved by Cambridgeshire 1 Research 
Ethics Committee (REC reference: 08/H0304/56+5).  
2.3 Animals 
All animals were housed either at the Central Research Facility (CRF), University of 
Glasgow, or the licensed facility located in the West Medical Building, University of 
Glasgow. All animals were maintained in a continuous 12 hour light/dark cycle with access 
to food and water ad libitum. All genetically modified animals were ear clipped by staff at 
the CRF and genetic background confirmed by genotyping. Where necessary, wild-type 
(WT) littermates were studied as controls. Where appropriate, all animals were randomly 
allocated to experimental groups and studied in a blinded manner. Experimental groups 
were un-blinded upon completion of analysis.   
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2.3.1 Wild-type Mice 
Inbred wild-type (WT) mice aged 7 weeks were obtained from Charles River (United 
Kingdom). Mice were housed at the CRF, University of Glasgow for a 1 week 
acclimatisation and monitoring period before use in any experimental procedures.  
2.3.2 BMPR-IIR899X+/- Mice 
Mice harbouring a heterozygous knock-in mutation within the BMPR-II gene (R899X, 
BMPR-II
R899X+/-
)
 
were kindly supplied by Professor Nicholas W. Morrell, University of 
Cambridge. Briefly, the BMPR-II gene was cloned and the R899X substitution mutation 
was introduced using site-directed mutagenesis. The vector containing the mutated BMPR-
II was transfected into 129S3 mouse embryonic stem cells by electroporation. The 
modified embryonic stem cells were then injected into blastocytes and implanted into a 
pseudopregnant C57Bl/6 female mouse. Chimeric male mice were then bred with female 
C57Bl/6 mice to produce heterozygous R899X offspring which were back-crossed to 
C57Bl/6 for 5 generations. BMPR-II
R899X+/-
 mice have previously been shown to exhibit a 
mild PH phenotype at 6 months of age (Long et al., 2011; Long et al., 2015). For 
experimental procedures subsequently mentioned, the BMPR-II
R899X+/-
 mice were utilised 
at 6 months of age and WT littermates studied as controls.   
2.4 Lung Histology 
2.4.1 Fixation, Paraffin Embedding and Sectioning of Lung Tissue 
At sacrifice the left lung of the mouse was gently flushed with sterile phosphate buffered 
saline (PBS) and inflated with 10% (v/v) neutral buffered formalin (NBF). The lung was 
then dissected free of the mouse cadaver, submerged in 10% NBF and kept overnight at 
room temperature on a shaker with slight agitation. Lungs were then processed through a 
series of dehydration steps and paraffin embedded (Table 2.1) using a Citadel 1000 tissue 
processor (Thermo Scientific, United Kingdom).  
Paraffin embedded lung blocks were stored at room temperature, but were briefly placed at 
-20°C prior to sectioning to aid with the cutting process. 5 µm frontal plane lung sections 
were cut using a microtome (Leica RM2125, Leica Microsystems, Milton Keynes, United 
Kingdom) and mounted onto polylysine coated glass microscope slides. Mounted lung 
sections were stored at room temperature. 
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Table 2.1 Fixation and paraffin embedding of mouse lung tissue 
   
2.4.2 Immunohistochemistry 
Lung sections were de-waxed in xylene for 30 minutes and rehydrated through an 
alcohol/water gradient consisting of 100% ethanol for 10 minutes, 100% ethanol for 5 
minutes, 90% ethanol for 2 minutes, 70% ethanol for 2 minutes and finally running tap 
water for 10 minutes. Rehydrated lung sections were then immersed in 10 mM citric acid 
buffer (Sigma Aldrich, Dorset, United Kingdom) at pH 6 and boiled in a microwave for 4x 
5 minutes in a process called heat-induced-epitope-retrieval. This step is also known as 
antigen retrieval and aids unmasking of antigen sites by breaking down protein cross-links 
which are formed during the fixation process. Lung sections were left to cool in the citric 
acid buffer at room temperature for 20 minutes before being washed in running tap water 
for 10 minutes. As most tissue contains endogenous peroxidase, addition of a horse-radish-
peroxidase conjugated antibody may result in non-specific background staining. To block 
endogenous peroxidase, lung sections were submerged in a solution of methanol 
containing 3% (v/v) hydrogen peroxide (Sigma Aldrich, Dorset, United Kingdom) for 30 
minutes before being washed in running tap water for 10 minutes. Following this, non-
specific blocking was carried out by blocking the lung sections with 2.5% (v/v) horse 
serum (ImmPRESS kit, Vector Labs, Peterborough, United Kingdom) for 1 hour in a 
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humidified chamber at room temperature. The α-smooth muscle actin (α-sma), 
proliferating cell nuclear antigen (PCNA) or von williebrand factor (vWF) primary 
antibody (diluted in 1% (w/v) bovine serum albumin (BSA) in 10mM phosphate buffered 
saline (PBS)) (Table 2.3) was then applied to the lung sections overnight in a humidified 
chamber at 4°C. An immunoglobulin G (IgG) negative control was used on duplicate lung 
sections at the same concentration to observe any non-specific binding. Next, lung sections 
were washed twice in tris-buffered saline (TBS) for 10 minutes and then incubated with 
anti-rabbit Ig peroxidase polymer secondary antibody (ImmPRESS kit, Vector Labs, 
Peterborough, United Kingdom) for 1 hour in a humidified chamber at room temperature. 
The secondary antibody should selectively bind to the primary antibody. Lung sections 
were then washed twice in TBS for 10 minutes. Immunolocalisation of α-smooth muscle 
actin was visualised via a 2-5 minute incubation with 3,3’-diaminobenzidine (DAB) and 
nickel substrate kit (Vector Labs, Peterborough, United Kingdom). A dark brown staining 
was indicative of positive immunolocalisation. To terminate the reaction lung sections 
were immersed in running tap water for 10 minutes.  Lung sections were then 
counterstained with haemotoxylin and eosin, which stains nuclear and cytoplasmic 
portions, respectively, for 5 minutes before a final wash in running tap water for 5 minutes. 
Lung sections were then rapidly dehydrated through a water/alcohol gradient consisting of 
70% ethanol for 1 minute, 90% ethanol for 1 minute, twice in 100% ethanol for 5 minutes 
and finally twice in histo-clear for 5 minutes. Cover slips were mounted onto the lung 
sections using Tissue-Tek (Sakura Finetek, Netherlands) and staining visualised on a Zeiss 
Imager M.1 AX10 and axiovision Rel. 4.8 (Carl Zeiss Microscopy Ltd, Cambridge, United 
Kingdom).   
2.4.3 Elastin Pico-Sirius Red Staining 
A modified Miller’s Elastin staining protocol was utilised protocol (Miller, 1971). Briefly, 
lung sections were de-waxed in histo-clear for 20 minutes and rehydrated through an 
alcohol/water gradient consisting of 100% ethanol for 5 minutes, 90% ethanol for 5 
minutes, 70% ethanol for 5 minutes and finally running tap water for 5 minutes. 
Rehydrated lung sections were then submerged into 0.5% (w/v) potassium permanganate 
solution for 5 minutes. This oxidises the lung tissue and enhances subsequent staining by 
eliminating the formalin pigment. Lung sections were then rinsed in running tap water for 
5 minutes before being placed in 1% (w/v) oxalic acid for 2-3 minutes. This decolourises 
the potassium permanganate from the sections. The lung sections were further rinsed in tap 
water and 95% ethanol. Sections were then submerged in Millers Elastin Stain (Thermo 
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Scientific, United Kingdom) for 2 hours. To remove excess staining, lung sections were 
rinsed in 95% ethanol and then running tap water. The lung sections were then very briefly 
counterstained with pico-sirius red and finally rinsed in running tap water before being 
rapidly dehydrated through a water/alcohol gradient consisting of 70% ethanol for 1 
minute, 90% ethanol for 1 minute, twice in 100% ethanol for 5 minutes and finally twice in 
histo-clear for 5 minutes. Cover slips were mounted onto the lung sections and staining 
visualised on a light microscope (Zeiss Imager M.1 AX10) as aforementioned. Elastin 
pico-sirius red staining highlights elastic fibres in black and collagen in red.    
2.4.4 In situ Hybridisation 
In situ hybridisation was performed as previously described (Pena et al., 2009). Briefly, 
lung sections were de-waxed in xylene for 30 minutes and rehydrated through an 
alcohol/water gradient consisting of 100% ethanol for 5 minutes, 100% ethanol for 5 
minutes, 95% ethanol for 5 minutes, 95% ethanol for 5 minutes, 70% ethanol for 5 minutes 
and finally RNAase free H2O for 10 minutes. Deproteinisation was then performed on 
rehydrated lung sections which consisted of each lung section being treated with pre-
warmed proteinase K (20µg/ml, Life Technologies, Paisley, United Kingdom) for 20 
minutes at 37°C in a humidified chamber. This step aids permeabilisation of the tissue and 
unmasking of hybridisation sites by breaking down protein cross-links which are formed 
during the fixation process specifically those associated with nucleic acids. To inactivate 
the proteinase K and preserve morphology of the lung sections were first washed in 0.1M 
glycine in TBS for 5 minutes at room temperature before being fixed with 4% para-
formaldehyde for 10 minutes at room temperature. Next, lung sections were washed in 
0.1M glycine in TBS for 5 minutes at room temperature then incubated in imidazole buffer 
(300mM NaCl, 0.1M 1-methylimidazole, pH 8) for 10 minutes at room temperature. The 
lung sections were washed once more in 0.1M glycine in TBS before a final fixation in 
EDC solution (300mM NaCl, 0.1M 1-methylimidazole, 0.1M N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride) for 2 hours at room 
temperature in a humidified chamber. The lung sections were then treated with acetylation 
buffer (1% (v/v) triethanolamine, 0.5% (v/v) acetic anhydride in RNAase free H2O) for 30 
minutes at room temperature before washing in TBS for 5 minutes at room temperature. 
The acetylation reaction eliminates any remaining positive charges in the lung sections and 
reduces the background signal. Lung sections were then pre-hybridised by applying 500µl 
of hybridisation solution (#H7782 Sigma Aldrich, Dorset, United Kingdom) to each 
section for 1 hour at probe annealing temperature before overnight probe annealing in 
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hybridisation oven. Double DIG-labelled (3’ and 5’) mercury LNA hsa-miR-96 probe 
(50nmol/L) and mercury LNA scramble-miR probe (negative control) were used at 
hybridisation temperature 52°C and 57°C respectively. To remove any unbound probe, 
post-hybridisation stringency washes were carried out on the lung sections. This involved a 
series of sodium citrate washes with increasing salt stringency. Lung sections were then 
washed in TBS before beginning immunodetection with the DIG nucleic acid detection kit 
(ROCHE #11175041910, Roche Life Sciences, Burgess Hill, United Kingdom) as per 
manufacturer’s instructions. Positive staining was evident by a purple colour. The reaction 
was terminated by immersing lung sections in H2O and cover slips were mounted onto the 
lung sections using VectaMount AQ aqueous mounting medium (Vector Laboratories, 
Peterborough, United Kingdom) and staining visualised on a Zeiss Imager M.1 AX10 and 
axiovision Rel. 4.8 (Carl Zeiss Microscopy Ltd, Cambridge, United Kingdom).   
2.5 Cell Culture 
All cell culture experiments were performed under sterile conditions in a class II laminar 
flow cabinet. When in culture all cells were maintained in a humidified incubator at 37°C 
with continuous supply of 5% CO2 and 95% air.   
2.5.1 Mouse Pulmonary Artery Smooth Muscle Cell Culture 
Mouse pulmonary artery smooth muscle cells (PASMCs) were generated and kindly 
supplied by Professor Nicholas W. Morrell, University of Cambridge. Mouse PASMCs 
were derived from pulmonary arteries of BMPR-II
R899X+/-
 and WT female and male mice. 
The SMC phenotype of the mouse PASMCs was confirmed by their general cell 
morphology. Mouse PASMCs were maintained in 75cm
3
 culture flasks containing 20% 
(v/v) foetal bovine serum (FBS, Sera Laboratories International, West Sussex, United 
Kingdom), 1% (v/v) antibiotic solution (10,000 units penicillin and 10mg streptomyocin, 
Sigma Aldrich, Dorset, United Kingdom) in Dulbecco’s Modified Eagle Medium (DMEM, 
Life Technologies, Paisley, United Kingdom) supplemented with smooth muscle cell 
growth factor kit (0.5ng/ml Epidermal Growth Factor, 2ng/ml Basic Fibroblast Growth 
Factor, 5µg/ml Insulin, Promocell, United Kingdom). DMEM was routinely replenished 
every 48 hours. Mouse PASMCs were passaged when they reached ~90% confluency 
(~90% monolayer coverage of culture flask). This involved aspirating the DMEM off the 
PASMCs, washing twice with sterile PBS warmed to 37°C and addition of 2ml of 
trypsin/EDTA solution (0.1% (w/v) EDTA in PBS, Life Technologies, Paisley United 
Kingdom) warmed to 37°C. The culture flask was then returned to the incubator for 1 
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minute to aid the trypsinisation process. Trypsin is a proteolytic enzyme and dissociates the 
adherent PASMCs from the culture flask. Once detached the PASMCs were immediately 
re-suspended in 8mls of 20% FBS DMEM. This action neutralises the trypsin and 
terminates the trypsinisation process. The new PASMC suspension is then further sub-
cultured accordingly. Mouse PASMCs were seeded at a density of 10,000 per cm
3
. DMEM 
was always replenished 24 hours (maximum) after a newly generated sub-culture. Mouse 
PASMCs were utilised for experiments between passages 4-8.        
2.5.2 Human Pulmonary Artery Smooth Muscle Cell Culture 
Human pulmonary artery smooth muscle cells (hPASMCs) were generated and kindly 
supplied by Professor Nicholas W. Morrell, University of Cambridge. HPASMCs were 
derived from distal pulmonary arteries (~1mm external diameter) of both female and male 
PAH patients and non-PAH patients (Table 2.2) as previously described (Wharton et al., 
2000). PAH patients were a mix of heritable PAH and idiopathic PAH and hPASMCs were 
explanted at lung transplantation. Non-PAH patients had no incidence of PAH disease and 
the lungs were macroscopically normal. Pathology reports were examined for the non-PAH 
patients and no evidence of pulmonary arterial remodelling was detailed. Non-PAH 
hPASMCs were explanted from donor tissue and studied as controls. The SMC phenotype 
of the hPASMCs was confirmed by their general cell morphology (Figure 2.1). HPASMCs 
were maintained in 75cm
3
 culture flasks containing 10% (v/v) FBS (Sera Laboratories 
International, West Sussex, United Kingdom), 1% (v/v) antibiotic antimycotic solution 
(10,000 units penicillin, 10mg streptomyocin and 25µg amphotericin B, Sigma Aldrich, 
Dorset, United Kingdom) in Dulbecco’s Modified Eagle Medium (DMEM, Life 
Technologies, Paisley, United Kingdom). HPASMC culture was carried out as described in 
2.5.1 except 10% FBS DMEM was used. HPASMCs were utilised for experiments 
between passages 3-8.    
2.5.3 HeLa Cells 
HeLa cells are an immortalized cell line which was initially derived from cervical cancer 
cells. HeLa cells were obtained commercially and were maintained in 150cm
3
 culture 
flasks containing 10% (v/v) FBS (Sera
 
Laboratories International, West Sussex, United 
Kingdom), 1% (v/v) antibiotic antimycotic solution (10,000 units penicillin, 10mg 
streptomyocin and 25µg amphotericin B, Sigma Aldrich, Dorset, United Kingdom) in 
DMEM (Life Technologies, Paisley, United Kingdom). HeLa cell culture was carried out 
as described in 2.5.1 except 10% FBS DMEM was used.   
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Figure 2-1 Morphology of distal pulmonary arterial smooth muscle cells  
Microphotograph of human distal pulmonary artery smooth muscle cells grown in a T75 
culture flask.    
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Table 2.2 Patient information for human pulmonary arterial smooth muscle cells 
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2.6 Pulmonary Artery Smooth Muscle Cell Proliferation Assay 
2.6.1 Haemocytometer Cell Counting 
HPASMCs were counted manually using a haemocytometer to evaluate cell proliferation. 
For proliferation assays hPASMCs were seeded in 24-well plates at a density of 10,000 
cells per well and maintained in 10% FBS DMEM until 60% confluency was reached. 
HPASMCs were then quiesced in 0.2% (v/v) FBS DMEM for 24 hours. Quiescing is 
necessary to synchronise cell cycle stage before subsequent stimulation. HPASMCs were 
stimulated with the appropriate agonist for a further 72 hours in the presence of 2.5% (v/v) 
FBS DMEM. A stimulation of 2.5% and 10% FBS DMEM was studied as a negative and 
positive control, respectively. Where necessary, hPASMCs were incubated with the 
appropriate antagonist for 1 hour prior to agonist stimulation. Each experimental condition 
was performed in triplicate. Upon completion of the 72 hour stimulation time point, 
DMEM was aspirated from the hPASMCs and cells were washed twice with 1ml of sterile 
PBS warmed to 37°. Next 150µl of trypsin/EDTA solution (Life Technologies, Paisley, 
United Kingdom) was added to each well. The 24-well plate was then returned to the 
incubator for 1 minute to aid the trypsinisation process. Once detached, the hPASMCs 
were immediately re-suspended in 500µls of 10% FBS DMEM per well and gently 
pipetted up and down. The total content of each well was then transferred to a 1.5ml 
eppendorf and spun in a pre-cooled centrifuge at 4°C at 3500xg for 10 minutes. The 
supernatant was then carefully aspirated off to ensure a cell pellet remained intact. The cell 
pellet was then re-suspended in 200µl of 10% FBS DMEM and vortexed briefly to obtain 
an even suspension. With the haemocytometer, 10µl of the cell suspension was pipetted 
into the square grid. Using a hand tally counter, the number of cells in each 16-squared 
red-outlined corner was counted (Figure 2.2). The average of the 4 corners was used to 
calculate the number of cells. The haemocytometer is designed so that the number of cells 
in one 16-square corner is equivalent to the number of cells x 10
4
/ml. As this provides a 
number per ml, the cell number was divided by 5 to obtain a number per 200µl (accounting 
for the dilution factor at re-suspension). Duplicate 24-well plates were studied to obtain 
RNA or protein lysates for further experimental analysis. 
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Figure 2-2 Haemocytometer counting grid 
A schematic representation of the haemocytometer counting grid. Pulmonary arterial 
smooth muscle cells were counted in each 16-square corner outlined in red and an average 
cell number count was obtained.  
 
 
 
2.6.2 5-bromo-2-deoxyuridine Incorporation  
PASMCs were also counted via the amount of 5-bromo-2-deoxyuridine (BrdU) 
incorporation into DNA. BrdU is a derivative of uridine and is a structural analogue of 
thymidine. When added to actively proliferating cells, it can mimic thymidine and be 
incorporated into newly synthesised DNA during the synthesis phase (S-phase) of the cell 
cycle. The BrdU incorporation assay is a common method to measure proliferation. As the 
BrdU assay is non-isotopic it is generally considered a safer alternative of proliferation 
assay than those involving tritiated substances. For assessment of proliferation the 
Calbiochem® BrdU Cell Proliferation Assay was utilised with the adherent cell protocol 
(Calbiochem, Merck Millipore, Germany). This is an enzyme immunoassay kit and uses 
colorimetric detection. Briefly, hPASMCs were seeded at 2,500 cells per well in a 96-well 
plate and maintained in 10% FBS DMEM until 60% confluency was reached. Two 
separate control conditions were utilised consisting of 10% FBS DMEM (blank control) 
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and no BrdU label (background control). HPASMCs were then quiesced in 0.2% (v/v) FBS 
DMEM for 24 hours. HPASMCs were stimulated with the appropriate agonist for a further 
72 hours in the presence of 2.5% (v/v) FBS DMEM. A stimulation of 2.5% and 10% FBS 
DMEM was studied as a negative and positive control respectively. Where necessary, 
hPASMCs were incubated with the appropriate antagonist for 1 hour prior to agonist 
stimulation. Each experimental condition was performed in quadruplicate. The BrdU label 
was prepared at a working stock of 1µl BrdU label in 2ml of 10% FBS DMEM and in the 
last 24 hour time period of the experiment 20µl of the working BrdU stock was added to 
each well (except for the background control wells). Following this, the contents of the 96-
well plate was removed by inverting over the sink. The 96-well plate was then carefully 
blotted dry with paper towels before addition of 200µl of fixative/denaturing solution to 
each well. This solution acts to fix, permeabilise and denature the DNA of the cells for the 
incorporated BrdU to be subsequently detected. After a 30 minute incubation period the 
contents of the 96-well plate was removed by inverting over the sink and carefully blotted 
dry. The 100x anti-BrdU antibody was diluted 1:100 in the antibody dilution buffer and 
100µl of the final solution was added to each well for one hour incubation at room 
temperature. The anti-BrdU monoclonal antibody binds to the incorporated BrdU in the 
cells. A working solution of 1x wash buffer was prepared by diluting the 20x stock 1:20 in 
distilled H2O (dH2O).  Each well was washed 3 times with 200µl 1x wash buffer and then 
carefully blotted dry. This allows removal of unbound antibody and prevents unwanted 
background labelling. The peroxidase goat anti-mouse IgG horse radish peroxidase (HRP) 
conjugate was prepared by diluting in the conjugate diluent and syringe filtered through a 
0.2µm filter. Next, 100µl of the diluted conjugate was added to each well and incubated at 
room temperature for 30 minutes. The HRP conjugate binds to the anti-BrdU antibody in 
the cells. Following this, each well washed a further 3 times with 200µl 1x wash buffer. 
The 96-well plate was then completely submerged in dH2O to flood each well and then 
carefully blotted dry. After this, 100µl of substrate solution was added to each well and 
incubated at room temperature in the dark for 15 minutes. The substrate solution contains 
the chromogenic substrate tetra-methylbenzidine (TMB) which is a colourless solution. 
The HRP enzyme of the conjugate catalyses the conversion of TMB to a blue solution of 
which the intensity is directly proportional to amount of BrdU incorporated into the cells. 
To terminate the reaction, 100µl of stop solution was added to each well. The absorbance 
was measured using a spectrophotometric plate reader at dual wavelength of 450-540nm 
within 30 minutes of adding the stop solution.  
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2.7 Transient Transfection of Pulmonary Artery Smooth Muscle Cells 
To assess the effect of miRNA-96 over-expression on 5-HT1B expression and 5-HT- 
induced proliferation, HPASMCs were transiently transfected with small RNA molecules. 
Briefly, HPASMCs were seeded in 6-well and 24-well plates at equal density in 10% (v/v) 
FBS DMEM. At 60% confluency cells underwent transient transfection with 1nM pre-
miR-96 (Ambion, PM10422) or 1nM pre-miR-negative control (Ambion, AM17110 #1) 
using Lipofectamine 2000 (Invitrogen) and optimem (Invitrogen) as per manufacturer’s 
instructions for a total of 6 hours before the media was replaced with 10% (v/v) FBS 
DMEM. For expression analysis each condition was performed in duplicate to allow RNA 
harvest 48 hours and protein harvest 72 hours post-transfection for Taqman and western 
blot analysis respectively. For proliferation analysis each condition was performed in 
triplicate and PASMCs were subsequently quiesced in 0.2% FBS and the proliferation 
protocol followed as of section 2.6.1.  
2.8 Western Blotting 
2.8.1 Protein Extraction and Preparation 
For PASMCs protein was extracted from either 6-well plates or T-75 flasks. Briefly, at 
experimental end point the culture dish containing PASMCs was immediately placed on 
ice. The media was aspirated off and cells washed twice with either 1ml or 5ml of cold 
PBS per well or flask, respectively. Following this 120µl (per well) or 300µl (per flask) of 
ice-cold radio immuno precipitation assay (RIPA, Thermo Fisher Scientific, 
Loughborough, United Kingdom) buffer supplemented with protease inhibitors 
(0.1mmol/L PMSF, 1µg/ml soybean trypsin inhibitor and 1µg/ml benzamidine) was added 
to the culture dish. RIPA buffer lyses whole cells and allows proteins to be released and 
solubilised. The protease inhibitors help prevent proteolysis, dephosphorylation and 
denaturation of the protein sample. Keeping the culture dish on ice, the cells were scraped 
using a sterile plastic scraper and cell lysates collected in a pre-chilled 1.5ml eppendorf. 
Samples were then left on ice for 30 minutes to allow disassociation of protein complexes. 
Alternatively, for whole lung samples protein was prepared as following. Upon dissection 
from the mouse cadaver the right lung lobe was either immediately snap-frozen in liquid 
nitrogen and stored in a freezer at -80°C, or placed in a pre-chilled 2ml eppendorf 
containing 500µl of RIPA buffer supplemented with protease inhibitors. A 5mm stainless 
steel bead (Qiagen, United Kingdom) was added to each sample eppendorf which was then 
placed in a Tissue Lyser II (Qiagen, United Kingdom) for homogenisation. This process 
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involved high-speed shaking (frequency 25Hz) for 4x 30 second intervals. After this, 
samples were left on ice for 30 minutes and sonicated on ice for 2 minutes to allow 
disassociation of protein complexes. Following this, samples were then spun in a pre-
chilled centrifuge at 4°C for 10 minutes at 8,500xg. After centrifugation the sample 
supernatant was transferred into a new pre-chilled eppendorf carefully avoiding the debris 
pellet and stored in a freezer at -80°C.      
2.8.2 Bicinchoninic Acid Assay  
To determine protein concentration a bicinchoninic acid (BCA) assay (Pierce, Thermo 
Fisher Scientific, Loughborough, United Kingdom) was performed. This assay involves 
protein induced reduction of Cu
2+
 to Cu
+
. Cu
+
 and bicinchoninic acid forms a purple 
complex which is directly proportional to the concentration of protein present (Smith et al., 
1985). To evaluate protein concentration within experimental samples, colorimetric 
detection was compared against a range of bovine serum albumin (BSA) standards (0-
2mg/ml BSA solution diluted in RIPA buffer). Briefly, BSA standards and experimental 
samples in duplicate were pipetted into a 96-well plate. BCA assay solution was prepared 
by adding together 9.8ml of reagent A to 200µl of reagent B and mixed thoroughly. 
Immediately 200µl of this solution was added to each well and left on a micro-plate shaker 
with gentle agitation for 20 minutes at room temperature. The 96-well plate was then read 
by a POLARstar OPTIMA microplate reader (BMG Labtech, Germany) at a wavelength of 
562nm. A standard curve (with R
2
 of ≥0.99) was obtained from the BSA standards and 
sample protein concentration determined.   
2.8.3 Sodium Dodecyl Sulphate- Polyacrylamide Gel Electrophoresis 
Protein samples were separated according to their molecular weight using Sodium Dodecyl 
Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE). 30µg of protein samples were 
prepared by adding NuPAGE reducing agent and NuPAGE sample buffer (containing 
SDS, Novex, Life Technologies, Paisley, United Kingdom) in a ratio of 10:2:4 
respectively. Protein samples were then denatured and reduced by heating at 70°C for 10 
minutes. This process is necessary to unfold the 3-dimensional conformation of the protein 
and enable antibody recognition. The SDS within the sample buffer binds to the protein 
and makes the protein negatively charged. As SDS binds to protein in a ratio of 1.4:1, the 
negative charge given to the protein by SDS is proportionate to its size (molecular weight). 
Samples were loaded into NuPAGE Novex 4-12% Bis-Tris Mini Gels along with the 
SeeBlue Plus2 (Invitrogen, Paisley, United Kingdom) pre-stained molecular weight 
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marker. The protein standard allowed observation of electrophoresis progression and 
determination of protein size. The gel was placed in NuPAGE MOPS SDS running buffer 
and run at 150Volts until adequate migration and separation of protein samples.  
2.8.4 Protein Transfer and Visualisation 
Proteins were transferred onto a polyvinylidene fluoride (PVDF) microporous membrane 
(Millipore Corporation, Massachusetts, USA) using a wet transfer method. To activate the 
PVDF membrane it was pre-treated in 100% methanol. The wet transfer tank was prepared 
containing 5% (v/v) NuPAGE transfer buffer, 20% (v/v) methanol in dH2O and run at 
30Volts for 2 hours. To check successful transfer, the membrane was immersed in 0.1% 
(w/v) Ponceau S in 5% (v/v) acetic acid solution for 1 minute to visualise protein bands on 
the membrane. Following this, the membrane was rinsed in dH2O twice to remove the 
Ponceau S stain. Before antibody detection, membranes were blocked to prevent non-
specific background binding of both primary and secondary antibodies. A 5% (w/v) non-
fat milk (marvel) solution in 0.1% (v/v) Tween 20 (Fisher Scientific, Loughborough, 
United Kingdom) in TBS (TBST) was prepared. The membrane was incubated in the 
blocking solution on a shaker for 1 hour at room temperature before being washed in 
TBST for 3x 10 minutes.     
2.8.5 Immunoblotting 
For specific protein analysis primary antibody was added to the membrane according to 
Table 2.3 diluted in 5% (w/v) marvel in TBST. Membranes were incubated overnight on a 
shaker at 4°C. The membrane was then washed in TBST for 3x 10 minutes. This allowed 
removal of any unbound primary antibody. Following this, membranes were incubated for 
1 hour on a shaker at room temperature with secondary antibody according to Table 2.3 
diluted in 5% (w/v) marvel in TBST. The membrane was then washed in TBST for 3x 10 
minutes. The secondary antibody is conjugated to HRP which allowed detection by 
enhanced chemiluminescence (ECL) using Immobilon western chemiluminescence HRP 
substrate (Merck Millipore, Massachusetts, USA) or Pierce ECL (Thermo Scientific, 
United Kingdom). The working ECL solution contains the chemiluminescent substrate 
luminal. In the presence of the HRP enzyme on the secondary antibody, luminol is 
oxidised. Oxidised luminal emits light which can be captured by exposure to x-ray film 
and allows visualisation of the specific protein. Membranes were then washed in TBST for 
10 minutes before being stripped using Restore western blot stripping buffer (Thermo 
Scientific, United Kingdom) for 15 minutes on a shaker at room temperature. To check 
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even protein loading, the membranes were re-probed with the loading control α-tubulin. 
Quantification of protein expression was carried out by densitometry analysis using 
TotalLab 1D gel analysis (TotalLab, United Kingdom) and the protein: α-tubulin ratio was 
calculated. 
Table 2.3 Antibody experimental conditions 
 
2.9 RNA Analysis 
2.9.1 RNA Extraction 
For PASMCs, RNA was extracted from either 6-well plates or T-75 flasks. Briefly, at 
experimental end point the culture dish containing PASMCs was immediately placed on 
ice. The media was aspirated off and cells washed twice with either 1ml or 5ml of cold 
PBS per well or flask respectively. Following this, 700µl QIAzol lysis reagent was added 
to each well or T75 flask. QIAzol is a phenol/guanidine-based lysis reagent which 
facilitates lysis of cells/tissues, inhibits RNases and removes DNA and proteins. Keeping 
the culture dish on ice, the cells were scraped using a sterile plastic scraper and cell lysates 
collected in a pre-chilled 1.5ml eppendorf. Alternatively, for whole tissue samples RNA 
was extracted via the following. Upon dissection from the mouse cadaver the right lung 
lobe was either immediately snap-frozen in liquid nitrogen and stored in a freezer at -80°C, 
or placed in a pre-chilled 2ml eppendorf containing 700µl of QIAzol. A 5mm stainless 
steel bead (Qiagen, United Kingdom) was added to each sample eppendorf which was then 
placed in a Tissue Lyser II (Qiagen, United Kingdom) for homogenisation for 4x 30 
second intervals. Further extraction and purification of RNA was performed using the 
miRNEASY extraction kit according to manufacturer’s instructions (Qiagen, United 
Kingdom). This kit allows extraction of RNA species as small as 18 nucleotides in length. 
Briefly, after homogenisation samples were left on the bench top at room temperature for 5 
 Chapter Two  Materials and Methods 
79 
 
minutes to help promote dissociation of nucleoprotein complexes. Following this 140µl of 
chloroform was added to each sample and vigorously shaken for 15 seconds to aid 
subsequent phase separation. Each sample was left for a further 3 minutes on the bench top 
at room temperature before being centrifuged at 12,000xg at 4°C for 15 minutes. This step 
separates the sample into 3 phases; an upper colourless aqueous phase, a middle white 
interphase and a lower red organic phase. The RNA is contained within the upper phase 
which is carefully transferred into a new eppendorf. To precipitate the RNA phase, 1.5 
volumes of 100% ethanol was added to each sample and mixed thoroughly by pipetting. 
Each sample was then loaded into an RNeasy Mini spin column in a 2ml collection tube 
and centrifuged at 8,500xg at room temperature for 15 seconds. The flow through in the 
collection tube was discarded. The RNA is captured in the mini spin column and is washed 
with 350µl of RWT buffer. The mini spin column in the collection tube is then centrifuged 
at 8,500xg at room temperature for 15 seconds. The flow through in the collection tube 
was discarded. To remove any residual amounts of DNA within the mini spin column, an 
on-column DNase digestion was performed on each sample. The DNase digestion solution 
was prepared by adding DNase I stock solution to buffer RDD in a ratio of 1:7. The 
working solution was mixed by gently inverting and 80µl was pipetted directly onto each 
mini spin column membrane to ensure complete digestion. Each sample was left to 
incubate at room temperature for 20 minutes before adding 350µl of RWT buffer to the 
mini spin column and centrifuging at 8,500xg at room temperature for 15 seconds. The 
flow through was discarded and 500µl of RPE buffer was added to each mini spin column. 
The sample was centrifuged at 8,500xg at room temperature for 15 seconds and again the 
flow through was discarded. This step was repeated but centrifuged for 2 minutes. The 
mini spin column was placed in a new 2ml collection tube and centrifuged at 8,500xg at 
room temperature for 1 minute to remove any residual RPE buffer. The mini spin column 
was then transferred into a new 1.5ml eppendorf and 30µl RNase free H2O pipetted 
directly onto each mini spin column membrane. Each sample was then centrifuged at 
8,500xg at room temperature for 1 minute to elute the RNA before being immediately 
transferred to ice or storage at -80°C.               
2.9.2 Quantification of RNA 
The quality and concentration of RNA within each sample was determined by a NanoDrop, 
ND-1000 spectrophotometer (Thermo Scientific, United Kingdom). The 
spectrophotometer measured the absorbance of each sample at 260nm (absorbance of 
RNA) and 280nm (absorbance of protein). The quality of RNA was analysed by the 
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260nm/280nm ratio. Samples with a ratio ~2 were accepted to have a good purity of RNA. 
The concentration of RNA was analysed using a modified Beer-Lambert equation and an 
extinction coefficient of 40ng-cm/µl as follows:  
Concentration of RNA (ng/µl) = (260nm Absorbance *extinction coefficient) 
      pathlength in cm      
2.9.3 Reverse Transcription 
For mRNA detection RNA samples were first reverse transcribed to complementary DNA 
(cDNA) using Taqman® reverse transcription reagents (Life Technologies, Paisley, United 
Kingdom) as per manufacturers guide. Briefly, 1µg of RNA template was prepared in a 96-
well plate with a reaction mix containing RT-buffer [10x], magnesium chloride [25mM], 
deoxynucleotide triphosphates (dNTPs) [2.5mM each], random hexamers [50µM], RNase 
inhibitor [20U/µl] and multiscribe [50U/µl]. The 96-well plate was briefly vortexed and 
centrifuged to ensure adequate mixing. Reverse transcription (RT) was performed using 
the Veriti® Thermal Cycler (Life Technologies, Paisley, United Kingdom) with the 
following temperature programme: 25°C for 10 minutes, 48°C for 30 minutes and 95°C for 
5 minutes. These conditions allow for RNA template annealing, reverse transcription and 
transcription inactivation, respectively. For miRNA detection RNA samples were first 
reversed transcribed using Taqman® microRNA reverse transcription kit (Life 
Technologies, Paisley, United Kingdom) as per manufacturers guide. Briefly, 5ng of RNA 
template was prepared in a 96-well plate with a reaction mix containing RT-buffer [10x], 
dNTPs [2.5mM each], RNase inhibitor [20U/µl], multiscribe [50U/µl], RNase free H2O 
and miRNA primer [5x] (Table 2.4). The temperature programme for miRNA RT was as 
follows: 16°C for 30 minutes, 42°C for 30 minutes and 85°C for 5 minutes.  
2.9.4 Quantitative Real Time-Polymerase Chain Reaction 
For mRNA and miRNA detection Taqman® universal PCR master mix and fluorescently 
tagged Taqman® primers (Life Technologies, Paisley, United Kingdom) were used 
according to Table 2.4. The ViiA7™ Real-Time PCR System (Life Technologies, Paisley, 
United Kingdom) was used for measuring fluorescence of the quantitative real time-
polymerase chain reaction (qRT-PCR). The fluorescence measured after each amplification 
cycle was proportional to level of PCR product. For mRNA expression the temperature 
cycle conditions were 50°C for 2 minutes, 95°C for 10 minutes and 50 cycles of 95°C for 
15 seconds, 60°C for 1 minute. For miRNA expression the temperature cycle conditions 
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were 95°C for 10 minutes and 50 cycles of 95°C for 15 seconds, 60°C for 1 minute. Each 
sample was performed in triplicate and expression analysis determined relative to 
housekeeping control primers as listed in Table 2.4. For quantification analysis the 
comparative cycle threshold (CT) method was used. CT is the number of cycles in the PCR 
reaction required for the accumulated fluorescence to surpass a threshold level of 
fluorescence. The CT number is inversely proportional to the measured mRNA or miRNA 
level. A ΔCT value is obtained from the difference between the CT of the RNA of interest 
and the CT of the housekeeper RNA. Further to this a ΔΔCT value is obtained from the 
difference in ΔCT of test sample and the ΔCT of control sample. A relative quantification 
(RQ) was calculated from 2
-ΔΔCT
. This method allows the control samples (i.e. non-patient 
data) to be expressed as 1 with test samples (i.e. patient data) expressed as a fold change.  
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Table 2.4 List of miRNA/mRNA Taqman primers 
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2.10 Molecular Cloning 
2.10.1 3’UTR PCR 
A 456 base pair (bp) length of the 5-HT1B 3’un-translated region (UTR) was PCR-
amplified from mouse genomic DNA (gDNA) using forward and reverse primers that 
introduced XhoI and NotI restriction endonuclease sites. The forward primer was 5’-
GGGTACCGCTCGAGGCTCTGGGGAGAACTCTGTG and the reverse primer was 5’-
ATAAGAATGCGGCCGCAGCAACCCAGCCTATCCTCT. The underlined regions 
denote the recognition sites for XhoI and NotI restriction endonucleases respectively. The 
different restriction sites allow for directional cloning. Briefly, in a 50µl reaction 100ng 
template gDNA was prepared with KOD buffer [1x],  betaine [1M], MgSO4 [1mM], 
dNTPs [0.2mM], KOD polymerase [0.01U/µl], (x) of H2O, forward primer [0.3µM] and 
reverse primer [0.3µM]. The following PCR cycling conditions were used: 98°C for 1 
minute, 30 cycles of 98°C for 10 seconds, 58°C for 30 seconds, 72°C for 30 seconds and a 
final 72°C for 10 minutes. To purify the PCR fragment from excess primers, nucleotides 
and polymerase a cleanup reaction was performed using the QIAquick PCR Purification 
Kit with microcentrifuge protocol as per manufacturer’s instructions. Briefly, 5 volumes of 
buffer PB were added to 1 volume of the PCR sample and mixed before being transferred 
into a QIAquick spin column in a 2ml collection tube. The sample was centrifuged for 1 
minute at room temperature to allow the DNA to bind to the silica membrane. The flow 
through was discarded and the sample washed with 750µl of buffer PE before being 
centrifuged again for 1 minute at room temperature. The flow through was discarded and 
the sample centrifuged again for 1 minute at room temperature to remove residual ethanol 
from the wash buffer. The QIAquick spin column was then transferred into a new 
eppendorf tube and 30µl of nuclease-free H2O was pipetted directly onto the spin column 
membrane. This was incubated for 1 minute before being centrifuged at 8,500xg for 1 
minute at room temperature to elute the DNA. Samples were then immediately transferred 
to ice or storage at -20°C.        
2.10.2 Agarose Gel Electrophoresis 
To separate and identify the size of DNA fragments agarose gel electrophoresis was 
utilised. This technique uses an electrical current and a porous agarose gel matrix to 
migrate negatively charged DNA towards a positive electrode. The migration of DNA is 
dependent on several factors including molecular size of DNA and concentration of 
agarose gel. DNA migrates through the agarose gel inversely proportional to its molecular 
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size i.e. small molecules will migrate faster than large molecules. The concentration of 
agarose gels utilised were either 0.8 or 1.5% (w/v) agarose (Invitrogen, Paisley, United 
Kingdom) in 1xTris-borate EDTA (TBE, 10mM Tris, 10mM boric acid, 10mM EDTA, pH 
8) solution depending on the size of DNA fragments being examined. Agarose gels with 
low concentration provide large pore sizes within the gel and were used to separate DNA 
fragments at >1kb size. Agarose gels with high concentration (1.5%) provide small pore 
sizes within the gel and were used to separate DNA fragments <1kb. Agarose gel 
electrophoresis was performed to ensure successful 3’UTR PCR and restriction 
endonuclease digest reactions. Briefly, samples were prepared with 6x blue/green loading 
dye (Invitrogen, Paisley, United Kingdom) and loaded into pre-cast wells on an agarose gel 
of appropriate concentration containing 10ng/ml ethidium bromide (Sigma Aldrich). 
Ethidium bromide binds to DNA and allows visualisation of DNA bands under ultraviolet 
light. A 100bp or 1kb DNA marker ladder was also loaded to allow standardisation of 
DNA bands. Gels were run constantly at 100V in a 1xTBE running buffer until loading dye 
had reached near the end of the gel. DNA bands were visualised on the gel by trans-
ultraviolet illumination on a ChemiDoc XRS+ Imaging System (Bio-Rad Laboratories, 
Hemel Hempstead, United Kingdom).      
2.10.3 Isolation of DNA Fragment from Agarose Gel 
To recover DNA from agarose gels the QIAquick® Gel Extraction Kit (Qiagen) was 
employed using the microcentrifuge protocol as per manufacturer’s instructions. Briefly, 
following agarose gel electrophoresis, DNA fragments were visualised using ultraviolet 
illumination. Using a clean, sharp scalpel the DNA gel fragment was carefully excised and 
placed in an eppendorf tube containing 3 volumes of buffer QG to 1 volume of gel 
fragment. Next, the eppendorf tube was incubated at 50°C for 10 minutes with vortexing 
every 2 minutes until the gel fragment had completely dissolved. Isopropanol was then 
added and mixed to the eppendorf at a volume equivalent to 1 volume of gel fragment. The 
sample was then loaded into a QIAquick spin column in a 2ml collection tube and 
centrifuged for 1 minute at room temperature. This step enables the DNA to bind to the 
silica membrane within the QIAquick spin column. The flow through was discarded and 
500µl of buffer QG added to QIAquick spin column before being centrifuged for 1 minute 
at room temperature. This ensures complete removal of agarose within the sample. The 
sample was then washed with 700µl of buffer PE by addition to the QIAquick spin column 
and centrifugation for 1 minute at room temperature. The flow through was discarded and 
the QIAquick spin column further centrifuged for 1 minute at room temperature to remove 
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any residual ethanol from the wash buffer. The QIAquick spin column was then transferred 
into a new eppendorf tube and 30µl of nuclease-free H2O was pipetted directly onto the 
spin column membrane. This was incubated for 1 minute before being centrifuged at 
8,500xg for 1 minute at room temperature to elute the DNA. Samples were then 
immediately transferred to ice or storage at -20°C.      
2.10.4 Restriction Endonuclease Digestion 
Restriction endonuclease digestion is a technique utilised to cut double stranded DNA in 
preparation for cloning. The digestion produces compatible “sticky” ends of both the insert 
(PCR fragment) and vector (psi-check-2) which can then be successfully ligated together. 
Using two different restriction endonucleases allows for directional insertion of the PCR 
fragment into the psi-check-2 vector. Briefly, in a 20µl reaction 1µg psi-check-2 vector 
was digested with XhoI [1U/µl] and NotI [1U/µl] restriction endonucleases (New England 
BioLabs) in  buffer 3 [1x] (New England BioLabs), BSA [1x] and (x) of H2O for 5 hours at 
37°C. Diagnostic digest of the psi-check-2 was also carried out using the restriction 
endonucleases BamHI and NotI (New England BioLabs). Analysis of successful digestion 
was carried out by agarose gel electrophoresis as of 2.9.2 and correctly digested DNA was 
extracted as of 2.9.3.  
2.10.5 Ligation of PCR fragment into Psi-Check-2 Vector 
To create a recombinant DNA molecule the PCR fragment was inserted into the psi-check-
2 vector via a ligation reaction. This was performed using T4 ligase (New England 
Biolabs) as per manufacturer’s instructions. Briefly, ligation reactions were performed 
using varying molar ratios of vector: insert i.e. 3:1, 1:1, 1:3 using the following formula: 
ng of insert = (ng of vector) x (kb size of insert) x (molar ratio) 
kb size of vector 
In a 20µl reaction 50ng of vector along with appropriate ratio of insert (PCR fragment) was 
added to DNA ligase buffer [1x], T4 DNA ligase [20U/µl] and made to volume with H2O. 
The reaction was incubated at 16°C overnight before being heat inactivated at 65°C for 10 
minutes. The eppendorf was then immediately placed on ice before proceeding to the 
transformation stage. 
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2.10.6 Transformation of Competent Bacteria 
To generate large quantities of recombinant DNA, the ligated vector and insert were 
transformed with Stellar™ Competent Cells (Clontech, France) as per manufacturer’s 
instructions. Stellar Competent Cells are an E.coli HST04 strain of bacteria which have 
been prepared to uptake foreign genetic material. Exogenous genetic material is 
incorporated into the bacteria host and replicated upon bacteria growth. Briefly, 50µl of 
competent cells were thawed on ice and mixed gently to ensure even distribution. The 
competent cells were then transferred into a pre-chilled 14ml round-bottom tube and 5ng 
of ligated DNA was added. The competent cells and DNA were incubated on ice for 30 
minutes before being heat-shocked for precisely 45 seconds at 42°C. This step allows the 
DNA to enter into the cell. The tube was then placed back on ice for 2 minutes before 
addition of 450µl of pre-warmed (37°C) super optimal broth with catabolite repression 
(SOC, Clontech, France) medium. Transformation samples were then placed in a shaking 
incubator at 150xg for 1 hour at 37°C. Working under an ethanol burner varying volumes 
of transformation samples were then pipetted and spread onto luria broth (LB, 10g/L 
bactotryptone, 5g/L bactoyeast extract, 5g/L NaCl, 15g/L agar, pH7.5) agar plates 
containing 100µg/ml of ampicillin. Plates were then incubated overnight at 37°C and 
checked for growth of colonies the following day. A positive (pUC19 vector) and negative 
control was utilised alongside the experimental ligated vector and insert.    
2.10.7 Plasmid DNA Purification 
2.10.7.1 Mini-Prep Small Scale  
Single bacterial colonies which had grown overnight were chosen from the above 
mentioned LB agar plates to inoculate starter cultures. The starter culture consisted of a 
pipette tip with the single colony on the end immersed in 10ml of LB containing 100µg/ml 
ampicillin in a 50ml culture tube with a loose lid for aeration. The starter culture was left to 
grow overnight in a shaking incubator (150xg) at 37°C. In this time larger amounts of 
recombinant plasmid DNA were obtained. For long-term storage and reference purposes 
glycerol stocks were made of each starter culture. Here, 800µl of culture was added to 
800µl of 40% (w/v) glycerol (Sigma Aldrich, Dorset, United Kingdom) and mixed 
thoroughly. The resultant mix was then stored at -80°C. For diagnostic purposes and to 
ensure successful cloning 2ml of the culture was purified for use in restriction 
endonuclease digestion reactions and sequencing. 
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Small scale plasmid DNA purification was performed using the PureLink® Quick Plasmid 
Miniprep Kit (Invitrogen, Paisley, United Kingdom) as per manufacturer’s instructions. 
This kit lyses bacterial cells utilising an alkaline/SDS procedure. Briefly, a 2ml culture was 
harvested by centrifugation at 5,000xg for 10 minutes to achieve a pellet. The LB media 
supernatant was removed and the pellet re-suspended in 250µl of re-suspension buffer R3. 
The solution was gently mixed until a homogenous suspension was obtained to ensure 
complete lyses in the following step. Next, 250µl of lysis buffer L7 was added and gently 
mixed by inverting until the mixture was homogenous. Here the alkaline and detergent 
lysis solution breaks down the bacterial cells releasing the plasmid DNA. This was then 
left to incubate on the bench-top for 5 minutes at room temperature. To precipitate the 
bacterial cells genomic DNA and proteins 350µl of precipitation buffer N4 was added and 
mixed immediately by inverting until the mixture was homogenous. The tube was then 
centrifuged for 10 minutes at 10,200xg at room temperature. To bind the DNA to the silica 
membrane the supernatant was then loaded into a spin column in a 2ml collection tube and 
centrifuged for 1 minute at 10,200xg at room temperature. The flow through was discarded 
and the spin column washed with 500µl of wash buffer W10. The spin column was left to 
incubate on the bench-top for 1 minute at room temperature before being centrifuged for 1 
minute at 10,200xg at room temperature. The flow through was discarded and the spin 
column washed further with 700µl of wash buffer W9. The spin column was centrifuged 
for 1 minute at 10,200xg at room temperature and the flow through was discarded. To 
remove any residual ethanol from the wash buffer the spin column was further centrifuged 
for 1 minute at 10,200xg at room temperature. Next, the spin column was transferred into a 
new eppendorf and 50µl of nuclease-free H2O was pipetted directly onto the spin column 
membrane. This was incubated for 1 minute before being centrifuged at 10,200xg for 2 
minutes at room temperature to elute the plasmid DNA. Samples were then immediately 
transferred to ice or storage at -20°C. Analytical restriction endonuclease digestion of 
mini-prep samples were then carried out as of 2.9.4 and examined by agarose gel 
electrophoresis as of 2.9.2  
2.10.7.2 Maxi-Prep Large Scale 
After successful mini-prep diagnostics the remaining starter culture was transferred into 
500ml of LB containing 100µg/ml ampicillin in a 1L conical flask and left to grow further 
overnight in a shaking incubator at 37°C. In this time larger amounts of recombinant 
plasmid DNA were obtained.  
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Large scale plasmid DNA purification was performed using the PureLink® HiPure 
Plasmid DNA Maxiprep Kit (Invitrogen, Paisley, United Kingdom) as per manufacturer’s 
instructions. This kit utilises the same alkaline/SDS lyses principals as of 2.9.7.1 but an 
anion-exchange resin is used to purify the plasmid DNA. Briefly, a 500ml culture was 
harvested by centrifugation at 5,000xg for 15 minutes at 4°C to achieve a pellet. The LB 
media supernatant was removed and the pellet re-suspended in 10ml of resuspension buffer 
R3 with RNase A. The solution was gently mixed until a homogenous suspension was 
obtained to ensure complete lyses in the following step. Next, 10ml of lysis buffer L7 was 
added and gently mixed by inverting until the mixture was homogenous. Here the alkaline 
and detergent lysis solution breaks down the bacterial cells releasing the DNA. This was 
then left to incubate on the bench-top for 5 minutes at room temperature. To precipitate the 
bacterial cells genomic DNA and proteins 10ml of precipitation buffer N3 was added and 
mixed immediately by inverting until the mixture was homogenous. The precipitated lysate 
was then transferred into an equilibrated HiPure filter maxi column and left to run through 
the filter by gravity. The flow through was discarded and the maxi column washed with 
10ml wash buffer W8 by letting the buffer run through the filter by gravity. Immediately 
after the wash buffer had finished flowing through the inner filtration cartridge was 
removed and the maxi column was further washed with 50ml of wash buffer W8. The 
buffer was again left to flow through by gravity and the maxi column transferred to a new 
50ml centrifuge tube. Next, to elute the DNA 15ml of elution buffer E4 was added to the 
maxi column and the solution again left to flow through by gravity. The maxi column was 
discarded and 10.5ml of isopropanol was added to the elution tube to precipitate the DNA 
and mixed well. The elution tube containing the precipitated DNA was centrifuged at 
10,200xg for 30 minutes at 4°C to obtain a DNA pellet. The supernatant was carefully 
removed and discarded. Following this, the DNA pellet was re-suspended in 5ml of 70% 
(v/v) ethanol until homogenous. The sample was centrifuged at 10,200xg for 5 minutes at 
4°C and again the supernatant was carefully discarded. The DNA pellet was then left to air 
dry for 10 minutes to ensure all residual ethanol was removed before being re-suspended in 
200µl of nuclease-free H2O. Samples were then immediately transferred to ice or storage at 
-20°C. Analytical restriction endonuclease digestion of mini-prep samples were then 
carried out as of 2.9.4 and examined by agarose gel electrophoresis as of 2.9.2         
2.10.8 DNA Sequencing 
To confirm the nucleotide sequence within the plasmid DNA the dideoxynucleotide 
sequencing method was utilised. This technique involves the use of fluorescently labelled 
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dideoxynucleotide triphosphates (ddNTPs) which instead of having a hydroxyl (OH) group 
attached to the 3’ end have hydrogen (H). As H molecules are unable to form 
phosphodiester bonds with a proceeding deoxynucleotide the elongation of the DNA 
sequence is terminated. This results in a series of DNA fragments which differ in length by 
a single nucleotide base with the last nucleotide in each fragment being fluorescently 
labelled. The DNA fragments are separated by size and the sequence analyser reads the 
fragments from small to large enabling the generation of the DNA sequence. 
Briefly, in a 25µl reaction, 100ng of template plasmid DNA was combined with 
sequencing buffer [0.8x] (Applied Biosystems, Paisley, United Kingdom), ready reaction 
mix [1x] (Applied Biosystems, Paisley, United Kingdom), forward or reverse primer 
[1.2µM] and sterile (x) of H2O. The temperature cycle conditions were as follows: 25 
cycles of 50 seconds at 96°C (for denaturation), 20 seconds at 50°C (for primer annealing) 
and 3 minutes at 60°C (for elongation). To purify the sequencing PCR reaction from 
excess primers and nucleotides a cleanup reaction was performed. This process utilises 
magnetic beads to purify the DNA extension fragments. Briefly, 10µl of cleanseq was 
added to each reaction well. Next, 62µl of 85% (v/v) ethanol was added and gently 
pipetted up and down before being briefly vortexed and centrifuged. The reaction plate was 
then placed on a magnetic base for 2 minutes to separate the magnetic beads (with attached 
DNA) and the ethanol. Keeping the plate on the magnetic base the plate was upturned to 
remove the ethanol. This process was repeated with 150µl of 85% (v/v) ethanol. The plate 
was left on the bench-top to air dry for 10 minutes before adding 40µl of nuclease free H2O 
to each reaction well. The sample was briefly pipetted up and down to mix and again 
placed on the magnetic base for 2 minutes. Taking care not to disrupt the magnetic beads, 
20µl of the sample was transferred into a new sequencing plate. The sample was then 
analysed on ABI 3730 automated sequencer and SeqScape v2.0 software (Applied 
Biosystems, Paisley, United Kingdom).      
2.10.9 Site-Directed-Mutagenesis 
To further examine the miRNA-96/5-HT1B relationship a targeted change within the seed 
region of the 5-HT1B 3’UTR molecular DNA sequence was generated. This was performed 
by site-directed mutagenesis and created a single point substitution mutation in the 5-HT1B 
3’UTR to assess miRNA-96 binding as a result of DNA manipulation. Briefly, the plasmid 
DNA was methylated by adding a methyl group using S-adenosylmethionine (SAM) and 
CpG methyltransferase (M.SssI). This allows for targeted degradation of the non-mutated 
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plasmid by DpnI endonuclease later on. In an eppendorf 14µl of nuclease free H2O was 
added to NEB buffer 2 [1x], SAM [160µM], 100ng of plasmid DNA and M.SssI [4U/µl]. 
The reaction was placed at 37°C for 1 hour for the methylation to take place before 
reaction termination by heating at 65°C for 20 minutes. Next, the mutagenesis PCR was 
performed using a forward mutagenic primer and a reverse non-mutagenic primer. The 
sequences of the forward and reverse primer were as follows: forward 5’-
CATGATGTGTGCTAGTGCCTAAGTCTGCAG-3’ and reverse 5’-
GGCACTAGCACACATCATGTTTTGAGTTGT-3’. Briefly, two PCR reactions were 
carried out in parallel, one using the forward mutagenic primer and one using the reverse 
primer. Each 25µl PCR reaction mix contained KOD buffer [1x], betaine [1M], MgSO4 
[1mM], dNTPs [0.2mM], 50ng methylated plasmid DNA, KOD polymerase [0.01U/µl] 
and (x) nuclease free water in addition to either forward or reverse mutagenic primer 
[0.3µM]. The two individual PCR reactions were run on a thermocycler as follows: 98°C 
for 30 seconds, 98°C for 10 seconds, 59°C for 30 seconds and 72°C for 6 minutes 30 
seconds. Immediately after the PCR cycle was finished the two reactions were combined 
and a further PCR was run with the following cycle: 98°C for 30 seconds, then 19 cycles 
of 98°C for 10 seconds, 59°C for 30 seconds, 72°C for 6 minutes 30 seconds and a final 
72°C for 10 minutes. This second PCR allowed for annealing and multiplying of 
mutagenic forward and reverse strands. To remove the methylated parental non-mutated 
plasmid DNA a DpnI digest was performed. This involved incubating the DNA with 1 unit 
of DpnI for 1 hour at 37°C. The reaction was then heat-inactivated at 80°C for 20 minutes. 
The resultant mutated plasmid DNA was then transformed, analysed and sequenced as per 
2.10.6, 2.10.4 and 2.10.8 respectively.             
2.11 Dual Luciferase Activity Reporter Assay 
2.11.1 Transient Transfection of HeLa Cells 
To compare the transcriptional activity of the cloned 5-HT1B 3’UTR in the absence and 
presence of pre-miR-96 a dual luciferase activity reporter assay was performed. Briefly, 
immortalised HeLa cells were plated and grown in 24-well tissue culture plates as of 
section 2.5.3. Once approximately 60% confluent, HeLa cells underwent a transient 
transfection protocol using Lipofectamine® 2000 (Invitrogen) as per manufacturer’s 
instructions. Initially the cells were washed twice with 500µl optimem (Invitrogen) before 
addition of 500µl of 10% FBS (v/v) DMEM with no antibiotic too each well. Next, 100µl 
of transfection mix was added to each well (Table 2.5) and the cells transferred back to the 
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humidified cell culture chamber. After 6 hours the transfection media was removed and 
replaced with 1ml of 10% FBS (v/v) DMEM with 1% (v/v) AA. Cells were then left to 
grow for a further 48 hours. Plates were carried out in duplicate to confirm successful pre-
miR-96 transfection by qRT-PCR.   
Table 2.5 Transfection conditions for transient transfection of HeLa Cells 
 
2.11.2 Lysate Preparation 
Growth media was aspirated from each well and each well washed with 1xPBS. The PBS 
was removed and 100µl of 1x passive lysis buffer (PLB) was added into each well of the 
24-well plate. Alternatively, for duplicate plates 250µl of QIAzol was added to each well 
for RNA extraction (section 2.8.1) and subsequent qRT-PCR analysis (2.8.4). The 24-well 
plate was transferred to -80°C for 5 minutes to flash freeze the lysates. Next the 24-well 
plate was placed on ice and gently agitated on a shaker for 10 minutes. Each well was then 
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scraped, contents placed in an eppendorf and centrifuged at 10,200xg for 5 minutes at 4°C. 
Next 7.5µl of supernatant was transferred into a single well of a white 96-well plate 
containing 12.5µl of 1xPLB per well.   
2.11.3 Stop N Glo 
To measure the luciferase activity of each sample the Dual-Glo Luciferase Assay System 
(Promega, Southampton, United Kingdom) was utilised as per manufacturer’s instructions. 
The procedure was performed and luminescence detected via a LUMIstar OPTIMA 
microplate reader (BMG Labtech). Briefly, the LUMIstar was set to pump 50µl of LARII 
reagent into each well and then measure firefly luciferase activity. Following this, 50µl of 
STOP N GLO was immediately pumped into each well and then the renilla luciferase 
activity was measured. The renilla luciferase activity was normalised to the internal firefly 
luciferase activity and data expressed as a percentage of the internal control. Each sample 
was performed in triplicate. 
2.12 Models of Pulmonary Hypertension 
2.12.1 Chronic Hypoxia 
To induce a PH phenotype, the chronic hypoxic model was utilised. Eight-week old wild-
type (WT) mice were continuously exposed to chronic hypoxia via a hypobaric hypoxic 
chamber at 550mbar for 14 days. The sustained reduction in pressure from atmospheric 
room pressure (1000mbar) was equivalent to a decrease in O2 availability to 10% O2. Low 
O2 levels result in pulmonary vasoconstriction and the development of a robust PH 
phenotype (Mair et al., 2014). The temperature and relative humidity were constantly 
monitored and maintained within optimal ranges at all times. Food, water and bedding 
were replenished every 5 days. Eight-week old WT mice were also placed in normoxic 
conditions (1000mbar) to act as controls. 
2.13 Administration of miRNA mimic 
To assess whether miRNA-96 was involved in the pathology of pulmonary hypertension, 
the miRNA-96 mimic (Applied Biosystems, #MC10422) was administered intravenously 
via the tail vein on day 0 and day 7 using the MaxSuppressor™ In Vivo RNA-LANCEr II 
delivery method as previously described to facilitate delivery to the lung (Trang et al., 
2011).  The mimic was prepared under sterile conditions in the delivery reagent as per 
manufacturing instructions at a dose of 1.5mg/kg per injection i.e. ~30ug per mouse per 
 Chapter Two  Materials and Methods 
93 
 
injection. This dose was based on a previously published delivery to lung (Trang et al., 
2011). Negative miRNA mimic (Applied Biosystems, #1) and PBS dosed animals were 
utilised as controls. On day 14 of the experimental timeline (Figure 2.3), characteristics of 
PH were assessed.  
 
 
 
Figure 2-3 In vivo Experimental timeline 
(A) Eight week old C57Bl/J mice were subjected to a 14 day hypoxic period. On day 0 and 
day 7 mice were dosed with either 1.5mg/kg miRNA-96 mimic, negative control or PBS 
and PAH phenotype assessed on day 14. (B) Six month old BMPR2
R899X+/- 
mice were 
subjected to dosing on day 0 and day 7 with either 1.5mg/kg miRNA-96 mimic, negative 
control and PAH phenotype assessed on day 14.  
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2.14 Assessment of Pulmonary Hypertension 
2.14.1 Anaesthetic Induction 
All mice were initially anaesthetised in an induction chamber containing 3% (v/v) 
isoflurane (Abbot Laboratories, Berkshire, United Kingdom) supplemented with O2 (flow 
rate, 0.5L/min). Post-induction mice were immediately weighed before being transferred to 
a face mask providing 1.5% isoflurane (v/v) supplemented with O2 (flow rate, 0.5L/min). 
The absence of a hind limb reflex was checked to ascertain appropriate level of 
anaesthesia. To ensure maintenance of anaesthesia the hind limb reflex was monitored 
repeatedly throughout the in vivo procedure along with breathing and heart rates.  
2.14.2 Systemic Arterial Pressure 
To allow continuous observation of systemic arterial pressure (SAP) the left common 
carotid artery was cannulated. Briefly, an incision was made in the ventral neck and the 
layers of smooth muscle carefully blunt dissected until the trachea was reached. Further 
blunt dissection to the left of the trachea was carried out to expose the left common carotid 
artery. The left common carotid artery was identified by its pulsation and the presence of 
the vagus nerve (white in appearance) running alongside it. Next the carotid artery was 
carefully isolated from the vagus nerve and cleaned of any connecting tissue. Surgical silk 
monofilament suture (size 5.0, Harvard Apparatus, Massachusetts, U.S.A.) was used to 
ligate the carotid artery at the proximal (head) end. A microsurgical artery clip (Fine 
Science Tools, Heidelberg, Germany, FST#18055-04) was carefully secured at the distal 
end of the carotid artery to temporarily occlude blood flow. A small incision was made in 
the artery above the suture tie and carefully held open with curved forceps. Next, a 
heparinised saline-filled micro-cannula (Harvard Apparatus, Massachusetts, U.S.A.) was 
inserted and advanced gently into the lumen of the carotid artery. The micro-cannula was 
then ligated in place with a 5.0 silk suture before removal of the artery clip. The micro-
cannula was connected to a transducer and data acquisition system (Biopac Systems, 
California, U.S.A.) for SAP reading (Figure 2.4). For analysis measurement of the mean 
SAP (mSAP) was obtained. 
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Figure 2-4 Systemic arterial Pressure Measurement 
A three second representative trace recording of a systemic arterial pressure in mouse. Y 
axis shown in mmHg.  
 
 
2.14.3 Right Ventricular Systolic Pressure 
Indirect assessment of pulmonary arterial pressure was obtained by catheterisation of the 
right ventricle of the heart to allow measurement of right ventricular pressure (RVP). This 
was done by a transdiaphragmatic approach, a well-documented technique (Morecroft et 
al., 2007; Dempsie et al., 2011; White et al., 2011a). Briefly, the ventral sternum of the 
mouse was exposed and a 25mm gauge needle centrally aligned. Using a micromanipulator 
(Warner Instruments, Connecticut, U.S.A.) the needle was moved 2mm to the right and 
then advanced underneath the sternum through the diaphragm (indicated by a negative 
pressure) and eventually to puncture the right ventricle wall into the right ventricle. A 
characteristic pressure trace was observed when the needle was successfully in the right 
ventricle (Figure 2.5). For analysis the right ventricular systolic pressure (RVSP) and heart 
rate (HR) was obtained from the pressure readings. The correct placement of the needle 
was additionally confirmed at whole heart dissection with a noticeable puncture in the right 
ventricle wall. After in vivo measurements were obtained mice were killed by anaesthetic 
overdose.  
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Figure 2-5 Right Ventricular Systolic Pressure Measurement 
(A) A schematic representation of catheter placement to achieve right ventricular pressure 
measurement. (B) A three second representative trace recording of a right ventricular 
pressure in non-PH mouse. (C)  A three second representative trace recording of a right 
ventricular pressure in PH mouse. Y axis shown in mmHg. RV= right ventricular.  
 
2.14.4 Right Ventricular Hypertrophy 
Upon termination of mice, the heart and lungs were gently flushed with ice-cold PBS by 
injection through the right ventricle. Whole hearts were then excised and cleared of 
adjoining fatty tissue and blood vessels. Both right and left atria were also removed. 
Measurement of right ventricular hypertrophy (RVH) is determined using Fulton’s index: 
the ratio of the free right ventricle (RV) wall weight and the left ventricle (LV) wall plus 
septum (S) weight (RV/LV+S) (Fulton et al., 1952) (Figure 2.6). The right ventricle was 
cut away, blotted dry and weighed. This was then repeated with the remaining left ventricle 
plus septum and the ratio calculated. 
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Figure 2-6 Diagrammatic illustration of right ventricular hypertrophy 
A schematic transverse section of the heart showing the left ventricle wall, septum and thin 
walled right ventricle in a normal non-PH heart (A) and hypertrophied right ventricle in a 
PH heart (B).  
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2.14.5 Pulmonary Artery Remodelling 
To assess the extent of remodelling in PH, 5µm frontal plane lung sections were prepared 
and stained with elastic pico-sirius red as per section 2.4.1 and section 2.4.3. Stained lung 
sections were then microscopically examined for non-remodelled and remodelled 
pulmonary arteries <80µm external diameter. Remodelled pulmonary arteries were 
determined by the presence of a double elastic lamina (Figure 2.7). The number of 
remodelled pulmonary arteries was expressed as a percentage of total number of 
pulmonary arteries (non-remodelled and remodelled) within the lung section. Assessment 
was carried out in a blinded fashion.  
 
Figure 2-7 Remodelling of a small pulmonary artery 
Representative images of small distal pulmonary arteries from non-PH lung section (A) 
and PH lung section (B). Note the presence of the double elastic lamina in panel (B). Scale 
bar 50µm.  
 
 
2.15 Statistical Analysis 
Values are expressed as mean ± standard error of the mean (SEM). A t-test or 1-way 
ANOVA followed by Tukey’s post-hoc test was performed to evaluate the statistical 
significance between all groups where appropriate. A probability level of p<0.05 was 
defined as being statistically significant. 
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3.1 Introduction 
The majority (~75%) of patients with HPAH and 20% of patients with IPAH present with 
mutations within the gene encoding BMPR-II (Atkinson et al., 2002; Machado et al., 
2006a; Hamid et al., 2009). BMPR-II mutations lead to a reduction in expression or 
reduction in function of the BMPR-II receptor resulting in reduced BMPR-II mediated 
signalling pathways (Atkinson et al., 2002; Yang et al., 2005). Within the pulmonary 
vasculature and more specifically the distal PASMCs a reduction in BMPR-II expression 
triggers aberrant proliferation (Teichert-Kuliszewska et al., 2006). Dysregulated PASMCs 
proliferation generates muscularisation and remodelling of small distal pulmonary arteries 
and initiates PAH development.    
BMPR-II mutations occur with reduced disease penetrance i.e. only 20% of mutation 
carriers will develop PAH. This implies BMPR-II mutations do not fully confer PAH 
disease susceptibility and secondary genetic or environmental factors are required for 
disease onset. One secondary factor of major interest is the serotonin system which has a 
wide implication in PAH development. Within the PASMCs of the distal pulmonary 
arteries serotonin plays an important role in pulmonary artery remodelling and pulmonary 
artery vasoconstriction, two major hallmarks of PAH disease (MacLean et al., 1996b; 
Long et al., 2006). Research from both human samples and experimental animal models 
highlight the fundamental involvement of the 5-HT1B receptor in pathological processes 
making it a favourable gene to therapeutically target (Keegan et al., 2001; Launay et al., 
2002; Morecroft et al., 2005).    
Within HPAH a gender disparity exists with a 2.7:1 female to male ratio suggesting 
interplay of sex with disease prevalence (Loyd et al., 1995). This sex bias is also observed 
in other PAH categories where a ~4:1 female to male ratio is demonstrated (Ling et al., 
2012). Investigations into the sex bias in PAH have suggested anomalous estrogen 
synthesis, signalling and/or metabolism may be pathogenic in PAH. For example an 
increase in the expression and function of aromatase (the estrogen synthesising enzyme) is 
associated with PAH and interestingly an aromatase inhibitor is effective in reducing a PH 
phenotype only in female mice and not males (Mair et al., 2014). Additionally, increased 
expression of ERα is demonstrated in female patient PAH and an ERα antagonist reduces 
the remodelling of pulmonary arteries in female mice (Rajkumar et al., 2010; Mair et al., 
2014). Overall it appears estrogen may confer susceptibility to PAH by involvement in 
proliferative and remodelling processes of pulmonary arteries.  
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More recently, miRNAs have been implicated in PAH with regards to their involvement in 
cellular processes such as proliferation and apoptosis. Amongst those mentioned in section 
1.7, a role for miRNA-21 and miRNA-145 show dysregulation in human PAH samples and 
hypoxic and monocrotaline animal models (Caruso et al., 2010; Caruso et al., 2012). It is 
recognised that sex differences exist in miRNA expression and therefore miRNAs which 
are influenced by sex may shape the architecture of female and male gene expression 
differently (Marco et al., 2013; Wu et al., 2013). Sexual dimorphism of miRNAs is 
thought to play a role in the development of sex bias diseases such as SLE with expression 
potentially regulated by the presence or absence of sex hormones (Dai et al., 2013; Ohta et 
al., 2013). With regards to PAH, it is currently unknown whether female and male 
differences in miRNA expression exist and could underlie female susceptibility in disease 
onset and development.    
Here, we examine female and male differences in miRNA expression in PASMCs from a 
BMPR-II mutation mouse model and PASMCs from human patients. Our data 
demonstrates a down-regulation of miRNA-96 only in female experimental and clinical 
PAH samples. This is associated with a concomitant up-regulation of the miRNA-96 target 
5-HT1B receptor. We also demonstrate estrogen may play a role in regulating miRNA-96 
and consequently the 5-HT1B receptor.  A dysregulated miRNA-96/5-HT1B axis may confer 
proliferation in female patient PASMCs and contribute to the female susceptibility in PAH.    
Aims of this chapter: 
1. To identify female and male sex differences in miRNA expression. 
2. To functionally validate a target for a sex specific miRNA.  
3. To examine if estrogen regulates the sex specific miRNA.  
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3.2 Results 
3.2.1 Female BMPR2R899X+/- mice exhibit an increase in remodelled and 
proliferating distal pulmonary arteries  
In the initial genesis of disease, normal non-muscularised distal pulmonary arteries become 
severely muscularised when PASMCs undergo aberrant proliferation. To assess sex 
differences arising from BMPR-II mutation we examined pulmonary artery 
muscularisation and proliferation by immunohistochemistry. Here we observed pulmonary 
arteries from female BMPR2
R889X+/- 
mice had a significantly greater wall thickness: vessel 
diameter ratio than male BMPR2
R889X+/- 
mice vs. their respective WT control as indicated 
by the intense staining for α-smooth muscle actin (Figure 3.1). This indicates that female 
BMPR2
R889X+/- 
pulmonary arteries are more muscularised than male BMPR2
R889X+/- 
pulmonary arteries.  In addition, there was intense positive staining for proliferating cell 
nuclear antigen (PCNA) in pulmonary arteries from female BMPR2
R889X+/- 
mice compared 
to female WT mice (Figure 3.2). This intense positive staining for PCNA was not observed 
in pulmonary arteries from male WT or BMPR2
R899X+/- 
mice with the level of PCNA 
staining in both, likened to that of pulmonary arteries from female WT mice. This suggests 
that in female BMPR2
R889X+/- 
mice more PASMCs are in the S-phase (DNA replication) of 
the cell cycle and more likely to be proliferating.  
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Figure 3-1 The degree of muscularisation of small distal pulmonary arteries is 
increased in female BMPR2
R899X+/- 
mice 
Representative immunolocalisation of α-smooth muscle actin (α-SMA), a marker for 
smooth muscle cell, in 5µm frontal plane lung sections from female and male wild-type 
(WT) and BMPR2
R899X+/- 
mice. Positive staining for α-SMA was visualised by the dark 
orange/brown colour (A). Quantification of muscularisation was assessed by expressing 
the ratio of the vessel wall thickness (as observed by the α-SMA positive stain): total 
vessel diameter (B). n=4 for female and male WT, n=8 for female and male BMPR2
R899X+/- 
mice per group, **p<0.01, ***p<0.001, One-way ANOVA followed by Tukey’s post-hoc 
test. Data is expressed as the mean ± SEM. Scale bar = 50µm. WT= wild-type  
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Figure 3-2 Immunolocalisation of PCNA in small distal pulmonary arteries highlights 
intense staining in female BMPR2
R899X+/- 
mice 
Representative immunolocalisation of proliferating cell nuclear antigen (PCNA), a marker 
for S-phase cell division, in 5µm frontal plane lung sections from female and male WT and 
BMPR2
R899X+/- 
mice. Positive staining for PCNA was visualised by the dark orange/brown 
colour. Scale bar = 50µm.   
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3.2.2 Sex affects microRNA expression in BMPR2R899X+/- PASMCs  
MiRNAs are known to be involved in proliferative processes, more specifically 
proliferation of PASMCs in PAH development. Sex differences are also known to exist 
between certain miRNAs yet it has not been investigated if sex differences in miRNA exist 
in PAH that could account for the sex bias/female susceptibility in disease. Thus we 
wished to examine whether sex differences in miRNA expression could underlie 
differences in proliferative/muscularisation phenotype in PASMCs from BMPR2
R899X+/-
 
mice. To do this we examined the expression profile of various miRNAs either previously 
associated with PAH development or which target genes are associated with PAH 
development (Table 3.1). From 18 miRNAs examined, sex and genotype did not 
significantly affect miRNA-16, miRNA-22, miRNA-27b, miRNA-98 and miRNA-224 
expression (Figure 3.3 and Figure 3.4). Expression of miRNA-17, miRNA-18a, miRNA-
19a, miRNA-21, miRNA-29b, miRNA-96, miRNA-424, miRNA-451 and miRNA-503 
were significantly reduced in female BMPR2
R889X+/- 
PASMCs compared to female WT 
PASMCs while remaining unchanged between male BMPR2
R889X+/- 
and WT PASMCs. 
MiRNA-145 and miRNA-206 were significantly up-regulated in both female and male 
BMPR2
R889X+/- 
PASMCs compared to respective WT PASMCs. A significant decrease in 
miRNA-203 expression was observed in male BMPR2
R889X+/- 
PASMCs compared to male 
WT PASMCs while remaining unchanged between female BMPR2
R889X+/- 
and WT 
PASMCs. MiRNA-155 was dysregulated in both female and male BMPR2
R889X+/-
 
PASMCs compared to WT with expression decreased in female BMPR2
R889X+/-
 but 
increased in male BMPR2
R889X+/-
 PASMCs. This data suggest sexual dimorphism with 
respect to miRNAs does exist within a PH setting.  
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Table 3.1 List of miRNA’s investigated and their gene target/association 
 
 
 
 
 Chapter Three In Vitro 
107 
 
 
Figure 3-3 Sex and BMPR2
R899X+/- 
mutation alters the expression of miRNAs in 
PASMCs 
Pulmonary artery smooth muscle cells (PASMCs) were explanted and cultured from 
female and male WT and BMPR2
R899X+/-
 mice. The expression of miRNA was assessed by 
Taqman quantitative Real Time-PCR. Results were normalised to the small nuclear RNA, 
U6. n=8 per group in triplicate, *p<0.05, **p<0.01, ***p<0.001, One-way ANOVA 
followed by Tukey’s post-hoc test. Data was expressed as the RQ ± RQmax/RQmin. RQ= 
relative quantification, WT= wild type.   
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Figure 3-4 Sex and BMPR2
R899X+/- 
mutation alters the expression of miRNAs in 
PASMCs Continued 
Pulmonary artery smooth muscle cells (PASMCs) were explanted and cultured from 
female and male WT and BMPR2
R899X+/-
 mice. The expression of miRNA was assessed by 
Taqman quantitative Real Time-PCR. Results were normalised to the small nuclear RNA, 
U6. n=8 per group in triplicate, *p<0.05, **p<0.01, ***p<0.001, One-way ANOVA 
followed by Tukey’s post-hoc test. Data was expressed as the RQ ± RQmax/RQmin. RQ= 
relative quantification, WT= wild type.  
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3.2.3 MiRNA-96  
As miRNA-96 was differentially expressed between female PASMCs and not male 
PASMCs and was a novel miRNA implicated in the PAH setting, we selected this miRNA 
for further analysis and investigation. MiRNA-96 has previously been implicated in 
various cancer models/tissues and as cancer is a proliferative disease akin to PAH this 
enhanced our interest in examining this miRNA.  The human miRNA-96 gene is located 
on chromosome 7 (mouse chromosome 6) and lies within an intergenic region in the 
genome. MiRNA-96 is also evolutionary conserved between several species indicating 
important function (Figure 3.5). MiRNA-96 also appears in a cluster with miRNA-182 and 
miRNA-183 however each miRNA has its own distinct pri-miRNA meaning expression 
can arise under different promoters. To understand if the whole cluster is dysregulated 
between sexes in PASMCs from BMPR2
R899X+/-
 mice, we examined the expression of 
mature miRNA-182/183 levels by Taqman analysis. Here we found that miRNA-182 was 
down-regulated in both female and male BMPR2
R899X+/-
 PASMCs compared to WT 
PASMCs with less expression observed in male BMPR2
R899X+/-
 PASMCs than female 
BMPR2
R899X+/-
 PASMCs (Figure 3.6). MiRNA-183 was down-regulated in male 
BMPR2
R899X+/-
 PASMCs compared to male WT PASMCs, however, was unchanged in 
female PASMCs.  Expression of miRNA-183 was also significantly down-regulated in 
male BMPR2
R899X+/-
 PASMCs vs. female BMPR2
R899X+/-
 PASMCs (Figure 3.6).  
Global tissue expression of miRNA-96 was assessed to understand whether miRNA-96 
was ubiquitously expressed or potentially selective/specific to the pulmonary system. 
Taqman qRT-PCR analysis revealed miRNA-96 expression was significantly greater in the 
lung compared to the liver, spleen and brain (Figure 3.7). The kidney and uterus expression 
level of miRNA-96 was also decreased compared to the lung however here statistical 
significance was not reached. This suggests that of the tissues analysed the highest 
expression of miRNA-96 is observed in the lung tissue. In addition it could suggest that 
miRNA-96 could have more of a physiological role in the lung compared to the tissues 
where there is less expression. It would also suggest that potential targets may also be co-
localised within the lung tissue.  
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Figure 3-5 The sequence of miRNA-96 is evolutionary conserved 
The miRNA-96 sequence is highly conserved amongst several species emphasising its 
important physiological role.   
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Figure 3-6 Sex and BMPR2
R899X+/- 
mutation alters the expression of miRNA-182/183 
in PASMCs  
Pulmonary artery smooth muscle cells (PASMCs) were explanted and cultured from 
female and male WT and BMPR2
R899X+/-
 mice. The expression of miRNA was assessed by 
Taqman quantitative Real Time-PCR. Results were normalised to the small nuclear RNA, 
U6. n=8 per group in triplicate, *p<0.05, **p<0.01, ***p<0.001 One-way ANOVA 
followed by Tukey’s post-hoc test. Data was expressed as the RQ ± RQmax/RQmin. RQ= 
relative quantification.    
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Figure 3-7 Global expression analysis highlights high expression of miRNA-96 in lung 
tissue 
The expression of miRNA-96 was assessed by Taqman quantitative Real Time-PCR in 
various tissues from WT mice. Results were normalised to the small nuclear RNA, U6. 
n=5 per group in triplicate, *p<0.05, ***p<0.001 One-way ANOVA followed by Tukey’s 
post-hoc test. Data was expressed as the RQ ± RQ
max
/RQ
min
. RQ= relative quantification.    
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3.2.4 MiRNA-96 is localised within the smooth muscle cell layer 
To ascertain the cellular location of miRNA-96 within lung tissue we performed in situ 
hybridisation. Analysis of mouse lung sections highlighted positive staining for miRNA-96 
within the pulmonary artery smooth muscle cell layer (Figure 3.8). Staining for miRNA-96 
was not detected in the endothelial cell layer within the pulmonary artery.   
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Figure 3-8 Localisation of miRNA-96 to smooth muscle cell layer in pulmonary artery 
in mouse lung sections 
Representative in situ hybridisation and immunohistochemistry localisation of miRNA-96, 
von-williebrand factor (a marker for endothelial cells) and α-smooth muscle actin (a 
marker for smooth muscle cells) in 5µm frontal plane lung sections from mice. Positive 
staining for miRNA-96 was visualised by a purple colour, von-williebrand and α-smooth 
muscle actin was visualised by the dark orange/brown colour. Scale bar = 50µm.   
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3.2.5 MiRNA-96 is down-regulated in human female PAH 
Having identified positive staining for miRNA-96 in the pulmonary artery smooth muscle 
cell layer of lung sections we wished to examine the relative expression of miRNA-96 
within human PASMCs from non-PAH and PAH patients. Here we showed female PAH 
patient PASMCs exhibited significantly decreased expression of miRNA-96 compared to 
female non-PAH PASMCs (Figure 3.9). There was no significant differences between 
male PASMCs and their expression level of miRNA-96 was comparable to female non-
PAH PASMCs. These results correlate with the expression of miRNA-96 within PASMCs 
from female and male BMPR2
R899X+/- 
mice. This data further suggest that sex may underlie 
differences in miRNA-96 expression in the setting of PAH disease.  
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Figure 3-9 Expression of miRNA-96 is down-regulated in female PASMCs from PAH 
patients only 
Pulmonary artery smooth muscle cells (PASMCs) were explanted and cultured from 
female and male PAH patient and non-patient donors. The expression of miRNA-96 was 
assessed by Taqman quantitative Real Time-PCR. Results were normalised to the small 
nuclear RNA, RNU48. n=4-6 human samples per group in triplicate, *p<0.05, **p<0.01, 
One-way ANOVA followed by Tukey’s post-hoc test. Data was expressed as the RQ ± 
RQ
max
/RQ
min
. RQ= relative quantification.    
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3.2.6 5-HT1B is a target of miRNA-96 
We next focused on investigating a putative target of miRNA-96. Online in silico target 
prediction software (www.mirwalk.com) showed a seed match for miRNA-96 in the 
3’UTR of the HTR1B gene (Figure 3.10) and also that miRNA-96 is the only predicted 
miRNA with a seed match in the 3’UTR of the HTR1B gene (www.mirwalk.com). The 
HTR1B gene encodes the 5-HT1B receptor which has previously been implicated and 
extensively characterised with regards to the development of PAH.  To begin to validate a 
relationship between miRNA-96 and 5-HT1B we initially performed Taqman qRT-PCR and 
western blot protein expression analysis on PASMCs from both BMPR2
R899X+/- 
mice and 
human samples. Here we found the mRNA and protein expression of the 5-HT1B receptor 
was significantly increased in female BMPR2
R899X+/- 
PASMCs compared to female WT 
and unchanged amongst males (Figure 3.11 and Figure 3.12). Likewise, the 5-HT1B 
receptor expression was also significantly increased in PASMCs from female PAH patient 
compared to female non-PAH at both mRNA and protein level (Figure 3.13 and Figure 
3.14). Again there was no change in 5-HT1B expression between male non-PAH and PAH 
PASMCs. These results showed us that miRNA-96 and the 5-HT1B receptor co-exist within 
PASMCs and more importantly that there is an inverse relationship between the two. This 
provides evidence to suggest 5-HT1B is a target of miRNA-96.     
 
Figure 3-10 The 5-HT1B mRNA contains a miRNA-96 binding site 
Schematic overview of the miRNA-96:5-HT1B mRNA interaction. The area highlighted 
yellow indicates the nucleotide binding in seed region.   
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Figure 3-11 The expression of 5-HT1B mRNA is selectively increased in PASMCs 
from female BMPR2
R899X+/- 
mice 
Pulmonary artery smooth muscle cells (PASMCs) were explanted and cultured from 
female and male wild-type (WT) and BMPR2
R899X+/-
 mice. The expression of 5-HT1B 
mRNA was assessed by Taqman quantitative Real Time-PCR. Results were normalised to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). n=6 per group in triplicate, 
*p<0.05, One-way ANOVA followed by Tukey’s post-hoc test. Data was expressed as the 
RQ ± RQ
max
/RQ
min
. RQ= relative quantification.    
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Figure 3-12 The expression of 5-HT1B protein is selectively increased in PASMCs 
from female BMPR2
R899X+/- 
mice 
Pulmonary artery smooth muscle cells (PASMCs) were explanted and cultured from 
female and male wild-type (WT) and BMPR2
R899X+/-
 mice. The expression of 5-HT1B 
protein was assessed by western blot and analysed by densitometric analysis (A). 
Representative immunoblot (B). α-tubulin was used as the internal loading control. n=6 
mice per group, *p<0.05, One-way ANOVA followed by Tukey’s post-hoc test. Data was 
expressed as the mean ± SEM.  
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Figure 3-13 The expression of 5-HT1B mRNA is selectively increased in PASMCs 
from female PAH patients 
Pulmonary artery smooth muscle cells (PASMCs) were explanted and cultured from 
female and male PAH patient and non-patient donors. The expression of 5-HT1B mRNA 
was assessed by Taqman quantitative Real Time-PCR. Results were normalised to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). n=4-6 samples per group in 
triplicate, *p<0.05, One-way ANOVA followed by Tukey’s post-hoc test. Data was 
expressed as the RQ ± RQ
max
/RQ
min
. RQ= relative quantification.    
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Figure 3-14 The expression of 5-HT1B protein is selectively increased in PASMCs 
from female PAH patients 
Pulmonary artery smooth muscle cells (PASMCs) were explanted and cultured from 
female and male PAH patient and non-patient donors. The expression of 5-HT1B protein 
was assessed by western blot and analysed by densitometric analysis (A). Representative 
immunoblot (B). α-tubulin was used as the internal loading control. n=4-6 samples per 
group in triplicate, ***p<0.001, One-way ANOVA followed by Tukey’s post-hoc test. 
Data was expressed as the mean ± SEM.  
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3.2.7 The 5-HT1B receptor is a direct target of miRNA-96 
To validate the 5-HT1B receptor as a target of miRNA-96 a dual luciferase reporter assay 
was performed. Initially a concentration gradient determined that the optimal pre-miRNA-
96 concentration to obtain a significant reduction in luciferase activity was 25nM (Figure 
3.15). Therefore both pre-miRNA-96 and pre-miRNA-negative control were used at a 
concentration of 25nM for further luciferase reporter assay experiments. 48 hours post-
transfection the luciferase activity of the construct containing the 5-HT1B 3’UTR was 
significantly reduced when co-transfected with pre-miRNA-96 but unaltered by co-
transfection with pre-miRNA-negative control (Figure 3.16). The selectivity of this 
interaction was emphasised by the inability of pre-miRNA-96 to reduce luciferase activity 
when a single point mutation was introduced within the seed region of the 5-HT1B 3’UTR 
(5-HT1B mutated). In addition, pre-miRNA-96 had no effect on luciferase activity of the 
control psicheck-2 construct. To verify successful transfection, RNA was harvested from 
duplicate plates and expression of miRNA-96 analysed. Here, results confirmed 
transfection of pre-miRNA-96 significantly increased mature miRNA-96 levels within the 
cells compared to a non-transfected control (NTC) (Figure 3.17). Transfection of pre-
miRNA-negative control had no significant effect on mature miRNA-96 expression. In 
summary these results indicate that miRNA-96 has the functional ability to bind to the seed 
match region within the 3’UTR of the 5-HT1B mRNA.  
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Figure 3-15 The luciferase activity of the 5-HT1B construct is dependent on the pre-
miRNA-96 concentration 
HeLa cells were co-transfected with either the 5-HT1B construct (A and B) or psicheck-2 
construct (C and D) and varying concentrations of pre-miRNA-96 (A and C) or pre-
miRNA negative control (B and D). Luciferase activity was measured 48 hours post-
transfection and the renilla luciferase activity was normalised to the internal firefly 
luciferase activity. n=3 per group in duplicate, **p<0.01, One-way ANOVA followed by 
Tukey’s post-hoc test. Data was expressed as a percentage of the internal control.  
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Figure 3-16 Transfection with 25nM miRNA-96 reduces the luciferase activity of the 
5-HT1B construct 
HeLa cells were co-transfected with either the psicheck-2 construct, the 5 -HT1B construct 
or the 5-HT1B mutated construct and 25nM of pre-miRNA-96 or pre-miRNA negative 
control. Luciferase activity was measured 48 hours post-transfection and the renilla 
luciferase activity was normalised to the internal firefly luciferase activity. n=3 per group 
in duplicate, **p<0.01, One-way ANOVA followed by Tukey’s post-hoc test. Data was 
expressed as a percentage of the internal control.  
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Figure 3-17 Expression of miRNA-96 is increased after transfection with pre-miRNA-
96 
HeLa cells were co-transfected with either the psicheck-2 construct, the 5 -HT1B construct 
or the 5-HT1B mutated construct and 25nM of pre-miRNA-96 or pre-miRNA negative 
control. The expression of miRNA-96 was assessed 48 hours post-transfection by Taqman 
quantitative Real Time-PCR. Results were normalised to the small nuclear RNA, RNU48. 
n=3 per group in triplicate, ****p<0.0001, One-way ANOVA followed by Tukey’s post-
hoc test. Data was expressed as the RQ ± RQ
max
/RQ
min
. RQ= relative quantification, NTC= 
non-transfected control.    
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3.2.8 Heightened 5-HT1B mediated proliferation in female PAH PASMCs 
As PASMCs from female PAH patient had a significantly greater expression of 5-HT1B 
compared to female non-PAH and male we wished to examine whether this translated into 
a biological effect. To investigate any pathophysiological consequence of dysregulated 5-
HT1B expression we analysed serotonin (5-HT) - induced proliferation of PASMCs from 
the four cell groups by cell counting and BrdU incorporation. After 72 hours stimulation 
with the pulmonary vascular mitogen serotonin, a proliferative response was observed only 
in female PAH patient PASMCs (Figure 3.18 and Figure 3.19). This was inhibited by the 
5-HT1B selective antagonist SB224289 suggesting the proliferative response to serotonin 
was mediated by the 5-HT1B receptor. In addition, the selective 5-HT1B agonist, CP94253, 
again induced proliferation only in female patient PASMCs and this was inhibited by 
SB224289.  
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Figure 3-18 Serotonin (5-HT) -induced proliferation in human PASMCs from female 
PAH patients is mediated by the 5-HT1B receptor as determined by cell counts 
Human PASMCs from female (A) and male (C) non-patients and female (B) and male (D) 
PAH patients were quiesced for 24 hours in 0.2% FBS. PASMCs were then pre-incubated 
with the selective 5-HT1B receptor antagonist SB224289 (300nM) for 1 hour prior to 
addition of 5-HT (1µM) or CP94253 (1µM) in the presence of 2.5% FBS. 10% FBS was 
utilised as a positive control. Cell counts were assessed 72 hours later by haemocytometer. 
n=3 human samples per group, in triplicate, *P<0.05, **P<0.01, ****P<0.0001, One-way 
ANOVA followed by Tukey’s post- hoc test. Data expressed as % of 2.5% control.     
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Figure 3-19 Serotonin (5-HT)-induced proliferation in human PASMCs from female 
PAH patients is mediated by the 5-HT1B receptor as determined by BrdU 
incorporation 
Human PASMCs from female (A) and male (C) non-patients and female (B) and male (D) 
PAH patients were quiesced for 24 hours in 0.2% FBS. PASMCs were then pre-incubated 
with the selective 5-HT1B receptor antagonist SB224289 (300nM) for 1 hour prior to 
addition of 5-HT (1µM) or CP94253 (1µM) in the presence of 2.5% FBS. 10% FBS was 
utilised as a positive control. BrdU label was added 48 hours after the initial stimulation 
and BrdU incorporation was assessed 24 hours later. n=4-6 samples per group, in triplicate, 
*P<0.05, **P<0.01, ***P<0.001, One-way ANOVA followed by Tukey’s post- hoc test. 
Data expressed as % of 2.5% control.     
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3.2.9 Over-expression of miRNA-96 in vitro reduces 5-HT1B expression and function 
To validate the functional significance of the miRNA-96 and 5-HT1B interaction we 
performed transient over-expression of miRNA-96 in vitro and analysed the subsequent 
effect on target 5-HT1B mRNA and protein. Initially, a concentration gradient 
demonstrated the optimal pre-miRNA-96 concentration to obtain a significant increase in 
mature miRNA-96 expression and reduction in 5-HT1B expression (Figure 3.20, Figure 
3.21 and Figure 3.22). Therefore both pre-miRNA-96 and pre-miRNA-negative control 
were used at a concentration of 1nM for further expression and functional analysis 
experiments. Results again showed successful transfection of pre-miRNA-96 lead to 
significantly increased expression of mature miRNA-96 levels within PASMCs with no 
effect from pre-miRNA-negative control transfection (Figure 3.23). The increase in 
miRNA-96 expression correlated with a significant reduction in 5-HT1B protein level 
however had no significant effect on 5-HT1B mRNA level (Figure 3.24 and Figure 3.25). 
This suggests that over-expression of miRNA-96 has the ability to bind 5-HT1B mRNA and 
prevent the translation of the transcript into protein but does not target the transcript for 
degradation. To examine the functional consequence we performed serotonin-induced 
proliferation in PASMCs from female PAH patients. Serotonin-induced proliferation was 
abolished in PASMCs transfected with pre-miRNA-96 whereas transfection with pre-
miRNA-negative control had no effect on proliferative response to serotonin (Figure 3.26). 
Moreover, the effect of pre-miRNA-96 was comparable to the effect of the 5-HT1B 
antagonist SB224289. These results suggest that serotonin-induced proliferation can be 
altered by modulating the expression of the 5-HT1B receptor via regulation of miRNA-96.  
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Figure 3-20 The expression of mature miRNA-96 is dependent on the transfected pre-
miRNA-96 concentration 
Human PASMCs were transfected with either pre-miRNA-96 or pre-miRNA negative 
control at a range of concentrations. The expression of mature miRNA-96 was assessed 48 
hours post-transfection by Taqman quantitative Real Time-PCR. Results were normalised 
to the small nuclear RNA, RNU48. n=3 per group in triplicate, *p<0.05, ***p<0.001, One-
way ANOVA followed by Tukey’s post-hoc test. Data was expressed as the RQ ± 
RQ
max
/RQ
min
. RQ= relative quantification, NTC= non-transfected control.    
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Figure 3-21 The expression of 5-HT1B mRNA is dependent on the transfected pre-
miRNA-96 concentration 
Human PASMCs were transfected with either pre-miRNA-96 or pre-miRNA negative 
control at a range of concentrations. The expression of 5-HT1B mRNA was assessed 48 
hours post-transfection by Taqman quantitative Real Time-PCR. Results were normalised 
to the GAPDH. n=3 per group in triplicate, *p<0.05, **p<0.01, One-way ANOVA 
followed by Tukey’s post-hoc test. Data was expressed as the RQ ± RQmax/RQmin.  RQ= 
relative quantification, NTC= non-transfected control.    
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Figure 3-22 The expression of 5-HT1B protein is dependent on the transfected pre-
miRNA-96 concentration 
Human PASMCs were transfected with either pre-miRNA-96 or pre-miRNA negative 
control at a range of concentrations. The expression of 5-HT1B protein was assessed 72 
hours post-transfection by western blotting and analysed by densitometric analysis (A). 
Representative immunoblot (B). α-tubulin was used as the internal loading control. n=3 per 
group in duplicate, *p<0.05, One-way ANOVA followed by Tukey’s post-hoc test. Data 
was expressed as the mean ± SEM. NTC= non-transfected control.    
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Figure 3-23 Transfection with 1nM pre-miRNA-96 increases the mature miRNA-96 
expression in human PASMCs 
Human PASMCs were transfected with either pre-miRNA-96 or pre-miRNA negative 
control at a concentration of 1nM. The expression of mature miRNA-96 was assessed 48 
hours post-transfection by Taqman quantitative Real Time-PCR. Results were normalised 
to the small nuclear RNA, RNU48. n=3 per group in triplicate, ****p<0.0001, One-way 
ANOVA followed by Tukey’s post-hoc test. Data was expressed as the RQ ± 
RQ
max
/RQ
min
. RQ= relative quantification.    
 
 Chapter Three In Vitro 
134 
 
 
Figure 3-24 Transfection with 1nM pre-miRNA-96 does not affect 5-HT1B mRNA 
expression in human PASMCs 
Human PASMCs were transfected with either pre-miRNA-96 or pre-miRNA negative 
control at a concentration of 1nM. The expression of 5-HT1B mRNA was assessed 48 hours 
post-transfection by Taqman quantitative Real Time-PCR. Results were normalised to 
GAPDH. n=3 per group in triplicate. Data was expressed as the RQ ± RQ
max
/RQ
min
. RQ= 
relative quantification.  
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Figure 3-25 Transfection with 1nM pre-miRNA-96 decreases 5-HT1B protein 
expression in human PASMCs 
Human PASMCs were transfected with either pre-miRNA-96 or pre-miRNA negative 
control at a concentration of 1nM. The expression of 5-HT1B protein was assessed 72 hours 
post-transfection by western blotting and analysed by densitometric analysis (A). 
Representative immunoblot (B). α-tubulin was used as the internal loading control. n=3 per 
group in triplicate, ***p<0.001, ****p<0.0001, One-way ANOVA followed by Tukey’s 
post-hoc test. Data was expressed as the mean ± SEM. NTC= non-transfection control.      
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Figure 3-26 Transfection with 1nM pre-miRNA-96 inhibits serotonin (5-HT) –
induced proliferation of human PASMCs from female PAH patients 
Human PASMCs from female PAH patients were quiesced for 24 hours in 0.2% FBS. 
PASMCs were then transfected with 1nM pre-miRNA-96 for 6 hours or pre-incubated with 
the selective 5-HT1B receptor antagonist SB224289 (300nM) for 1 hour prior to addition of 
5-HT (1µM) in the presence of 2.5% FBS. 10% FBS was utilised as a positive control. Cell 
counts were assessed 72 hours later by haemocytometer. n=3 samples per group, in 
triplicate, *P<0.05, **P<0.01, ****P<0.0001, One-way ANOVA followed by Tukey’s 
post- hoc test. Data expressed as % of 2.5% control.     
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3.2.10 Estrogen affects miRNA-96 and 5-HT1B expression 
To understand why the miRNA-96/5-HT1B axis was only prominent in female PAH 
PASMCs we investigated a role for estrogen in miRNA-96 regulation. Previous studies 
have demonstrated a link between estrogen and the serotonin system. More specifically, 
PASMCs stimulated with 17β-estradiol showed an increase in the 5-HT1B receptor, SERT 
and TPH1 protein expression (White et al., 2011a). We therefore wished to examine the 
effect of 17β-estradiol on miRNA-96 expression. First we found that PASMCs stimulated 
with 17β-estradiol had a significantly decreased expression of miRNA-96 compared to un-
stimulated cells (Figure 3.27). Secondly, we analysed lung tissue from mice with reduced  
circulating  estrogen levels. Here we found that female mice dosed with anastrozole 
(inhibitor of estrogen synthesising enzyme aromatase) had significantly increased levels of 
miRNA-96 compared to female mice dosed with vehicle (Figure 3.28). The increase in 
miRNA-96 corresponded with a significant decrease in 5-HT1B mRNA. Interestingly this 
observation was only noted in lung tissue from female mice as dosing with anastrozole had 
no effect on miRNA-96 or 5-HT1B mRNA expression in lung tissue from male mice. These 
results indicate that estrogen may modulate the 5-HT1B receptor via regulation of miRNA-
96 in females.     
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Figure 3-27 17β-estradiol (E2) decreases the expression of miRNA-96  
Human PASMCs were quiesced for 24 hours in 0.2% FBS. PASMCs were then stimulated 
with E2 (1nM) in the presence of 2.5% FBS. The expression of mature miRNA-96 was 
assessed 48 hours post-stimulation by Taqman quantitative Real Time-PCR. Results were 
normalised to the small nuclear RNA, RNU48. n=6 per group in triplicate, *P<0.05, un-
paired t-test. Data was expressed as the RQ ± RQ
max
/RQ
min
. 
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Figure 3-28 Inhibiting estrogen synthesis with the aromatase inhibitor anastrozole, 
increases miRNA-96 expression and decreases 5-HT1B mRNA expression in female 
mice 
Mice were dosed with anastrozole (3mg/kg) or vehicle (1% carboxymethylcellulose) via 
subcutaneous injection for 14 days to reduce endogenous estrogen levels (Mair et al., 
2014). Whole lung homogenates were assessed for miRNA-96 expression in female (A) 
and male (C) tissue and 5-HT1B mRNA expression in female (B) and male (D) tissue by 
Taqman quantitative Real Time-PCR. Results for miRNA-96 expression were normalised 
to the small nuclear RNA, RNU48 and to GAPDH for 5-HT1B mRNA expression. n=5 per 
group in triplicate, *P<0.05, **P<0.01, un-paired t-test. Data was expressed as the RQ ± 
RQ
max
/RQ
min
. 
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3.3 Discussion 
Mutations within the BMPR-II gene are associated with HPAH however they occur with 
reduced disease penetrance. This suggests second hit factors are required for disease onset. 
Contributions from the serotonin system have been reported to have involvement in PAH 
development (MacLean et al., 1996b; Long et al., 2006; MacLean et al., 2009; Maclean et 
al., 2010). Furthermore, genetic modifications underpinned by alterations in miRNA 
expression are also thought to be key in PAH pathogenesis (Caruso et al., 2010; 
Bienertova-Vasku et al., 2015; Zhou et al., 2015). PAH occurs four-fold more frequently 
in women than in men; however, explanation towards the underlying reasons are limited 
(Ling et al., 2012). Emerging literature highlights evidence in support of a causative role 
for estrogens in female susceptibility to PAH development (Rajkumar et al., 2010; White 
et al., 2012; Mair et al., 2014). On the contrary estrogen has also been shown to improve 
right ventricular ejection fraction and cardiac output in the SU-HX rat model (Liu et al., 
2014; Frump et al., 2015). This chapter summarises data which implicates a sex specific 
genetic change in the 5-HT1B receptor expression and function in both BMPR2
R899X+/- 
mouse model and human clinical PAH samples is underpinned by dysregulation in 
miRNA-96 which is potentially under the regulatory control of the female sex hormone 
estrogen.    
It has recently been highlighted that female PASMCs exhibit reduced expression of lung 
BMPR-II, SMAD, Id1 and Id3 expression compared to male PASMCs which could 
predispose females to even less expression in the event of BMPR-II happloinsufficiency 
(Mair et al., 2015) or predispose females to an increased susceptibility of a second hit. This 
is thought to contribute to enhanced female susceptibility in PAH development related to 
BMPR-II deficiency. The BMPR2
R899X+/- 
mouse model generates a mild PH phenotype 
however sex was not taken into account when data analysed (Long et al., 2011; Long et al., 
2015). Here we analysed remodelling of the small distal pulmonary arteries by measuring 
the muscularisation and proliferation of PASMCs in pulmonary arteries. Data revealed 
distinct sex differences in remodelling of BMPR2
R899X+/- 
mice. Female BMPR2
R899X+/-
 
mice had significantly increased percentage of muscularisation and proliferation compared 
to WT mice. This difference was not observed in the male cohort. This could be explained 
by the above mentioned idea that females are predisposed to a reduction in BMPR-II 
pathway which in turn can lead to unopposed p38MAPK/ERK signalling and increased 
proliferation. Additionally, other contributing factors could be facilitating an augmented 
proliferative phenotype in female BMPR2
R899X+/- 
mice. For example, it has been reported 
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that exogenous administration of serotonin can uncover a PH phenotype in a similar 
BMPR2
+/-
 mouse model (Long et al., 2006) therefore perhaps mediators of the serotonin 
system are enhanced in female BMPR2
R899X+/- 
mice and not males, and contribute to 
enhanced proliferation. Furthermore, sex differences between female BMPR2
R899X+/- 
mice 
and male BMPR2
R899X+/- 
mice could be attributed to differences in sex hormone pathways. 
For example, in other mouse models which exhibit female susceptibility in remodelling of 
pulmonary arteries, anomalous estrogen metabolism was found to be associated with 
disease susceptibility (White et al., 2011a; White et al., 2011b). Therefore, it would be 
interesting to ascertain if alterations within the estrogen pathway are established within the 
female BMPR2
R899X+/- 
and not males which could potentially play a role in the sex 
differences in remodelling observed within this study.  
Another explanation for the sex differences observed in remodelling between female and 
male BMPR2
R899X+/- 
mice could be due to differences within miRNA expression as a 
consequence of BMPR-II mutation. The data above mentioned presents the novel finding 
that sex does influence miRNA expression in PASMCs from the BMPR2
R899X+/-
 mouse 
model of PH. Sexual dimorphism in miRNA expression has been previously observed in 
other models of sex bias diseases e.g. SLE (Dai et al., 2013; Ohta et al., 2013). Here, 
dysregulated miRNA signatures were found in female mice after disease onset and not in 
age-matched male mice (Dai et al., 2013). This is the first study to report sexual 
dimorphism in miRNA expression regarding PAH.  As the model under investigation 
involves dysregulation of the BMPR-II gene, an aspect mirrored in human disease, it 
suggests that our results could potentially help us understand the sex bias in human PAH. 
As the sex differences were selective and not apparent for every miRNA under 
examination we can suggest that sex was not affecting the biogenesis of the miRNAs 
studied. However, the main female sex hormone 17β-estradiol has been reported to 
influence the expression of the biogenic DICER gene via an ERα binding site in its 
promoter region (Bhat-Nakshatri et al., 2009). 17β-estradiol was found to up-regulate 
DICER gene expression and subsequently miRNA expression depending on the cell type 
involved. Therefore, as 17β-estradiol levels are higher in females compared to males 
(Dighe et al., 2005) it could potentially affect the biogenesis of miRNAs. Without further 
examining the components of the miRNA biogenesis pathway e.g. expression of DICER or 
DROSHA we cannot be certain that they are not influenced by sex within this study. It is 
known that the BMPR-II signalling pathway can influence regulation of certain miRNAs 
via their biogenesis. For example, SMAD proteins interact with DROSHA to increase the 
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biogenic processing of pri-miRNA-21 into mature miRNA-21 (Davis et al., 2008). With 
regards to BMPR-II mutations downstream SMAD expression is reduced and therefore 
interaction with DROSHA could also be expected to be reduced thus reducing the biogenic 
processing of miRNAs. This could possibly explain dysregulation of miRNA expression 
when occurring in both female and male BMPR2
R899X+/- 
PASMCs e.g. miRNA-145 and 
miRNA-206. However, when the dysregulation is selective for one sex i.e. occurring in 
female BMPR2
R899X+/- 
PASMCs and not male BMPR2
R899X+/- 
PASMCs then it would 
suggest other factors independent of the BMPR-II pathway are playing a regulatory role. 
Likewise, for miRNAs that are oppositely dysregulated e.g. miRNA-155 is down-regulated 
in female BMPR2
R899X+/- 
PASMCs but up-regulated in male BMPR2
R899X+/- 
PASMCs 
compared to WT, this would also suggest secondary contributing factors are controlling 
miRNA expression. Ultimately, understanding these differences is imperative to improving 
PAH therapies. Consistent differences in miRNA expression profile could be one potential 
reason why women and men respond differently to current PAH treatment (Gabler et al., 
2012) and could signify that women and men with PAH need to be treated depending on 
their sex.  
For further examination in this study we focused on miRNA-96, a novel miRNA 
implicated in the context of PAH. Here we show miRNA-96 expression is significantly 
down-regulated in PASMCs from female BMPR2
R899X+/-
 mice only and not males. This 
sex specific difference observed was consistent with results from clinical PAH samples 
which also showed only PASMCs from female PAH patients and not males had decreased 
expression of miRNA-96. This translational finding suggests a decreased expression of 
miRNA-96 has a conserved role in PAH pathogenesis. Furthermore, as the female PAH 
patient samples were from a mixed PAH population and not solely from those harbouring a 
BMPR-II mutation we can suggest that down-regulation of miRNA-96 is not due 
specifically to dysregulation of BMPR-II expression/signalling but from a wider 
contributing factor in PAH pathogenesis. However, as BMPR-II is thought to also be 
dysfunctional in some reports of IPAH (Machado et al., 2006a), without knowing if 
BMPR-II expression and signalling is decreased in our patient cohort we cannot further 
elaborate on the relationship with BMPR-II and miRNA-96. More recently it was reported 
that BMP-4 stimulation down-regulated the expression of miRNA-96 (Kim et al., 2014). 
As BMP-4 stimulation increases proliferation of distal PASMCs and leads to pulmonary 
arterial remodelling (Yang et al., 2005), we can suggest that there is a pathologically link 
 Chapter Three In Vitro 
143 
 
between decreased miRNA-96 expression and aberrant proliferation with regards to distal 
PASMCs.   
As this was the first study implicating miRNA-96 in PAH we sought to investigate a 
functional role and a possible target in PAH pathobiology. In silico bioinformatic analysis 
suggested the 5-HT1B receptor as a putative target of miRNA-96. In addition, a 
polymorphism in the 3’UTR of the 5-HT1B receptor mRNA disrupts binding of miRNA-96 
(Jensen et al., 2009). We validated the 5-HT1B receptor was a target of miRNA-96 through 
luciferase reporter assay and confirmed this with site-directed-mutagenesis. A reduction in 
miRNA-96 within PASMCs from female BMPR2
R899X+/- 
mice corresponded with an 
increase in target 5-HT1B receptor. This demonstrates an interesting interplay between the 
serotonin system and BMPR-II in a BMPR-II model of disease. This interaction has been 
proposed before when a PH phenotype was unmasked in BMPR2
+/-
 mice after exposure to 
heightened levels of serotonin (Long et al., 2006). Expression analysis of female PAH 
patient samples also showed a concomitant increase in 5-HT1B receptor expression in 
PASMCs with decreased miRNA-96 expression compared with female non-PAH patient 
samples. Increased expression of 5-HT1B receptor has been previously documented in 
remodelled pulmonary arteries from PAH patients as well as a number of animal models of 
PH (Heeley R.P., 1998; Launay et al., 2002; Morecroft et al., 2005), however, differences 
between sexes have not previously been distinguished. As the most abundant serotonin 
receptor within the pulmonary vasculature mediating both PASMC contraction and 
proliferation, the 5-HT1B receptor is an attractive therapeutic target (Morecroft et al., 
1999). With regards to PAH the 5-HT1B receptor expression or function has not previously 
been targeted using epigenetic modulation. Here, we also demonstrated direct over-
expression of miRNA-96 (via transfection of pre-miRNA-96) in human PASMCs could 
decrease expression of target 5-HT1B receptor protein in in vitro cell culture. This acute 
over-expression of the miRNA-96 had no effect on 5-HT1B receptor mRNA suggesting that 
after 48 hours the miRNA-96 is binding to the 3’UTR of 5-HT1B receptor mRNA and 
silencing the translation to protein without actual degradation of the mRNA.  
Serotonin is a well-documented mitogen within the pulmonary circulation (Eddahibi et al., 
1999; Eddahibi et al., 2000; MacLean et al., 2000). Thus far there is no knowledge 
regarding its sex differences in mitogenic response. We demonstrated that serotonin-
induced proliferation of human PASMCs from female patients was mediated by the 5-
HT1B receptor as the effect was replicated by a 5-HT1B receptor agonist and abolished by a 
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5-HT1B receptor selective antagonist. These results are consistent with previous studies 
showing the importance of the 5-HT1B receptor mediating human PASMC proliferation 
(Lawrie et al., 2005; Morecroft et al., 2010; Liu et al., 2013). Interestingly, proliferation to 
serotonin in human PASMCs was only observed in female patient PASMCs. This 
correlates with low miRNA-96 and high 5-HT1B receptor expression in this patient cohort. 
No serotonin induced proliferation was demonstrated in any other cell line. This is despite 
there being low expression levels of the 5-HT1B receptor in male PAH patient and female 
and male non-patient PASMCs. The 5-HT1B receptor is coupled to the Gi protein and 
responses can be regulated by synergistic influences where a threshold for activation is 
required (Dickenson et al., 1996; Dickenson et al., 1998). Indeed, activity and/or 
expression of the 5-HT1B receptor can be increased synergistically by Gq-linked receptor 
stimulation (Sweeney et al., 1995; MacLean, 1999; MacLean et al., 2001; Lawrie et al., 
2005), estrogen (White et al., 2011a), co-activation of the serotonin transporter (Lawrie et 
al., 2005; Morecroft et al., 2005; Morecroft et al., 2010) and pERK (Liu et al., 2004; Mair 
et al., 2008). Estrogen synthesis is increased in female human PASMCs (Mair et al., 2014) 
providing a stimulus for over-expression of 5-HT1B and SERT (White et al., 2011a) which 
is over-expressed in patient PASMCs. In addition, pERK2 expression is elevated in female 
human PASMCs and further enhanced in PASMCs from PAH patients (Yang et al., 2005; 
Mair et al., 2008). In addition, there is increased expression of Gq-linked receptors (e.g. 
PDGF, endothelin-1) in PASMCs from patients with PAH (Davie et al., 2002). Hence 
female PASMC from PAH patients are influenced by a unique combination of synergins 
(SERT, Gq-stimulation, estrogen) that can facilitate 5-HT1B receptor-mediated responses.  
We further show miRNA-96 is expressed more in the lung compared to the liver, spleen 
and brain. Specifically, within the lung miRNA-96 localises to the smooth muscle cell 
layer of the pulmonary artery indicating that miRNA-96 may potentially play a role in the 
PASMCs i.e. the proliferative processes of PASMCs within PAH development. This was 
confirmed by the ability of over-expression of miRNA-96 to prevent serotonin-induced 
proliferation of PASMCs from female PAH patients. Thus within the female PAH patient 
PASMCs, down-regulation of miRNA-96 may lead to over-expression of 5-HT1B receptor 
which subsequently increased the capacity of serotonin to induce proliferation. This is the 
first report that miRNA-96 expression influences distal human PASMCs proliferation and 
that manipulation of miRNA-96 can influence proliferation through targeting the 5-HT1B 
receptor.  
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Little is currently known about the role miRNA-96 plays in vascular physiology and 
pathology. Aberrant expression of miRNA-96 has been observed in cancer biology where 
it has been described as being either oncogenic (Haflidadottir et al., 2013) or anti-
oncogenic (Yu et al., 2010). MiRNA-96 has previously been associated with breast cancer 
(Lin et al., 2010) a disease strongly influenced by estrogen and suggests that there could be 
an association between estrogen and miRNA-96 expression. Indeed estrogen can alter 
miRNA expression through three mechanisms, firstly through estrogen-response-elements 
(ERE) in the promoter element of the pri-miRNA gene (Di Leva et al., 2010), secondly 
through transcription of estrogen related genes e.g. c-MYC which can in turn interact with 
transcription of primary-miRNA gene (Castellano et al., 2009) and thirdly through 
interaction with miRNA biogenesis as there is an ERα binding site in the promoter region 
of the Dicer gene (Bhat-Nakshatri et al., 2009). We have previously demonstrated that 
estrogen increases the protein expression of the 5-HT1B receptor in human PASMCs and 
also estrogen-induced proliferation of human PASMCs can be inhibited by a 5-HT1B 
selective antagonist (White et al., 2011a). It was therefore of interest to investigate if 
estrogen could potentially influence 5-HT1B receptor expression through modulating 
epigenetic control. Stimulation of human PASMCs with estrogen decreased the expression 
of miRNA-96 suggesting that estrogen could influence 5-HT1B receptor expression via 
regulation of miRNA-96. This is consistent with bioinformatic analysis showing the 
primary-miRNA-96 gene harbours an ERE in the promoter region (Matys et al., 2003). As 
estrogen is also a potent mitogen within PASMCs and mediates its proliferative effect 
through the 5-HT1B receptor, it would be interesting to see if over-expression of miRNA-
96 (which would reduce 5-HT1B receptor expression) could abolish estrogen induced 
proliferation of PASMCs. A potential role for estrogen in regulation of miRNA-96 
expression could help explain the sexual dimorphism of miRNA-96 expression within both 
PASMCs from BMPR2
R899X+/- 
mice and human patient samples.  
Previous studies have shown that exogenously administered estrogen can protect against 
PH in male mice (Lahm et al., 2012). We recently demonstrated expression of aromatase 
(the estrogen synthesising enzyme) in human, rat and mouse pulmonary artery smooth 
muscle which was greater in females (Mair et al., 2014). In addition, we showed that 
inhibition of endogenous aromatase by anastrozole can prevent and reverse PH in the 
hypoxic mouse and rat SU-HX model but only in females (Mair et al., 2014). Also 
anastrozole treatment restored a reduced expression of BMPR-II in lung samples from 
hypoxic female mice but not males (Mair et al., 2014). Anastrozole decreases endogenous 
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circulating estrogen. This suggests that endogenous estrogen plays a role in the 
development of PH in female mice and rats, but not males, and that the combination of 
circulating estrogen and local endogenous synthesis of estrogen in pulmonary arteries 
drives a PH phenotype in females. Here, we found lungs from mice treated with 
anastrozole demonstrated a significantly higher expression of miRNA-96 compared to 
control lung. This increase in miRNA-96 was associated with a decrease in 5-HT1B 
receptor expression and was only observed in lungs from female mice not males. 
Collectively, our results suggest that endogenous estrogen regulates miRNA-96 expression 
only in female lung. However, we must also consider the input from male sex hormones. 
Inhibiting aromatase with anastrozole would favour the conversion of androstenedione to 
testosterone. Testosterone’s metabolite 5α-dihydrotestosterone (DHT) is known to regulate 
miRNA expression in prostate adenocarcinoma (Waltering et al., 2011). It would be of 
interest to assess the effect of testosterone and its metabolites on miRNA-96 expression to 
greater understand the hormonal control of miRNA-96 and reasons underlying its 
differential expression between sexes. Although it is also worthy to note that unpublished 
data has shown castration (thus removal of male sex hormones) has no effect on the 
development of PH in male mice (Audrey Wright, unpublished). Altogether this supports 
the hypothesis that sex plays an important role in the regulation of miRNAs.  
In summary, our data indicates that estrogen and BMPR-II deficiency can decrease 
miRNA-96 expression in PASMCs causing an increase in 5-HT1B receptor expression 
which may influence the pathobiology of PAH in females. Furthermore, increasing the 
expression of miRNA-96 has the ability to prevent proliferation which is a hallmark of 
PAH disease and makes enhancing miRNA-96 levels an attractive target for PAH therapy.  
Overall this data strengthens the presence of sex differences within PAH disease and a 
stratified approach of 5-HT1B receptor or miR-96 targeted therapies aimed at female 
patients may prove beneficial. 
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Chapter Four 
4 The Effect of Restoring miRNA-96 Levels In Vivo
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4.1 Introduction 
The 5-HT1B receptor and the wider serotonin system have well documented associations 
with PAH development. A general hyperactivity of serotonin synthesis and signalling leads 
to pulmonary artery vasoconstriction and remodelling, two major hallmarks of PAH 
(Herve et al., 1995; Morecroft et al., 1999; Eddahibi et al., 2006). The majority of receptor 
led serotonin signalling in the human pulmonary circulation is mediated via the 5-HT1B 
receptor making it a desirable target for pulmonary artery specificity (Morecroft et al., 
1999). The 5-HT1B receptor is a GPCR which is coupled with the Gi/0 protein and upon 
receptor activation will inhibit adenylate cyclase and reduce the production of cAMP. 
Increased expression of 5-HT1B receptor has been documented in remodelled pulmonary 
arteries of PAH patient lungs and also within a variety of animal models including the 
hypoxic model (Heeley R.P., 1998; Launay et al., 2002). In Chapter 3 we showed an 
increase in 5-HT1B receptor expression and proliferative function specific to female PAH 
patient PASMCs. Experimentally the 5-HT1B receptor has successfully been 
therapeutically challenged by classical pharmacological antagonism in the hypoxic rat 
model (Keegan et al., 2001). However, classical pharmacological antagonism does not 
resolve the underlying over-expression of the 5-HT1B receptor documented within PAH 
and therefore an upstream regulator of this serotonin receptor may prove more beneficial.  
In recent years the advent of miRNA based therapy has grown considerable interest. 
MiRNAs are non-coding RNAs which can direct expression of target genes in a post-
transcriptional manner, some of which can be similarly dysregulated in disease. The idea 
of manipulating a possible subset of pathologically linked genes through one single 
miRNA provided promise of a very powerful therapeutic tool. Influencing miRNA levels 
in vivo can be achieved by either miRNA mimic or antagomir. A dynamic expression 
profile of miRNAs has previously been associated with PAH development (Caruso et al., 
2010). Results from in vivo studies have revealed inhibition of miRNA-17 via an 
antagomir had the ability to reverse both a hypoxic and monocrotaline PH phenotype in 
rats (Pullamsetti et al., 2012). This was thought to be partly via up-regulation of the pro-
apoptotic miRNA-17 target p21. Furthermore, delivery of a miRNA-204 mimic can 
reverse monocrotaline induced PH in rats via reducing the expression of the proliferative 
target nuclear factor of activated T cells (NFAT) (Courboulin et al., 2011). Thus the 
imbalance of proliferative and apoptotic genes (and their downstream effect) involved in 
PAH pathogenesis can be modulated in vivo by miRNA regulation.    
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As PAH is a sex bias disease (Ling et al., 2012) and sexual dimorphism in miRNAs is 
known to exist (Marco et al., 2013; Wu et al., 2013), we hypothesised in Chapter 3 that sex 
differences in miRNA expression could underlie female susceptibility in PAH 
development. In Chapter 3 we found that miRNA-96 was differentially expressed between 
sexes. The down-regulation of miRNA-96 in females contributed to an enhanced 
proliferative phenotype only observed in females via targeting the 5-HT1B receptor. We 
confirmed restoration of miRNA-96 levels in PASMCs in vitro inhibited proliferation, 
however, it remained unclear if restoration of miRNA-96 could prevent and/or reverse the 
onset of PAH development. 
Here, we examine the effect of intravenous in vivo delivery of miRNA-96 mimic on the 
ability to prevent a PH phenotype in female WT mice and also reverse a mild PH 
phenotype in female BMPR2
R899X+/- 
mice. Our data shows successful delivery of miRNA-
96 mimic to the pulmonary arteries by intravenous tail vein injection. Additionally, we 
highlight this is able to restore deficiencies of miRNA-96 in the lungs of both hypoxic and 
BMPR2
R899X+/- 
mice. Most importantly we demonstrate intravenous in vivo delivery of 
miRNA-96 mimic can prevent the induction of a hypoxic PH phenotype and also reverse 
an established disease phenotype in BMPR2
R899X+/- 
mice. Furthermore, we show data 
confirming the therapeutic effect is mediated through targeted reduction of the 5-HT1B 
receptor in both of these models.   
Aims of this chapter: 
1. To examine if intravenous tail vein injection successfully delivered miRNA-96 mimic to 
the pulmonary arteries. 
2. To evaluate if miRNA-96 mimic can prevent and reverse a PH phenotype in female 
mice. 
3. To ascertain if miRNA-96 mimic can effectively regulate the 5-HT1B receptor in vivo.      
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4.2 Results 
4.2.1 Intravenous delivery of miRNA-96 mimic increases miRNA-96 expression in 
the pulmonary artery 
One of the major hurdles in PAH therapy is successful delivery of the drug to the 
pulmonary arteries of the lung. To ensure intravenous tail vein injection of miRNA-96 
mimic successfully reached the pulmonary artery and more specifically the smooth muscle 
cell layer we performed Taqman q-RT-PCR and in situ hybridisation. Our results indicate 
that dosing with 1.5mg/kg (2nmoles) miRNA-96 mimic on day 0 and day 7 as per Figure 
2.3 is substantial to obtain an increase in miRNA-96 expression within the pulmonary 
arteries (Figure 4.1). Furthermore, miRNA-96 expression was localised within smooth 
muscle cells of the small distal pulmonary arteries as shown by the staining for α-smooth 
muscle actin in mice dosed with miRNA-96 mimic (Figure 4.2).   
 
Figure 4-1 Intravenous dosing with a miRNA-96 mimic increases the miRNA-96 
expression in pulmonary arteries  
Mice were dosed with a miRNA-96 mimic (1.5mg/kg) or negative control (1.5mg/kg) via 
intravenous tail vein injection on day 0 and day 7. On day 14 pulmonary artery 
homogenates were assessed for miRNA-96 expression by Taqman quantitative Real Time-
PCR. Results for miRNA-96 expression were normalised to the small nuclear RNA, U6. 
n=5 per group in triplicate, *P<0.05, un-paired t-test. Data was expressed as the RQ ± 
RQ
max
/RQ
min
. 
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Figure 4-2 MiRNA-96 expression is localised to smooth muscle cell layer after 
intravenous miRNA-96 mimic dosing 
Representative in situ hybridisation and immunohistochemistry localisation of miRNA-96, 
von-williebrand factor (a marker for endothelial cells) and α-smooth muscle actin (a 
marker for smooth muscle cells) in 5µm frontal plane lung sections from mice dosed with a 
miRNA-96 mimic or negative control. Positive staining for miRNA-96 was visualised by a 
purple colour, von-williebrand and α-smooth muscle actin was visualised by the dark 
orange/brown colour. Scale bar = 50µm.   
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4.2.2 Intravenous delivery of miRNA-96 mimic prevents a PH phenotype in female 
hypoxic mice 
To investigate the effect of a miRNA-96 mimic on the development of a PH phenotype we 
assessed right ventricular systolic pressure (RVSP), right ventricular hypertrophy (RVH) 
and remodelling in hypoxic female mice. Importantly our data demonstrates successful 
induction of a hypoxic PH phenotype as witnessed by the significant increase in all three 
measured parameters within the normoxic PBS dosed mice vs. hypoxic PBS dosed mice. 
Treatment with negative control mimic showed no effect on RVSP, RVH and remodelling 
of both normoxic and hypoxic mice. We observed that delivery of miRNA-96 mimic to the 
pulmonary arteries reduced RVSP in hypoxic mice as compared to both PBS and negative 
control mimic dosed mice (Figure 4.3). In hypoxia a miRNA-96 mimic also decreased the 
weight of the right ventricle reducing RVH compared to control mice (Figure 4.4). In 
addition, to ascertain if a miRNA-96 mimic affected remodelling of the small distal 
pulmonary arteries we assessed the percentage of pulmonary arteries with double elastic 
lamina within lung sections (Figure 4.5). Here our data indicates that treatment with 
miRNA-96 significantly reduced the number of remodelled pulmonary arteries in hypoxic 
mice compared to both PBS and negative control mimic dosed mice. As the number of 
remodelled pulmonary arteries in the hypoxic miRNA-96 mimic dosed group is not 
significantly different from the normoxic miRNA-96 mimic dosed group we can suggest 
that treatment with miRNA-96 mimic prevented the processes involved in hypoxia- 
induced remodelling. Administration of miRNA-96 mimic had no significant effect under 
normoxic conditions in all three assessed PH parameters. From this data we can suggest 
that miRNA-96 has a critical function in modulating hypoxia- induced PH in female mice. 
However, as all three parameters are not reduced to normoxic levels we can suggest that 
miRNA-96 may not solely be responsible for hypoxic induced PH and that other 
contributing factors are potentially playing a role.  
 Chapter Four In Vivo 
153 
 
 
Figure 4-3 Reduction in hypoxia-induced right ventricular systolic pressure by a 
miRNA-96 mimic 
Female wild-type C57Bl/6 mice were exposed to hypoxia (10% oxygen) or normoxia for 
14 days. On day 0 and day 7 mice were dosed with 1.5mg/kg miRNA-96 mimic, negative 
control or PBS via intravenous tail vein injection. Right ventricular systolic pressure 
(RVSP) was assessed by right heart catheterisation. n=10, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001, One-way ANOVA followed by a Tukey’s post-hoc test. Data was 
expressed as the mean ± SEM.   
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Figure 4-4 Reduction in hypoxia-induced right ventricular hypertrophy by a miRNA-
96 mimic 
Female wild-type C57Bl/6 mice were exposed to hypoxia (10% oxygen) or normoxia for 
14 days. On day 0 and day 7 mice were dosed with 1.5mg/kg miRNA-96 mimic, negative 
control or PBS via intravenous tail vein injection. Right ventricular hypertrophy (RVH) 
was assessed by measuring the right ventricle weight over the left ventricle plus septum 
(RV/LV+S). n=10, *p<0.05, **p<0.01, ****p<0.0001, One-way ANOVA followed by a 
Tukey’s post-hoc test. Data was expressed as the mean ± SEM.   
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Figure 4-5 Reduction in hypoxia-induced pulmonary artery remodelling by a 
miRNA-96 mimic 
Female wild-type C57Bl/6 mice were exposed to hypoxia (10% oxygen) or normoxia for 
14 days. On day 0 and day 7 mice were dosed with 1.5mg/kg miRNA-96 mimic, negative 
control or PBS via intravenous tail vein injection. Remodelling of pulmonary arteries was 
assessed by counting the number of remodelled (double elastic lamina) and non-
remodelled arteries (single elastic lamina) and expressing the percentage of remodelled 
arteries over the total number of arteries counted (A). Representative images are shown in 
the bottom panel (B). n=10, ***p<0.001, ****p<0.0001, One-way ANOVA followed by a 
Tukey’s post-hoc test. Data was expressed as the mean ± SEM. Scale bar =50µm.   
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4.2.3 Intravenous delivery of miRNA-96 mimic had no effect on systemic 
parameters in female hypoxic mice 
As the haemodynamics of mice administered a miRNA-96 mimic had not previously been 
explored, it was crucial to also examine the effects on both systemic arterial pressure 
(SAP) (Figure 4.6) and heart rate (HR) (Figure 4.7). Here our data highlighted that neither 
hypoxic conditions nor administration of PBS, negative control mimic or miRNA-96 
mimic had any significant effect on both SAP and HR. This data importantly suggests that 
effects modulated by the miRNA-96 mimic are specific to the pulmonary circulation and 
therefore unwanted side effects mediated by the systemic circulation may be limited. In 
addition no significant differences were observed between body weights of all six 
experimental groups (Figure 4.8).    
 
 
Figure 4-6 Administration of a miRNA-96 mimic or hypoxia had no effect on mean 
systemic arterial pressure in hypoxia-induced pulmonary hypertension 
Female wild-type C57Bl/6 mice were exposed to hypoxia (10% oxygen) or normoxia for 
14 days. On day 0 and day 7 mice were dosed with 1.5mg/kg miRNA-96 mimic, negative 
control or PBS via intravenous tail vein injection. Mean systemic arterial pressure (mSAP) 
was assessed by catheterisation of the left common carotid artery. n=10, data was 
expressed as the mean ± SEM.   
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Figure 4-7 Administration of a miRNA-96 mimic or hypoxia had no effect on heart 
rate in hypoxia-induced pulmonary hypertension 
Female wild-type C57Bl/6 mice were exposed to hypoxia (10% oxygen) or normoxia for 
14 days. On day 0 and day 7 mice were dosed with 1.5mg/kg miRNA-96 mimic, negative 
control or PBS via intravenous tail vein injection. Heart rate was assessed by measuring 
the number of heart beats per minute (bpm). n=10, data was expressed as the mean ± SEM.  
 
 
 
 
 
 Chapter Four In Vivo 
158 
 
 
Figure 4-8 Administration of a miRNA-96 mimic or hypoxia had no effect on body 
weight in hypoxia-induced pulmonary hypertension 
Female wild-type C57Bl/6 mice were exposed to hypoxia (10% oxygen) or normoxia for 
14 days. On day 0 and day 7 mice were dosed with 1.5mg/kg miRNA-96 mimic, negative 
control or PBS via intravenous tail vein injection. Body weight was assessed before in vivo 
haemodynamics were performed. n=10, data was expressed as the mean ± SEM.   
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4.2.4 Intravenous delivery of miRNA-96 mimic restored the miRNA-96 deficiency in 
lung of female hypoxic mice 
In chapter 3 we observed a miRNA-96 deficiency in both experimental animal model and 
clinical PAH samples from females. To assess if the deficiency was also evident in the 
hypoxic model we examined miRNA-96 expression in lung samples from both normoxic 
and hypoxic female mice. Here our data shows that hypoxia decreases the expression of 
miRNA-96 in the lung compared to normoxia (Figure 4.9). In addition, intravenous 
administration of miRNA-96 mimic increases the expression of miRNA-96 in both 
normoxic and hypoxic conditions and restores the observed hypoxic deficiency.   
To assess the global tissue distribution of miRNA-96 after intravenous tail vein injection of 
miRNA-96 mimic we examined miRNA-96 expression levels in liver, kidney and spleen 
by Taqman qRT-PCR. In mice dosed with the miRNA-96 mimic there was no significant 
up-regulation of miRNA-96 expression compared to those dosed with the negative control 
mimic in any of the tissues analysed (Figure 4.10). Interestingly our data shows a 
deficiency in miRNA-96 expression at baseline in hypoxic spleens vs. normoxic spleens. 
These results strengthen the limited systemic side effects from intravenous miRNA-96 
mimic administration.   
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Figure 4-9 Hypoxia and administration of a miRNA-96 mimic alters the expression of 
miRNA-96 in the lung 
Female wild-type C57Bl/6 mice were exposed to hypoxia (10% oxygen) or normoxia for 
14 days. On day 0 and day 7 mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control via intravenous tail vein injection. The expression of miRNA-96 was 
assessed in whole lung homogenates by Taqman quantitative Real Time-PCR. Results 
were normalised to the small nuclear RNA, U6. n=6 in triplicate, *p<0.05, ***p<0.001, 
One-way ANOVA followed by Tukey’s post-hoc test. Data was expressed as the RQ ± 
RQ
max
/RQ
min
. RQ= relative quantification.    
 
 
 
 
 
 
 Chapter Four In Vivo 
161 
 
 
Figure 4-10 Hypoxia and administration of a miRNA-96 mimic alters the expression 
of miRNA-96 in the spleen but not kidney or liver 
Female wild-type C57Bl/6 mice were exposed to hypoxia (10% oxygen) or normoxia for 
14 days. On day 0 and day 7 mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control via intravenous tail vein injection. The expression of miRNA-96 was 
assessed in whole liver (A), kidney (B) and spleen (C) homogenates by Taqman 
quantitative Real Time-PCR. Results were normalised to the small nuclear RNA, U6. n=6 
in triplicate, *p<0.05, One-way ANOVA followed by Tukey’s post-hoc test. Data was 
expressed as the RQ ± RQ
max
/RQ
min
. RQ= relative quantification.    
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4.2.5 Intravenous delivery of miRNA-96 mimic decreased target 5-HT1B protein in 
lungs of female hypoxic mice 
In Chapter 3 we confirmed by in vitro experiments that the 5-HT1B receptor was a true 
target of miRNA-96 and miRNA-96 may be controlling proliferation of PASMCs via 
modulation of the 5-HT1B receptor expression. To examine whether or not this regulation 
could be translated in vivo, we assessed the expression of the 5-HT1B receptor via Taqman 
and western blot in mice administered with the miRNA-96 mimic. Our results highlight a 
concomitant decrease in miRNA-96 expression with an increase in 5-HT1B protein 
expression in lungs from hypoxic control mice (Figure 4.12). Likewise, in lungs from 
hypoxic mice dosed with a miRNA-96 mimic there is an associated significant decrease in 
5-HT1B protein expression compared to control mice. These results indicate that within an 
in vivo setting miRNA-96 has the ability to regulate the expression of the target 5-HT1B 
receptor at protein level. The 5-HT1B mRNA expression was not affected by either hypoxic 
or drug treatment (Figure 4.11).  
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Figure 4-11 Hypoxia and administration of a miRNA-96 mimic does not affect the 
expression of 5-HT1B mRNA in the lung 
Female wild-type C57Bl/6 mice were exposed to hypoxia (10% oxygen) or normoxia for 
14 days. On day 0 and day 7 mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control via intravenous tail vein injection. The expression of 5-HT1B mRNA was 
assessed in whole lung homogenates by Taqman quantitative Real Time-PCR. Results 
were normalised to the GAPDH. n=6 in triplicate, data was expressed as the RQ ± 
RQ
max
/RQ
min
. RQ= relative quantification.    
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Figure 4-12 Hypoxia and administration of a miRNA-96 mimic alters the expression 
of 5-HT1B protein in the lung 
Female wild-type C57Bl/6 mice were exposed to hypoxia (10% oxygen) or normoxia for 
14 days. On day 0 and day 7 mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control via intravenous tail vein injection. The expression of 5-HT1B protein was 
assessed by western blotting and analysed by densitometric analysis (A). Representative 
immunoblot (B). α-tubulin was used as the internal loading control. n=6 per group in 
duplicate, *p<0.05, ***p<0.001, One-way ANOVA followed by Tukey’s post-hoc test. 
Data was expressed as the mean ± SEM. 
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4.2.6 Intravenous delivery of miRNA-96 mimic increases components of the BMPR-
II pathway in lungs of female hypoxic mice 
As the BMPR-II pathway is integral to HPAH and some cases of IPAH we wished to 
investigate the effects of a miRNA-96 mimic on the components of the BMPR-II system 
within the lung. For this we examined the mRNA expression of BMPR-II, SMAD1, ID1 
and ID3 by Taqman analysis (Figure 4.13). We found that hypoxia only significantly 
reduced BMPR-II expression but this significance was lost in those mice dosed with a 
miRNA-96 mimic. Interestingly we also demonstrated that in hypoxic mice dosed with 
miRNA-96 mimic there was a significant increase in both SMAD1 and ID1 expression 
compared to both normoxic mice dosed with miRNA-96 mimic and hypoxic mice dosed 
with negative control. There was no change observed in ID3 expression across any of the 
experimental groups. These results suggest that miRNA-96 mimic could also be possibly 
exerting beneficial therapeutic effects through increasing components of the BMPR-II 
pathway.  
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Figure 4-13 Hypoxia and administration of a miRNA-96 mimic alters the expression 
of the BMPR-II signalling pathway in the lung 
Female wild-type C57Bl/6 mice were exposed to hypoxia (10% oxygen) or normoxia for 
14 days. On day 0 and day 7 mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control via intravenous tail vein injection. The expression of BMPR-II (A), 
SMAD1 (B), ID1 (C) and ID3 (D) mRNA were assessed in whole lung homogenates by 
Taqman quantitative Real Time-PCR. Results were normalised to the GAPDH. n=6 in 
triplicate, *p<0.05, ***p<0.001, One-way ANOVA followed by Tukey’s post-hoc test. 
Data was expressed as the RQ ± RQ
max
/RQ
min
. RQ= relative quantification.    
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4.2.7 Intravenous delivery of miRNA-96 mimic reverses a PH phenotype in female 
BMPR2
R899X+/- 
mice 
Having demonstrated the effectiveness of miRNA-96 mimic therapy at preventing a PH 
phenotype we wanted to investigate its potential at reversing a PH phenotype as this is 
more clinically relevant. For this we utilised the BMPR2
R899X+/- 
mouse model of PH. At 6 
months of age these mice exhibit an established mild phenotype of PH as observed by 
increased RVSP, RVH and remodelling compared to WT littermates (Figure 4.14, Figure 
4.15 and Figure 4.16). Treatment with miRNA-96 mimic reversed the increases in both 
RVSP and remodelling.  The RVH was not significantly different in BMPR2
R899X+/- 
miRNA-96 mimic dosed mice compared to negative control mimic dosed mice. However, 
the RVH of the BMPR2
R899X+/- 
miRNA-96 mimic dosed mice was also not significantly 
different from baseline WT level. This result could be due to the mild phenotype observed 
not providing a large enough therapeutic window or suggests that perhaps the BMPR-II 
mutation may have independent effects on the heart not associated with increased RVSP 
that are not targeted by miRNA-96 treatment. Overall, our data further indicates the 
fundamental role miRNA-96 plays in PH development.  
We once again demonstrated no effects on systemic parameters including mSAP, HR and 
body weight with miRNA-96 mimic treatment (Figure 4.17, Figure 4.18 and Figure 4.19). 
These results reiterate the potential pulmonary circulation selectiveness of miRNA-96 
mimic therapy.       
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Figure 4-14 Reduction in right ventricular systolic pressure by a miRNA-96 mimic in 
the BMPR2
R899X+/- 
model 
Female wild-type and BMPR2
R899X+/-
 mice were dosed with 1.5mg/kg miRNA-96 mimic 
or negative control on day 0 and day 7 mice by intravenous tail vein injection. On day 14 
right ventricular systolic pressure (RVSP) was assessed by right heart catheterisation. n=5-
8, *p<0.05, One-way ANOVA followed by a Tukey’s post-hoc test. Data was expressed as 
the mean ± SEM.   
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Figure 4-15 Right ventricular hypertrophy is increased in the BMPR2
R899X+/- 
model 
but not affected by miRNA-96 mimic  
Female wild-type and BMPR2
R899X+/- 
mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control on day 0 and day 7 mice by intravenous tail vein injection. On day 14 
right ventricular hypertrophy (RVH) was assessed by measuring the right ventricle weight 
over the left ventricle plus septum (RV/LV+S). n=5-8, *p<0.05, One-way ANOVA 
followed by a Tukey’s post-hoc test. Data was expressed as the mean ± SEM.   
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Figure 4-16 Reduction in pulmonary artery remodelling by a miRNA-96 mimic in the 
BMPR2
R899X+/- 
model 
Female wild-type and BMPR2
R899X+/- 
mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control on day 0 and day 7 mice by intravenous tail vein injection. On day 14 
remodelling of pulmonary arteries was assessed by counting the number of remodelled 
(double elastic lamina) and non-remodelled arteries (single elastic lamina) and expressing 
the percentage of remodelled arteries over the total number of arteries counted (A). 
Representative images are shown in the bottom panel (B). n=5-8, ****p<0.0001, One-way 
ANOVA followed by a Tukey’s post-hoc test. Data was expressed as the mean ± SEM. 
Scale bar =50µm.   
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Figure 4-17 Administration of a miRNA-96 mimic or BMPR2
R899X+/- 
mutation had no 
effect on mean systemic arterial pressure  
Female wild-type and BMPR2
R899X+/- 
mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control on day 0 and day 7 mice by intravenous tail vein injection. On day 14 
mean systemic arterial pressure (mSAP) was assessed by catheterisation of the left 
common carotid artery. n=5-8, data was expressed as the mean ± SEM.   
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Figure 4-18 Administration of a miRNA-96 mimic or BMPR2
R899X+/- 
mutation had no 
effect on heart rate 
Female wild-type and BMPR2
R899X+/- 
mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control on day 0 and day 7 by intravenous tail vein injection. Heart rate was 
assessed by measuring the number of heart beats per minute (bpm). n=5-8, data was 
expressed as the mean ± SEM.  
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Figure 4-19 Administration of a miRNA-96 mimic or BMPR2
R899X+/- 
mutation had no 
effect on body weight 
Female wild-type and BMPR2
R899X+/- 
mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control on day 0 and day 7 by intravenous tail vein injection. Body weight was 
assessed before in vivo haemodynamics were performed. n=5-8, data was expressed as the 
mean ± SEM.   
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4.2.8 Intravenous delivery of miRNA-96 mimic restored the miRNA-96 deficiency in 
lungs of female BMPR2
R899X+/- 
mice 
Thus far we have demonstrated a reduction of miRNA-96 expression in PASMCs from 
female BMPR2
R899X+/- 
mice, female PAH patient samples and female hypoxic lungs. Here, 
we confirm a reduction of miRNA-96 expression in female BMPR2
R899X+/-
 lungs at 
baseline. Administration of a miRNA-96 mimic increases the miRNA-96 expression in 
BMPR2
R899X+/-
 lungs and restores the deficiency (Figure 4.20).   
 
 
 
Figure 4-20 BMPR2
R899X+/- 
mutation and administration of a miRNA-96 mimic alters 
the expression of miRNA-96 in the lung 
Female wild-type and BMPR2
R899X+/- 
mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control on day 0 and day 7 by intravenous tail vein injection. On day 14 the 
expression of miRNA-96 was assessed in whole lung homogenates by Taqman quantitative 
Real Time-PCR. Results were normalised to the small nuclear RNA, U6. n=5-8 in 
triplicate, *p<0.05, ***p<0.001, One-way ANOVA followed by Tukey’s post-hoc test. 
Data was expressed as the RQ ± RQ
max
/RQ
min
. RQ= relative quantification.    
 
 Chapter Four In Vivo 
175 
 
4.2.9 Intravenous delivery of miRNA-96 mimic reverses the increase in 5-HT1B 
receptor protein in lungs of female BMPR2
R899X+/- 
mice 
We previously demonstrated a decrease in miRNA-96 expression in female BMPR2
R899X+/- 
PASMCs was associated with an increase in target 5-HT1B receptor expression. Here our 
results show this is also true for 5-HT1B receptor protein expression in whole lung from 
female BMPR2
R899X+/-
 mice. Similar to the hypoxic model we show that intravenous 
delivery of miRNA-96 mimic can reduce the expression of 5-HT1B protein expression 
within the lung compared to control mice restoring it to baseline level (Figure 4.22). This 
result strengthens the successful ability of a miRNA-96 mimic to control target 5-HT1B 
receptor protein expression in vivo. The 5-HT1B mRNA expression was not affected by 
either genotype or drug treatment (Figure 4.21).  
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Figure 4-21 BMPR2
R899X+/- 
mutation and administration of a miRNA-96 mimic does 
not affect the expression of 5-HT1B mRNA in the lung 
Female wild-type and BMPR2
R899X+/- 
mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control on day 0 and day 7 by intravenous tail vein injection. On day 14 the 
expression of 5-HT1B mRNA was assessed in whole lung homogenates by Taqman 
quantitative Real Time-PCR. Results were normalised to the GAPDH. n=5-8 in triplicate, 
data was expressed as the RQ ± RQ
max
/RQ
min
. RQ= relative quantification.    
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Figure 4-22 BMPR2
R899X+/- 
mutation and administration of a miRNA-96 mimic alters 
the expression of 5-HT1B protein in the lung 
Female wild-type and BMPR2
R899X+/- 
mice were dosed with 1.5mg/kg miRNA-96 mimic or 
negative control on day 0 and day 7 by intravenous tail vein injection. On day 14 the 
expression of 5-HT1B protein was assessed by western blotting and analysed by 
densitometric analysis (A). Representative immunoblot (B). α-tubulin was used as the 
internal loading control. n=5-6 per group in duplicate, *p<0.05, **p<0.01, One-way 
ANOVA followed by Tukey’s post-hoc test. Data was expressed as the mean ± SEM. 
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4.3 Discussion 
According to the REVEAL registry it is recognised that 80% of PAH patients are female 
(Badesch et al., 2010). This has led researchers to believe that female sex may predispose 
to the development of PAH. However, sex differences in PAH are highly understudied. In 
Chapter 3 we explored sex differences in miRNA expression as a possible factor in female 
susceptibility and identified a potential role for miRNA-96 in the pathogenesis of female 
PAH. Through in vitro investigations we highlighted a deficiency in miRNA-96 led to an 
increase in target 5-HT1B receptor and ultimately increased proliferation of female 
PASMCs. Aberrant proliferation of PASMCs is a major hallmark of PAH development as 
it is an initiating process in the remodelling of pulmonary arteries (Zhang et al., 2003). A 
role for miRNA-96 in disease development had not been investigated in vivo. This chapter 
summarises data which implicates re-establishing miRNA-96 expression in models of PH 
which are deficient in miRNA-96 has the ability to both prevent and reverse PH disease 
parameters including remodelling of small distal pulmonary arteries by potentially 
reducing disease associated increases in 5-HT1B receptor expression.      
Recent studies have demonstrated that dysregulation of miRNA-96 is associated with 
certain forms of cancer (Yu et al., 2010). For example a decrease in miRNA-96 expression 
is highlighted in pancreatic cancer (Feng et al., 2014). As cancer is a disease also coupled 
with aberrant proliferation, perhaps miRNA-96 deficiency may underlie processes which 
contribute to anomalous cellular proliferation. Thought to serve as a tumour suppressor in 
pancreatic cancer, up-regulation of miRNA-96 represses pancreatic cell proliferation, 
migration and invasion in vitro (Feng et al., 2014). In addition, the growth of pancreatic 
tumours is significantly decreased upon introduction of miRNA-96 in an in vivo mouse 
model. This result was due to repression of the up-regulated pro-proliferative oncogene 
HERG1. Thus therapeutic success was achieved by decreasing a pro-proliferative gene via 
enhancing miRNA-96 expression.   
In Chapter 3 we showed that augmenting levels of miRNA-96 could decrease 5-HT1B 
receptor expression and prevent serotonin induced proliferation of PASMCs. To 
investigate if restoration of miRNA-96 expression in vivo can protect against and reverse a 
PH phenotype via the 5-HT1B receptor, we performed two separate in vivo studies to 
examine the effects of a miRNA-96 mimic. We utilised the hypoxic mouse model and 
BMPR2
R899X+/- 
mouse model to investigate the prevention and reversal of disease 
respectively. We first confirmed that our chosen route of administration, intravenous tail 
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vein injection, successfully delivered miRNA-96 mimic to the pulmonary arteries of the 
lung. This was indicated by the increase in miRNA-96 expression in the pulmonary 
arteries. We also show that the increase in miRNA-96 expression via the miRNA-96 mimic 
was located within the smooth muscle cell layer of the distal pulmonary arteries. This is a 
key strength of this study as targeting the small distal pulmonary arteries is a major hurdle 
in PAH therapeutics. Furthermore, our previous data demonstrated a deficiency in miRNA-
96 within distal PASMCs and therefore augmentation of expression here would be 
necessary to restore the imbalance. As our present research has focused on PASMCs we do 
not know the role, if any, miRNA-96 plays in PAECs. However, interestingly our in situ 
hybridisation results do not indicate detection of miRNA-96 expression within PAEC. 
Therefore we can suggest that within this study miRNA-96 is not playing a role within 
PAEC.  
The hypoxic mouse model of PH produces a robust disease phenotype including decreased 
BMPR-II signalling (Long et al., 2009; Mair et al., 2015). Deficiencies in the BMPR-II 
signalling pathway play a key involvement in ~70% of HPAH and ~40% IPAH patients 
(Machado et al., 2006a). Deficiencies in the BMPR-II pathway can occur due to mutations 
with the BMPR-II gene (Atkinson et al., 2002; Yang et al., 2005). The BMPR2
R899X+/-
 
mouse is a model with a knock-in BMPR-II gene mutation which develops mild PH at 6 
months of age (Long et al., 2011; Long et al., 2015). Here, we report that within both the 
hypoxic and BMPR2
R899X+/- 
mouse models there is a significantly reduced expression of 
miRNA-96 and increased expression of 5-HT1B receptor protein expression within lung 
tissue of control dosed mice. Results from both of our in vivo studies indicate that 
intravenous administration of miRNA-96 mimic can both prevent and reverse increases in 
PH characteristics including RVSP, RVH and pulmonary arterial remodelling. This was 
associated with an increase in lung miRNA-96 expression and decrease in 5-HT1B receptor 
expression. This substantiates our hypothesis that PH is associated with increased 5-HT1B 
receptor mediated remodelling/proliferation under the control of miRNA-96. The miRNA-
96 mimic had no effect on mean systemic arterial pressure or heart rate in either model 
suggesting that this therapeutic strategy could be pulmonary selective. 
For investigations into the in vivo effects of a miRNA-96 mimic on PH we focused on a 
dose of 1.5mg/kg on day 0 and day 7. This was based on a previous study which showed at 
this dose a miRNA mimic delivered using the MaxSuppressor in vivo RNALancerII kit 
accumulated mostly within lung tissue and lung tissue had the highest expression increase 
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compared to non-treated mice (Trang et al., 2011). Within the in vivo data presented here, 
the selected dose of miRNA-96 mimic increased the miRNA-96 between ~threefold and 
fivefold within the whole lung. This seems a small increase in miRNA-96 expression 
however this dose still demonstrated a therapeutic effect and it is known that the extent of 
change within miRNA expression does not correlate with its effective outcome (Calin et 
al., 2004; He et al., 2005). It would be of interest to increase the administered dose to 
potentially observe a greater therapeutic outcome. However, as with all exogenously 
administered drugs, increasing the dose could potentially lead to unwanted off target side 
effects. Perhaps only the need for restoring levels and re-balancing the deficiency is 
sufficient for therapeutic success rather than excessive increases in expression. Similarly, 
altering the route of administration may increase delivery to smooth muscle cells of small 
distal pulmonary arteries. For example, more direct local routes of administration i.e. 
intratracheal or intranasal have demonstrated successful delivery of miRNA agents to 
pulmonary arteries (Courboulin et al., 2011; Kim et al., 2013). These routes of 
administration are also perhaps more clinically relevant. We examined the effects of a 
miRNA-96 mimic in both the hypoxic and BMPR2
R899X+/- 
mouse models. Even though 
these models produce a PH phenotype they fail to recapitulate aspects of human PAH such 
as plexiform lesions. The SU-HX model of PH is thought to best mirror the formation of 
plexiform lesions similar to human disease thus investigating the therapeutic effect of a 
miRNA-96 mimic in vivo within the SU-HX model is imperative. 
The therapeutic effects observed with a miRNA-96 mimic could be extrapolated from both 
an increase in miRNA-96 expression and decrease in 5-HT1B receptor expression. The 5-
HT1B receptor has a well-defined role in PAH with involvement in mediating both 
proliferation and contraction of PASMCs. Excessive 5-HT1B receptor expression is 
documented in remodelled pulmonary arteries of PAH patient lungs (Launay et al., 2002), 
within a variety of animal models (Heeley R.P., 1998; Rondelet et al., 2003; Morecroft et 
al., 2005) and we have also previously shown in Chapter 3 a sex-specific increase in 5-
HT1B receptor expression in PASMCs from female PAH patients. Decreasing the 
expression of the 5-HT1B receptor would greatly reduce its involvement in the above 
mentioned functions. Previous in vivo analysis has demonstrated inhibition of the 5-HT1B 
receptor by receptor antagonism is able to reduce the development of hypoxia-induced 
pulmonary artery remodelling, contraction and overall PAH phenotype (Keegan et al., 
2001). However, these experiments have not shown whether the therapeutic effect matched 
with a decrease in 5-HT1B receptor expression or signalling. Tackling the source of the 
 Chapter Four In Vivo 
181 
 
increase in 5-HT1B expression (via miRNA-96) rather than inhibiting the 5-HT1B activity 
(via a pharmacological antagonist) could perhaps prove more beneficial.  
By definition, miRNAs have the ability to direct the expression of more than one target 
gene, with many miRNAs regulating up to 1000 genes. Therefore the beneficial effects 
from increasing miRNA-96 will not solely be through regulation of the 5-HT1B receptor 
but potentially through a plethora of other targets. This concept raises the concern of many 
other possible “on-target” and “off-target” effects mediated by miRNA-96. Within this 
present study we began to explore these possible effects first by examining the distribution 
of the miRNA-96 mimic. We found no significant changes in miRNA-96 expression in 
liver, kidney or spleen within our dosed mice. However, without further global tissue 
analysis we cannot comment on the complete miRNA-96 mimic distribution which could 
potentially generate negative systemic side effects. We only explored the 5-HT1B receptor 
as a target of miRNA-96 although there are other putative and published targets. The 
therapeutic effect observed from the miRNA-96 mimic could perhaps be from modulation 
of other miRNA-96 targets which could also be assisting disease prevention and 
regression. Further investigation into other miRNA-96 targets and their association with 
PAH is warranted.  
It has previously been demonstrated that BMPR-II expression is reduced in the hypoxic 
mouse, the monocrotaline rat and the SU-HX rat models of PH (Long et al., 2009; Mair et 
al., 2014). We confirmed that BMPR-II mRNA expression was reduced in the lungs of the 
hypoxic mice. This reduction was lost in mice dosed with a miRNA-96 mimic suggesting 
that increasing miRNA-96 expression was augmenting BMPR-II expression. We also 
showed that via increasing miRNA-96 levels we could increase the expression of SMAD1 
and ID1 mRNA within whole lung. The BMPR-II pathway has been shown to be integral 
in PAH biology with a general reduction in the pathway associated with the development 
of PAH (Teichert-Kuliszewska et al., 2006). Experimental therapies restoring the BMPR-II 
signalling pathway represents a novel therapeutic strategy. Evidence from mice deficient in 
BMPR-II and the SU-HX rat model highlights rescuing the BMPR-II pathway with FK506 
prevents a PH phenotype (Spiekerkoetter et al., 2013). A miRNA-96 mimic is potentially a 
novel therapeutic way to increase a deficient BMPR-II pathway. This preliminary data 
warrants further examination of the relationship between miRNA-96 and BMPR-II 
signalling. We could assume that miRNA-96 does not increases the BMPR-II pathway by 
directly targeting the above mentioned genes as an increase in miRNA-96 would typically 
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reduce any putative target. It suggests that possibly BMPR-II, SMAD1 and ID1 are 
indirect targets of miRNA-96 with another intermediate gene/miRNA mediator existing 
between them. This data reiterates the necessity to investigate further targets of miRNA-96 
which may or may not be direct targets of miRNA-96.  
In summary, the data presented proposes restoration of deficiencies in miRNA-96 
expression in the lungs of both hypoxic and BMPR2
R899X+/- 
mice by intravenous in vivo 
delivery of miRNA-96 mimic can prevent the induction of a hypoxic PH phenotype and 
also reverse an established disease phenotype in BMPR2
R899X+/- 
mice. Furthermore, 
increasing the expression of miRNA-96 in vivo has the ability to reduce increases in the 
target 5-HT1B receptor in both of these models. Overall, this data further implicates the 
importance of miRNA-96 in PAH biology and reinforces the possibility of miRNA-96 
based therapies for PAH. 
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5.1 General Discussion 
PAH is currently an incurable vasculopathy which affects the arteries of the pulmonary 
circulation. In the 1950’s Dresdale documented an increase in frequency of female PAH 
patients (Dresdale et al., 1951). This recognised female susceptibility to PAH remains 
today, as recent advanced epidemiological studies highlight 70-80% of PAH patients are 
female (Badesch et al., 2010; Ling et al., 2012). This is in contrast to other PAH 
demographics which have changed over time i.e. the age of diagnosis now ranges from 50-
65 years old compared to 36 years old and patients are now diagnosed with more severe 
PAH (Hoeper et al., 2014). However, the reasons underlying the imbalanced female to 
male ratio regarding disease prevalence remain relatively obscure. Current PAH therapies 
do not incorporate this sex bias. This is in despite of recent studies having shown sex 
differences in treatment response (Gabler et al., 2012; Shapiro et al., 2012). It is important 
to further understand the reasons owing to this to improve clinical outcome.  
One suggestion towards explaining the female susceptibility in PAH is that the female sex 
hormone estrogen plays a causative role. In support of this, eliminating circulating estrogen 
levels via ovariectomy can abolish a PH phenotype in female susceptible experimental 
models including SERT+ mice (White et al., 2011a), MTS1+ mice (Dempsie et al., 2011) 
and dexfenfluramine mice (Dempsie et al., 2013). In addition, reduction of local estrogen 
within the pulmonary arteries via the inhibition of the estrogen synthesising enzyme 
aromatase can also prevent and reverse a PH phenotype in the hypoxic mouse and SU-HX 
rat model respectively (Mair et al., 2014). Furthermore, the estrogen receptor ERα is up-
regulated in PAH and is thought to be linked to pathological signalling pathways 
(Rajkumar et al., 2010; Mair et al., 2014; Wright et al., 2015). Indeed inhibition of ERα 
prevents the development of a hypoxic phenotype in female mice (Mair et al., 2014). There 
is also substantial evidence to suggest the metabolites of estrogen play an important role in 
PAH development. The formation of 16α-OHE1 by the estrogen metabolising enzyme 
CYP1B1 can lead to aberrant proliferation of PASMCs and induction of a PH phenotype 
(White et al., 2012). Therapeutic success by inhibition of CYP1B1 has been proven in both 
hypoxic and SU-HX models of PH. As of yet there are no approved estrogen based 
therapies for PAH. However, the aforementioned research supports the fundamental 
importance of the estrogen pathway in PAH pathogenesis.  
Estrogen can exert control over a number of genes including TPH1, SERT and 5-HT1B in 
PASMCs which are known mediators of PAH (White et al., 2011a). In addition, estrogen 
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can also facilitate the regulation of miRNAs (Bhat-Nakshatri et al., 2009). In 
circumstances when estrogen or estrogen signalling is dysregulated then miRNAs which 
are under the control of estrogen may also become dysregulated and contribute to disease 
processes (Morgan et al., 2011). The estrogen pathway is known to be affected in diseases 
such as breast cancer and SLE both of which have a higher female prevalence (Ohta et al., 
2013). In an experimental model of SLE which mirrors the female susceptibility there was 
recognition of sexual dimorphism of miRNA expression after the disease onset (Dai et al., 
2013). Thus female specific changes in miRNAs were associated with a female susceptible 
disease. Regarding this evidence, the aim of this thesis was to investigate the potential of 
sexual dimorphism of miRNAs in PAH that could account for the sex bias in disease and 
provide a new miRNA candidate for a novel PAH therapy.  
In Chapter 3 the sex differences of 20 miRNAs were investigated in PASMCs from 
BMPR2
R899X+/- 
mice by qRT-PCR. Mutations in BMPR-II cause deficiencies within the 
BMPR-II signalling pathway and play a key involvement in ~70% of HPAH and ~40% of 
IPAH patients (Atkinson et al., 2002; Yang et al., 2005; Machado et al., 2006a). It has 
recently been documented that female control PASMCs are pre-disposed to reduced 
expression of BMPR-II and downstream signalling components compared to male 
PASMCs (Mair et al., 2015). This could contribute to an enhanced consequence of further 
BMPR-II reduction brought about by mutation in female PASMCs. Thus even in WT 
PASMCs differential BMPR-II levels could be affecting miRNA expression. This is the 
first study to report sexual dimorphism of miRNAs within the context of PAH. Some of the 
miRNAs studied have been previously implicated in PAH, however, the differential 
expression between sexes was not known e.g. miRNA-21 (White et al., 2014), miRNA-
424, miRNA-503 (Kim et al., 2013). These novel findings could underpin the sex bias 
observed in PAH susceptibility. We focused the subsequent research on miRNA-96 as this 
was a novel miRNA in relation with PAH development.  
The BMPR2
R899X+/- 
model of PH produces a mild phenotype in vivo (Long et al., 2011; 
Long et al., 2015) and does not completely recapitulate all characteristics of human PAH 
therefore we also investigated the expression pattern of miRNA-96 in human PASMCs 
from PAH patients and non-patients. Similar down-regulation of miRNA-96 in mouse 
female disease PAMCs was confirmed in human PASMCs from distal pulmonary arteries. 
Conservation of miRNA expression pattern is not always found between experimental and 
human samples. For example, miRNA-451 has been shown to be up-regulated in the 
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monocrotaline rat model of PH but unchanged in human PAH samples (Caruso et al., 
2010). The conserved expression pattern of miRNA-96 suggests that dysregulation of 
miRNA-96 plays a vital role in female PAH pathogenesis. As both the mouse 
BMPR2
R899X+/- 
PASMCs and human PASMCs are representative systems of pre-
existing/end-stage PAH, we do not know if the miRNA-96 dysregulation observed is one 
of which occurs at the initial stage of PAH pathology and persists throughout disease or 
one which occurs as a consequence of disease. To begin to understand this it would be 
necessary to observe if PAH characteristics could be induced by incurring a decrease in 
miRNA-96. This could be done in vitro by anti-miRNA-96 treatment to PASMCs or in 
vivo by inducing miRNA-96 knockdown.        
The list of miRNAs examined was by no means extensive and a complete unbiased 
microarray analysis of miRNAs should be performed to assess sexual dimorphism of other 
miRNAs in relation to PAH. This would ultimately produce more novel miRNAs with 
differential expression pattern dependent on sex which could help elucidate the underlying 
genetic changes contributing to the sex bias in PAH. Further to this, examination of 
miRNA expression within PASMCs provides specific insight into the changes within this 
one cell type. It is known miRNA biology greatly depends on the cell type under 
investigation (He et al., 2012). In the pulmonary vasculature it is both PASMCs and 
PAECs which contribute to PAH development (Zhang et al., 2003; Teichert-Kuliszewska 
et al., 2006). Therefore, further analysis of sexual dimorphism of miRNAs within PAECs 
would significantly add to our findings.  
In Chapter 3 our results revealed the 5-HT1B receptor was a direct target of miRNA-96. In 
addition, a reduction in miRNA-96 expression was associated with an increase in 5-HT1B 
receptor expression in both female BMPR2
R899X+/- 
PASMCs and human PASMCs from 
female PAH patients. The 5-HT1B receptor has previously been pathologically associated 
with PAH. Within the pulmonary vasculature the 5-HT1B receptor is the most abundantly 
expressed serotonin receptor involved in the aberrant proliferation and contraction of 
PASMCs (Morecroft et al., 1999). An increased expression of 5-HT1B receptor has been 
shown in remodelled pulmonary arteries from PAH patients (Launay et al., 2002); 
however, our results highlighting its specific up-regulation within female disease, is a 
novel finding. Furthermore, the finding of serotonin-induced proliferation mediated by the 
5-HT1B receptor specifically in female PASMCs was also an original observation. This 
suggests that the estrogen system may be influencing the 5-HT1B expression here.   
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The estrogen system has previously been shown to interplay with the serotonin system 
(White et al., 2011a). White et al. showed that stimulation of PASMCs with estrogen can 
up-regulate the expression of the 5-HT1B receptor. In addition, estrogen-induced 
proliferation of PASMCs was also found to be mediated by the 5-HT1B receptor. However, 
the mechanism for such regulation was not investigated. Here, within this thesis we 
suggest that the influence estrogen was having on the expression of 5-HT1B receptor 
expression was through epigenetic control via miRNA-96. We show stimulation of 
PASMCs with estrogen can down-regulate miRNA-96 expression. We further show that an 
inhibitor of the estrogen synthesising enzyme aromatase can trigger an increase in miRNA-
96 and a decrease  in 5-HT1B receptor expression. In addition, we show by augmenting the 
miRNA-96 expression both in vitro and in vivo can decrease directly the expression of the 
5-HT1B receptor. With this regulation axis in mind we can propose that a mechanism for 
the original miRNA-96 dysregulation in both the female BMPR2
R899X+/- 
and human 
PASMCs originates from estrogen. Dysregulated estrogen levels could lead to the 
reduction in miRNA-96 and subsequent increase in 5-HT1B receptor. Investigating the 
estrogen levels and estrogen signalling pathway within the female BMPR2
R899X+/- 
mice and 
female human PASMCs utilised would provide insight into whether dysregulation of the 
estrogen system was occurring. Previous evidence using similar female PASMC samples 
has shown that the expression of aromatase is unchanged between female PAH patient and 
non-patients, however, changes in aromatase activity or estrogen levels are unknown (Mair 
et al., 2014).  
Within the vasculature the role of miRNA-96 is relatively elusive. However, a role for 
miRNA-96 has been described in the cancer field. Aberrant expression of miRNA-96 is 
thought to contribute to both oncogenic and anti-oncogenic properties perhaps depending 
on which cell type under investigation (Yu et al., 2010; Haflidadottir et al., 2013; Feng et 
al., 2014). As anomalous proliferation is a major hallmark of PASMCs within PAH we 
investigated the role of miRNA-96 with regards to both PASMC proliferation and 
pulmonary artery remodelling. We found that by restoring miRNA-96 deficiencies by pre-
miRNA-96 and miRNA-96 mimics in vitro and in vivo, respectively, we could inhibit 
serotonin-induced proliferation of PASMCs and inhibit the remodelling of small distal 
pulmonary arteries within the lung. More importantly our data showed that within the 
BMPR2
R899X+/- 
mice with an established mild PH phenotype, the miRNA-96 mimic could 
reverse the increased percentage of remodelled pulmonary arteries. Regression of PAH 
disease characteristics especially remodelled pulmonary arteries is therapeutically 
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attractive. Current PAH therapies focus on alleviating the intense vasoconstriction of the 
pulmonary arteries and therefore a treatment which incorporates regression of remodelled 
pulmonary arteries may prove additionally beneficial. Research into the ability of miRNA-
96 to regulate regeneration of pulmonary arteries is warranted. In addition, we have shown 
that by restoring miRNA-96 expression in the lung we can improve pulmonary vascular 
haemodynamics and reduce hypertrophy of the right ventricle in female mice. Even though 
miRNA-96 dysregulation was only observed in females, it would be of interest to examine 
whether miRNA-96 mimic has a therapeutic effect in male mice to begin to understand if a 
miRNA-96 based therapy would be specific to female patients.      
Overall this thesis has introduced the novel finding that sexual dimorphism of miRNA 
expression does exist within PAH and this could contribute to sex differences in PAH 
prevalence. Furthermore, this research implicates a novel miRNA dysregulated in PAH 
pathogenesis, miRNA-96. Through miRNA-96 we have linked two highly associated 
contributing factors of PAH, the estrogen and serotonin system. Under the proposed 
control of estrogen, miRNA-96 targets the 5-HT1B receptor to exert control of PASMC 
proliferation, a major hallmark of PAH pathogenesis (Figure 5.1). Even though further 
research into the female specific miRNA-96/5-HT1B axis is warranted this thesis provides 
extensive knowledge into a novel miRNA-96 based therapeutic for PAH.  
MiRNA based research and implications in disease has grown exponentially over the past 
two decades, however, the reality of miRNA based therapies not only in PAH but in 
general is still questionable. Out of the hundreds of miRNAs found to be implicated in 
disease pathologies only two targets have progressed to the clinical trials stage (miR-122, 
miR-34) (He et al., 2007; Liu et al., 2011; Hu et al., 2013; Janssen et al., 2013). However, 
considering miRNAs were only discovered in humans ~15 years ago, the rapid progression 
to clinical development is remarkable and promising. With regards to miRNA based 
therapeutics, two main challenges are faced. Firstly, successful delivery to target cell type 
and secondly appropriate modulation of gene target(s). From a pharmacokinetic view, 
miRNA drug molecules are negatively charged due to their phosphate backbone. 
Negatively charged molecules do not cross the cellular membrane well thus increasing the 
lipophilicity of miRNA drug molecules is crucial to increase their therapeutic capacity. 
This typically involves encapsulating the miRNA molecule into a lipid formulation. With 
regards to the miRNA-96 mimic utilised in vivo within this thesis, we incorporated the 
miRNA-96 mimic into a neutral lipid compartment using the MaxSuppressor In Vivo 
 Chapter Five General Discussion   
189 
 
RNA-LANCEr II technique (Trang et al., 2011). With this method we demonstrated 
successful accumulation of miRNA-96 within PASMCs from mice dosed with miRNA-96 
mimic. Other similar miRNA carriers have also proven successful with delivery to the lung 
but the magnitude of the delivery does depend on the carrier tested and does not always 
favour the lung over other tissues (Wu et al., 2011; Bala et al., 2015). Optimising the best 
carrier formulation for miRNA based drugs will be vital for successful delivery to the 
pulmonary arteries. However, before the miRNA drug molecule can enter the desired cell 
type it first must reach the intended cell type. For such tissue/cell specific delivery the 
miRNA drug molecule must be sufficiently “tagged”. For example, the LNA- antisense 
oligonucleotide against miRNA-122 has a phosphorothiate modification which leads to its 
preferential congregation within the liver where its target gene is located (Janssen et al., 
2013). Finding an appropriate modification suited to PASMC accumulation could greatly 
improve miRNA selective delivery and therapeutic effectiveness in PAH. Similarly adeno-
associated virus (AAV) - assisted delivery of miRNAs could allow tissue specificity due to 
their natural tropism for different tissues and ability to utilise tissue specific promoters 
(Robson et al., 2003). We did not find any significant increases in miRNA-96 expression 
within either liver, kidney or spleen tissue after in vivo miRNA-96 mimic delivery, 
however, full global tissue analysis was not completed and further tissue analysis would be 
required to confirm tissue specificity. One tissue in particular requiring examination would 
be the brain. As miRNA-96 targets the 5-HT1B receptor which is highly expressed within 
the brain, any target modulation within the brain by a miRNA-96 mimic could potentially 
trigger unwanted side effects. It will be crucial to see if a miRNA-96 mimic has the 
capacity to cross the blood brain barrier and function within brain tissue to clarify any 
potential side effects. 
One key miRNA may modulate multiple disease associated signalling pathways. Therefore 
within a pathological setting, a single miRNA could be the common denominator involved 
in several complex dysregulated gene networks. Therapeutically, even minor alterations in 
the expression of a single miRNA could accumulate to have a profound synergistic effect 
through modifying numerous gene targets. However, this could prove undesirable when a 
miRNA target is not involved/dysregulated within the disease or the gene targeted is 
altered in the opposite direction to the primary gene target. Identification and investigation 
of further miRNA-96 targets would inform us of other potential signalling pathways which 
could be synergistically facilitating the therapeutic success of miRNA-96 mimic observed 
within the in vivo studies of this thesis. With regards to the miRNA-96 mimic utilised in 
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this thesis, achieving the correct level of miRNA-96 restoration is crucial. In theory, 
replenishing the deficient PASMCs with miRNA-96 should also restore normal function of 
the miRNA and therefore not have any unwanted side effects. This is greatly dependent on 
the correct dose of miRNA-96 administered, as too much could offset the balance in the 
opposite direction. Any potential unwanted effects are likely to arise when the mimic is 
introduced into cells where it is not normally endogenously expressed. Further examination 
of global miRNA-96 expression and function after in vivo miRNA-96 mimic 
administration would need to be investigated before commenting on the potential side 
effects in these present studies. Knowledge of long-term effects of miRNA based therapies 
is limited due to the lack of longitudinal experimental studies. To better understand the 
tolerability of a miRNA-96 mimic a toxicity report should be performed to provide insight 
into cytokine levels as well as liver and kidney function tests. Examining the half-life of a 
miRNA-96 mimic would assist further in vivo studies where dose and route of 
administration are being investigated. 
Another therapeutic alternative to restore miRNA-96 expression within PAH could be to 
find a small molecule drug which could endogenously up-regulate miRNA-96. For 
example, we showed a link between estrogen levels and endogenous miRNA-96 
expression. Administration of anastrozole, which is an inhibitor of the estrogen 
synthesising enzyme aromatase, decreases estrogen levels (Mair et al., 2014). Within this 
thesis we further show that this is associated with an up-regulation in endogenous miRNA-
96 expression and a decrease in target 5-HT1B receptor expression. Therefore there is 
potential to increase miRNA-96 expression via administration of anastrozole. Anastrozole 
has already proven to be a successful therapy in experimental models of PH (Mair et al., 
2014). Perhaps combining anastrozole with miRNA-96 mimic could augment the 
therapeutic effect. Combining small molecules with miRNA mimics has been documented 
previously in cancer research. Here it was highlighted that using a combination of the 
tyrosine kinase inhibitor, Erlotinib, with the miRNA-34 mimic, MRX34, created a 
synergistic therapeutic effect (Zhao et al., 2014). Furthermore, this study found that 
Erlotinib resistant cancer cell lines became sensitive to drug treatment when MRX34 was 
used in combination (Zhao et al., 2014). This type of adjunctive therapy has not been 
examined in a PAH setting, however, could play an important role in stratification of PAH 
therapies.  
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Figure 5-1 Proposed mechanism of miRNA-96 dysregulation in PAH 
A schematic overview of key findings from this thesis. We show that miRNA-96 targets 
the 5-HT1B receptor which exerts control of proliferation in female PAH PASMCs. In 
addition we show that BMPR-II mutations in females, hypoxia and estrogen can all down-
regulate miRNA-96. This leads to a concomitant increase in 5-HT1B receptor expression 
which contributes to an increase in PASMC proliferation in females and ultimately a PAH 
phenotype.   
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5.2 Future Perspective 
This investigation not only demonstrates the importance of sex in miRNA regulation with 
regards to PAH but also that restoring miRNA-96 expression represents a novel therapeutic 
target for female PAH. Going forward, a complete microarray analysis of sexually 
dimorphic miRNAs should be performed in female and male PAH patient vs. non-PAH 
patient samples. This would further our understanding of miRNAs which are dysregulated 
in females only, males only and also those which are dysregulated in both. The differences 
observed within this current study suggest that potential miRNAs for therapeutic 
exploitation would be individual to sex and therefore their use in PAH therapy would have 
to be stratified accordingly.  
With regards to miRNA-96, we propose that successful miRNA-96 mimic treatment may 
be specific to the female PAH patient. However, without further investigation into the 
effect of a miRNA-96 mimic within male mice, we cannot say that this therapy would be 
sex-specific. Following on from this, identifying a network of further miRNA-96 target 
genes is imperative. This would clarify other potential miRNA-96 mediated pathways 
possibly moderating the therapeutic effect of a miRNA-96 mimic. Fine tuning the specific 
delivery and dose of a miRNA-96 mimic for targeting PASMCs would also be clinically 
relevant. For example, inhalational administration may allow for more targeted/direct 
delivery to the pulmonary circulation which could potentially minimise unwanted side 
effects. Additionally, an inhalational based miRNA therapy would have better patient 
compliance than intravenous administration. For the advancement of a miRNA-96 mimic 
therapy, longitudinal experimental studies focusing on the tolerability and potential 
toxicity of this miRNA are greatly advised. Standard toxicology studies, including those 
encompassing effects on all vital organs and effects of repeated administration of the drug 
candidate, should be performed. For miRNA based therapies the cause of toxicity can be 
classed into hybridisation-dependent and hybridisation-independent events, thus both 
should be taken into consideration (Cheng et al.). Hybridisation-dependent toxicology 
events include those which could occur due to exaggerated pharmacology i.e. when the 
miRNA-mimic accumulates to an extent where too much target repression occurs. 
Hybridisation-independent toxicology events include those in relation to the chemistry of 
the miRNA mimic. For example, as miRNA based therapies involve introduction of RNA 
into the body, this could produce an innate immune response and trigger inflammatory 
signalling.  
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Studies have shown miRNAs can be easily identified within accessible patient samples e.g. 
blood/plasma. Therefore examination of miRNA-96 as a feasible biomarker for (female) 
PAH is also warranted.  
This thesis strongly emphasises the promise of miRNA based treatments within PAH 
however provides novel data which envisions that patient sex should be incorporated as a 
variable factor. The sex differences of treatment response have recently been highlighted 
within the PAH field and our data further emphasises the use of stratified medicine with 
regards to sex in PAH.  
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